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Introduction
Background 
The care of elderly patients is a challenging task. Clinicians have to make difficult 
decisions influencing and causing disability, which may have major impacts on 
the quality of life and functioning. It is therefore important for the clinician to use 
a multidimensional approach, which takes into account aspects of social, mental, 
and physical health when taking care of elderly patients. The process of aging is 
associated with loss of functional reserve of multiple organ systems, increased 
prevalence of chronic diseases and enhanced susceptibility to stress. This pro-
cess occurs at different ages, resulting in a large variance in phenotype of elderly 
persons with a certain biological age. The concept of frailty as a state of increased 
vulnerability to adverse outcomes may be a more valuable entity [1]. 
One third up to one half of the patients with cancer older than 70 years 
of age can be qualified as frail [2]. The increasing prevalence of cancer in the el-
derly, together with the process of aging, results in a large heterogeneity within 
the group of elderly patients with cancer. Geriatric assessment (GA) may be a 
useful tool in the management and follow-up of elderly patients with cancer. A 
GA provides the combined objective and subjective information on comorbid-
ity, nutrition, cognition, functional and psychosocial status [3, 4]. In elderly pa-
tients, cancer treatments should be adjusted to life expectancy and the expected 
increased risk of toxicity aiming for optimal efficacy, acceptable toxicity and the 
highest attainable quality of life. 
There is a paucity of data in the literature concerning treatment strate-
gies of patients with cancer older than 70 years of age. They are often not men-
tioned in guidelines or state of the art reviews and not in relation to existing 
comorbidities and limited life expectancy [5-7]. Due to age restrictions elderly 
patients are often excluded from trial participation and therefore, clinical rec-
ommendations are frequently not evidence based [8]. In general, findings from 
studies in patients with cancer cannot be extrapolated to elderly patients. For ex-
ample, the prediction of recurrences of breast cancer by the Adjuvant! program 
proved to be unreliable in patients older than 65 years of age [9]. In other words, 
it is largely unclear what the predictors are for the outcome of treatment in the 
older patient group. Moreover, systematic data on toxicity of chemotherapy are 
limited in elderly patients [10], although some progress has been made in recent 
years [11, 12]. It is of great importance to collect and analyze more data on the 
various forms of treatment of the elderly group of patients with cancer. Although 
a survival benefit of chemotherapy of the elderly with lymphoma has been dem-
onstrated [13], this is less clear for elderly patients with a variety of solid tumors. 
It is likely that the use of standard chemotherapy in the elderly –developed and 
tested in patients with cancer of younger age groups– may contribute to sub-
stantial toxicity and consequently excess number of deaths. In this elderly group 
there is a need for better predictors to select those patients who are likely to 
benefit from standard chemotherapy [14, 15]. 
The above mentioned multidimensional approach of the elderly patient 
with cancer is at present often executed by performing a comprehensive geriat-
ric assessment (CGA). A CGA should be helpful to determine a coördinated and 
integrated plan for treatment and long-term follow-up of the elderly patient with 
cancer [4]. Research on the different characteristics of the elderly patient with 
cancer and the predictive value of a CGA, both for the feasibility of treatment with 
chemotherapy and the overall survival, forms the basis of this thesis.  
Epidemiology
The older population is an important and fast growing segment in the Western 
world [16, 17]. The incidence and mortality of patients with cancer increases 
with age. Worldwide, cancer accounted for 8.2 million deaths in 2012. The most 
commonly diagnosed malignancies were lung (i.e., 1.82 million), breast (i.e., 1.67 
million), and colorectal tumors (i.e., 1.36 million) [18]. Projections show that 
these numbers will increase strongly in the following years rising to more than 
13 million worldwide in 2030 [19].
In the Netherlands, the proportion of elderly persons among the total 
population aged 70 years and over will rise for men from 10% in 2015 to 19% in 
2045 and for women from 13% in 2015 to 22% in 2045 (figure 1). This age influ-
ence will become stronger by the improved life expectancy of the elderly due to 
improvement of healthcare and living conditions.
Advancing age is a high risk factor for cancer. Figure 2 shows the incidence of 
all cancers and specificly non-Hodgkin lymphoma, breast- and colon cancer in 
the Netherlands in 2013 [20]. In the Western world and also in the Netherlands, 
more than 2-3 times as many of the invasive cancers occurred in patients aged 70 
years and older. More than forty percent of all new patients were between 60 and 
75 years old of age, while thirty percent were 75 years or older [20, 21]. 
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Results of the population-based EUROCARE-5 study of cancer survival in Europe 
show improving rates in cancer survival. Five-year survival rates were higher for 
patients diagnosed between 2005 and 2007 than for patients diagnosed between 
1999 and 2001. The increase in relative survival was over 5% for patients with 
rectal cancer, prostate cancer, and non-Hodgkin lymphoma [22].
Projections for the year 2015 show increasing survival for lung-, colo-
rectal-, prostate-, stomach cancer and leukemia in men, and for breast-, colorec-
tal-, uterus-, stomach cancer and leukemia in women. However, the lung cancer 
death rate in women is rising sharply and expected to take over the breast cancer 
death rate soon. Pancreatic cancer shows a slowly rising death rate in both sexes 
between 2009 and 2015 [23].
The rising incidence and prevalence of cancer with increasing age, in 
combination with increasing comorbidities, functional-, mental- en social short-
comings specific for older age, will complicate the care for elderly patients and 
will require special expertise in both oncology and geriatrics by physicians and 
other caregivers. 
Figure 1.  Projection of the expected proportions of men and women aged 70 years and over relative 
  to the whole population until 2050.
CBS 2014
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Figure 2. The incidence rate of cancer per 100.000 subjects per year (crude rate, CR) of all cancers,
 non-Hodgkin lymphoma, breast- and colon cancer in the Netherlands in 2013 
The comprehensive geriatric assessment 
CGA in the general population.
The health status of the elderly is compromised by unknown disabilities and un-
reported needs, as such reported in the literature for the first time in 1964 [24]. 
The need for geriatric assessments in a geriatric unit was recognized and de-
scribed in 1987. In this way, a (C)GA has been developed as a tool to find deficits 
and define frailty in elderly patients in order to create a tailor-made treatment- 
and intervention plan [25]. A meta-analysis of trials with CGA showed a larger 
likelihood to live at home and improved survival through the application of CGA 
[26]. A controlled trial on the effects of intervention programs with geriatric ex-
pertise and management did not show advantage in survival, but demonstrated 
mental and physical improvement of functions [27]. Other studies demonstrated 
the usefulness of the application of frailty criteria to guide interventions in health 
care of the elderly patient [28-30].
Comprehensive geriatric assessment in patients with cancer and the applica-
tion of screening tools.
Elderly with cancer form a heterogeneous group of patients. Chronological age as 
an indicator for health risks can differ significantly from biological or functional 
age. CGA can be used to systematically assess medical, functional, cognitive, so-
cial, nutritional and psychological parameters in older people with cancer [31-
Figure	  2. The	  incidence	  rate	  of cancer per 100.000 subjects per year (crude	  rate, CR) of all cancers,
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38]. There is, however, much controversy about which elements should be part of 
the CGA and there is a great overlap of the different domains between the assess-
ments and screening tools. To conduct a full CGA is time consuming and prob-
ably not necessary for every older patient. Therefore, a two-step approach by us-
ing a brief assessment or screening tool has been developed to identify patients 
who need a full CGA [39-41]. However, it must be realized that currently used 
screening tools lack adequate sensitivity, specificity and sufficient discriminative 
power to replace the full CGA [40, 41]. Recently, the International Society of Geri-
atric Oncology (SIOG) updated recommendations on geriatric assessment (GA) 
in elderly patients with cancer [4]. The panel recommended that the following 
domains should be evaluated in a GA: functional status, comorbidity, cognition, 
mental health status, fatigue, social status and support, nutrition, polypharmacy 
and presence of geriatric syndromes.
Functional status includes person’s ability to perform tasks of everyday 
living, such as eating, bathing, dressing, toileting, transferring, using a telephone, 
doing laundry, and handling finances. This may be measured by the Activities of 
Daily Living (ADL) [42], the Instrumental Activities of Daily Living scale (IADL) 
[43] and the Eastern Cooperative Oncology Group Performance Status (ECOG PS)
[44]. Mobility can be measured by the Get Up and Go test (GUG) [45] and muscle
function by the Handgrip strength test (HGS) [46].
Mental status assessment includes cognition and mood and can be meas-
ured by the Mini-Mental State Examination (MMSE) [47], the Geriatric Depres-
sion Scale (GDS) [48], the Hospital Anxiety and Depression scale (HADS) [49] 
and the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) 
[50].
Physical status assessment includes the number of prescribed drugs 
and comorbidity; the latter may be measured by the Charlson comorbidity in-
dex (CCMI) [51] and The Cumulative Illness Rating Scale for Geriatrics (CIRS-G) 
[52]. The nutritional status can be measured by the Mini Nutritional Assessment 
(MNA) [53]. 
The different domains form a part of and are measured by screening 
tools. The most frequently used tools are the Vulnerable Elders Survey (VES-13) 
[2, 54], the abbreviated CGA [55], the Flemish version of the Triage Risk Screen-
ing Tool (fTRST) [56, 57], the Groningen Frailty Indicator (GFI) [58] and the Geri-
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Aim and outline of the thesis
Comprehensive Geriatric Assessment in a broad sense is time consuming and 
expensive. Therefore, it was decided to concentrate on a limited dataset that 
comprised items of nutrition, comorbidity, functional status, psychosocial status, 
cognition, and laboratory values. The following questionnaires and tests were 
considered appropriate to obtain a practical GA: MNA, GFI, IQCODE, MMSE, and 
laboratory values of albumin, creatinine, lactate dehydrogenase and hemoglobin. 
If shortcomings occurred with the questionnaires a geriatrician and/or dietician 
could be consulted.
The main questions we tried to answer were firstly to assess the predic-
tive value prior to the start of chemotherapy of the chosen GA with respect to 
the probability to complete the planned chemotherapy and overall survival and 
secondly to analyze and determine wich elements of the chosen GA were inde-
pendently predictive to complete chemotherapy and which elements predicted 
early mortality.
A first analysis of the role of GA in 202 patients with a variety of cancers, 
all of them treated in the Reinier de Graaf Hospital in Delft, is described in Chap-
ter 2. Tumor-specific analyses are presented in Chapters 3 through 5. Chapter 
3 provides details on 55 patients with breast cancer. Analyses have been per-
formed of the results of GA and laboratory tests for albumin, hemoglobin, creati-
nine and lactate dehydrogenase in relation to the outcome of palliative therapy 
with chemotherapy. The analysis of GA on 143 patients with colorectal cancer 
is described in Chapter 4, separately for patients treated with palliative or ad-
juvant intent. The additional value of GA and laboratory tests, apart from and in 
comparison with the age-adjusted International Prognostic Index, on the out-
come of 44 patients with aggressive non-Hodgkin lymphoma treated with com-
bination chemo-immunotherapy (R-CHOP), is described in Chapter 5. Finally, a 
more detailed analysis was performed to elucidate which elements of GA have 
the most impact on the outcome of the whole cohort of 494 patients collected in 
the region of the Comprehensive Cancer Center West (Reinier de Graaf hospital-
Delft, HAGA hospital-The Hague, Groene Hart hospital-Gouda and Leiden Univer-
sity Medical Center-Leiden) and selected by the treating clinician who estimated 
that chemotherapy was feasible on clinical grounds. The results of this analysis 
are described in Chapter 6. Based on these results we constructed a Geriatric 
Prognostic Index as risk profile for mortality prior to chemotherapy in the el-
derly. In Chapter 7 our findings are summarized, discussed in a broader context 
and put in perspective. 
Overview of the studies presented in this thesis
Overview	  of	  the	  studies	  presented	  in	  this	  thesis
	  Instruments	  of	  geriatric	  assessment:
	  Mini	  Nutritional	  Assessment	  (MNA)
	  Informant	  Questionnaire	  on	  Cognitive	  Decline	  in	  the	  Elderly	  (IQCODE)
	  Groningen	  Frailty	  Index	  (GFI)
	  Mini	  Mental	  State	  Examination	  (MMSE)
202	  patients	  with	  cancer	  
(mean	  age	  77	  years;	  55%	  women)	  
55	  patients	  with	  breast	  cancer	  
(mean	  age	  76	  years;	  96%	  women)
143	  patients	  with	  colorectal	  cancer	  
(mean	  age	  75	  years;	  41%	  women)	  
44	  patients	  with	  non-­‐Hodgkin	  lymphoma	  
(mean	  age	  of	  78	  years;	  57%	  women)	  
	  Outcomes:
	  	  Feasibility	  of	  chemotherapy	  
	  All-­‐cause	  mortality	  after	  chemotherapy
	  Geriatric	  Prognostic	  Index	  (GPI):
	  Independently	  predictive	  items
	  ‘declining	  food	  intake	  in	  past	  3	  months’
	  ‘using	  >3	  prescript	  drugs’
	  ‘dependent	  shopping’
494	  patients	  with	  cancer	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cent of all cancers and 70% of cancer mortality is found above 65 years of age [1]. 
As a result of the ageing population in western countries the demand for care of 
older people with cancer will strongly increase in the coming decades, also due 
to comorbidity, diminished organ functions, impairment of daily vital functions 
and development of cognitive dysfunctions. It seems to be logical to use biologic 
age as an indicator for health risks in the elderly but it is not a very sensitive and 
specific risk marker. The concept of frailty may be more valuable. Comprehen-
sive geriatric assessment (CGA) provides information on the functional status of 
older cancer patients [2, 3, 4], consisting of objective information on comorbid-
ity, functional status, nutritional status and psychosocial status. CGA can there-
fore disclose the existence of geriatric syndromes, which may complicate cancer 
treatment and vice versa may deteriorate during the course of treatment. 
Several cross sectional studies have demonstrated associations between 
CGA and toxicity, morbidity and mortality during cancer treatment in older pa-
tients [5, 6, 7, 8, 9, 10, 11]. The effects of chemotherapy on cognitive function have 
been extensively studied prospectively in women with breast cancer [12, 13]. In 
other types of cancer, geriatric assessment has been studied more scarcely [14, 
15]. Deterioration of cognition during chemotherapy has been hypothesized to 
be due to either direct chemical toxicity affecting neuroneogenesis, or by indirect 
effect through an increased (auto)inflammatory reaction [16, 17].
In the present study, we describe a basic GA of 202 cancer patients aged 
70 years and above, with the aim to assess its prognostic value for treatment with 
chemotherapy, both with respect to the probability to complete chemotherapy 
and with respect to survival probabilities. Furthermore, among 51 patients the 
assessment was repeated after at least four courses of chemotherapy or at six 
months after start of treatment with the aim to assess the impact of chemother-
apy on GA. 
Patients and Methods
Patients
Between May 2004 and September 2007 all patients with cancer older than 70 
years of age (n=202) for whom chemotherapy was prescribed by their medical 
oncologist in the hospital of the Reinier de Graaf Groep (Delft, the Netherlands), 
were prospectively assessed before chemotherapy using the following tests: Mini 
Nutritional Assessment (MNA), Informant Questionnaire on Cognitive Decline in 
the Elderly (IQCODE), Groningen Frailty Indicator (GFI) and Mini Mental State 
Abstract
Introduction. Comprehensive geriatric assessment (CGA) gives useful informa-
tion on the functional status of older cancer patients. However, its meaning for 
a proper selection of elderly patients before chemotherapy and, even more im-
portant, the influence of chemotherapy on the outcome of geriatric assessment 
is unknown. 
Methods. 202 cancer patients, for whom an indication for chemotherapy was 
made by the medical oncologist, underwent a GA before start of chemotherapy 
by Mini Nutritional Assessment (MNA), Informant Questionnaire on Cognitive 
Decline in the Elderly (IQCODE), Groningen Frailty Index (GFI) and Mini Men-
tal State Examination (MMSE). After completion of a minimum of four cycles 
of chemotherapy or at six months after the start of chemotherapy the GFI and 
MMSE assessment was repeated.
Results. Frailty was shown in 10% of patients by means of MMSE, 32% by MNA, 
37% by GFI and in 15% by IQ-CODE. Compared to patients who received 4 or 
more cycles of chemotherapy, the MNA and MMSE scores were significantly low-
er for patients treated with less than 4 cycles (p=0.001 and p=0.04 respectively). 
The mortality rate after start of chemotherapy was increased for patients with 
low MNA and high GFI scores with hazard ratios of 2.19 (95% confidence interval 
[CI]: 1.42-3.39; p<0.001) and 1.80 (95% CI: 1.17-2.78; p=0.007), respectively. Af-
ter adjusting for sex, age, purpose of chemotherapy and type of malignancy these 
hazard ratios remained significant (p<0.001 and p= 0.004), respectively. Finally, 
for the 51 patients who underwent repeated post-chemotherapy evaluation by 
GFI and MMSE, a statistically significant deterioration for the MMSE (p=0.041) 
was found but not for the GFI. 
Conclusions. Both inferior MNA and MMSE scores increased the probability not 
to complete chemotherapy. Also, an inferior score for MNA and GFI showed an 
increased mortality risk after the start of chemotherapy. The mean MMSE score 
worsened significantly during chemotherapy. 
Introduction
The incidence and mortality of patients with cancer increases with age. Sixty per-
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Examination (MMSE). The tests were performed by trained nurses. All patients 
who underwent Geriatric Assessment (GA) started with chemotherapy. The test 
evaluation did not induce any delay in chemotherapy that the patients received. 
Patients completing at least four cycles of chemotherapy were again assessed 
by GFI and MMSE at the end of chemotherapy or six months after the start of 
chemotherapy. If indicated by the test results, a dietician and/or a geriatrician 
were consulted. 
The MNA is a stepwise test and is comprised of two sections. First, there 
is the screening section (6 items). When the score is less than 12 points, indicat-
ing the possibility of malnutrition, the assessment section (12 items) is filled in. 
With the assessment section, a score of 24-30 points is indicative of being well-
nourished, 17-23.5 points for being at risk of malnutrition, and a score less than 
17 points for being malnourished. The test makes it possible to identify patients 
at risk for malnutrition, before severe changes in weight or albumin levels occur 
[18, 19]. This scoring system for malnutrition has a sensitivity of 96%, specificity 
of 98% and positive predictive value of 97% [20]. 
The IQCODE is a well validated instrument that screens for cognitive de-
cline by interviewing family members or care givers [21]. The 16 items are rated 
on 5-point Likert scales, ranging from much improved to much worsened, and 
the average score is used in the analyses that ranges from 1 to 5. We used the 
short Dutch translation IQCODE-N [22]. In clinical settings, a cut-off score of 3.31 
is a reasonably balance between sensitivity and specificity on the outcome of 
cognitive decline [23, 24]. Patients with a score of 3.30 or higher were examined 
by a geriatrician. 
The risk for individual mortality, which can be seen as the ultimate out-
come of age and frailty, can be predicted better by frailty than by chronologic 
age [25, 26]. The GFI has been developed as a simple screening instrument for 
frailty and a case finder for elderly patients who would benefit from integrated 
(geriatric) care [27, 28]. The GFI screens on physical, cognitive, social and emo-
tional items. The maximum score is 15 points (see appendix). Patients scoring 4 
or more points were considered moderately frail and were examined by a geri-
atrician. 
The MMSE has been tested extensively and is considered to be a stand-
ard test for cognitive function. Sensitivity of the MMSE for cognitive dysfunction 
is 88%, the specificity is 93% [29, 30, 31, 32]. Patients scoring 24 points or less 
were seen by a geriatrician.
Statistical analysis
Categorical variables are presented as numbers and percentages and continu-
ous variables as means ± standard deviations (SD), with their range. Chi-square 
tests were used for the analysis of categorical variables. Survival probabilities 
were estimated using Kaplan Meier curves and the log-rank test was used to test 
for difference in survival between categories of baseline CGA data. Cox propor-
tional hazard regression was used to calculate hazard ratios (for MNA 2 catego-
ries were used: well nourished and risk of malnutrition / malnourished). Hazard 
ratios were adjusted for sex, age, purpose of chemotherapy (using 3 categories: 
adjuvant/curative; palliative and unknown) and type of malignancy (using 5 cat-
egories: digestive tract; breast cancer; ovarian cancer; hematological malignan-
cies; other or missing). Changes in GA data over time were analyzed using the 
paired sample t-test. A p value less than 0.05 was considered significant. SPSS 
17.0 for Windows® (SPSS inc. Chicago, IL.) was used for statistical analyses.
Results
Table 1 shows the baseline characteristics of the 202 included patients: 90 men 
(45%) and 112 women (55%). The mean age was 77.2 years (range 71─92). Fifty 
percent of patients received at least four cycles of chemotherapy. The duration of 
the follow-up, defined as the difference between the date of the first GA and the 
date of the last follow-up, showed a median of nine months (range 1-33).
Table 2 shows the results of geriatric assessment at baseline. With MNA, 
65% of the patients were well nourished, while 30% of the patients were at risk 
for malnutrition and 3% were malnourished. A MMSE score of 24 points or lower, 
meaning a serious cognitive reduction, was seen in 10% of the patients. IQCODE 
showed an average score of 3.10 points. A GFI score of 4 or more points, meaning 
increased frailty, was found in 37% of the patients.
Table 3 depicts the results comparing less than 4 versus 4 or more 
chemotherapy cycles. With MNA and MMSE , there was a significant difference 
between the number of patients who underwent less than 4 cycles compared to 
patients who underwent 4 cycles or more. The mean reasons for not finishing 
the 4 cycles of chemotherapy were cancer progression, toxicity and insufficient 
benefit. 
Figure 1 shows the Kaplan-Meier curves of overall survival according to 
predefined cut-off scores for the MNA, IQCODE, GFI and MMSE. Patients scoring 
lower than 24 points for MNA and 4 or more points for GFI showed significantly 
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worse survival (p < 0.001 and p = 0.007, respectively). 
Table 4 gives the hazard ratios for mortality, indicating that a worse 
MNA score was associated with an increased mortality risk with a hazard ratio 
(HR) of 2.19 (95% confidence interval [CI]: 1.42-3.39; p<0.001) and a worse GFI 
score was associated with an increased risk with a HR of 1.80 (95% CI: 1.17-2.78; 
p=0.007). The sex- and age-adjusted hazard ratios for mortality were largely un-
affected (model 1). When we additionally adjusted for the purpose of chemother-
apy and type of malignancy, the hazard ratios for mortality with worse MNA and 
GFI scores were 2.54 (95% CI: 1.55-4.15; p<0.001) and 2.00 (95% CI: 1.26-3.17; 
p=0.004), respectively (model 2). 
For the 51 patients with complete data for MMSE and GFI scores at base-
line and after four or more cycles of chemotherapy, the MMSE showed a statisti-
cally significant deterioration after the chemotherapy (p=0.04; see Table 5). 
Discussion
In this study, a basic GA was obtained of patients with cancer above the age of 70 
years who were treated with chemotherapy. After at least four cycles of chemo-
therapy or at six months after the start of treatment, the GA was partly repeated 
with GFI and MMSE. The aim of this study was to develop tools for medical on-
cologists in their advice concerning treatment of elderly patients with chemo-
therapy. Malnutrition and cognition appeared independently related to the prob-
ability not to complete chemotherapy, while malnutrition and frailty (defined by 
GFI of 4 or more points) were associated with increased mortality. In addition, 
MMSE deteriorated slightly during the course of chemotherapy. 
Traditionally, the Karnofsky Performance Scale or the World Health 
Organisation scores are used to determine the performance status of cancer 
patients. However, geriatricians have developed other scales to assess the func-
tional status of older patients, for instance with ADL, IADL and the Charlson Co-
morbidity Index. We pragmatically selected the GFI, IQCODE, MMSE and MNA 
tests for performing a GA, striving for a maximum of 45 minutes to complete 
the interview. For the second assessment we repeated the GFI and MMSE. The 
IQCODE could not be used in the second assessment, because this instrument 
gives information on cognitive function over the past ten years. With the MMSE 
it is possible to measure deterioration after a short period. The used batch of 
tests should give a broad spectrum of data for coverage of GA with little overlap 
between the tests. 
Approaches that are often used to assess functional status of older can-
cer patients are the Vulnerable Elders Survey (VES-13) [33], the abbreviated CGA 
(aCGA) [34], the clinical criteria by Fried et al. [35], the Edmonton Frailty scale 
[36] and the Groningen Frailty Indicator [37]. Puts et al. [38] demonstrated the
importance of psychological markers in the concept of frailty. They showed that
frailty was an independent risk factor for a decline in physical functioning, in-
stitutionalization and mortality. To measure frailty, the GFI is a short and easy
practical instrument, and it seems a reasonable and manageable alternative com-
pared to chronological age as a selection criterion for interventions [27]. Slaets
et al. investigated the predictive values of chronologic age and frailty and the
predictive power of the GFI in clinical studies comparing the GFI with the Quality 
of life Questionnaire (QLQ) C-30, the Charlson comorbidity index (CCMI) and the
10- to 30-day morbidity index. The GFI could predict most of the QLQ C-30 scales
significantly. They found clinical relevant and significant differences between the
frail and the nonfrail groups in mean scores on physical-, role-, and emotional
function and fatigue [37]. The present analysis also showed a relation between
GFI and survival, which remained significant after multivariable adjustment for
sex, age, purpose of chemotherapy and type of malignancy.
The results of the MNA were almost identical with the findings of Tolius-
iene et al, who found that 50% of older men with prostate cancer were at risk for 
malnutrition [18]. Patients at risk were referred to a dietician because weight 
loss, low body mass index (BMI) and poor nutritional status are associated with 
increased risk of mortality, and more depressive symptoms [39, 40, 41, 42]. In 
the present study patients with normal MNA scores had a higher probability to 
complete pre-planned chemotherapy and a better survival, also after adjusting 
for the confounders mentioned earlier for GFI. 
With MMSE, 11% of the patients showed serious cognitive impairment. 
Other studies found cognitive impairment in 25% to 38% of patients [3, 43, 44, 
45, 46]. The present study showed, that a worse score for MMSE was associated 
with a larger probability of not completing 4 or more cycles of chemotherapy. 
Furthermore, the MMSE score at the second assessment in a limited number of 
patients was somewhat worsened compared to the assessment at baseline. Al-
though this difference was significant, it did not appear to be a clinically mean-
ingful difference. Comparison with other studies is difficult because there is no 
consistency in the definitions of cognitive dysfunction used in the literature [47, 
48]. Hurria et al. found that fifty percent of the patients of 65 years or older, hav-
ing received chemotherapy, reported cognitive decline 6 months after chemo-
therapy, especially concerning declined memory and the ability to learn new in-
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formation [14]. The duration of cognitive impairment after chemotherapy is not 
clear. Some studies reported cognitive dysfunction in patients 2 to 10 years post 
chemotherapy [49, 50] but most patients in these studies were younger than 65 
years. For patients over 70 years of age severity of cognitive impairment is prob-
ably more important than its duration. Fried et al. reported that if the outcome 
for a certain treatment was cure at the cost of severe functional- or cognitive 
impairment, 74.4 % and 88.8 % of serious ill patients, respectively, would not 
choose this treatment [44]. 
The multivariate analysis of the present study stipulates the importance 
of screening with MNA and GFI, as poor test results predicted for an increased 
mortality rate. The MMSE might contribute to the prediction whether chemo-
therapy can be completed, which was more powerful shown for the MNA. The 
IQCODE, which gives information of cognitive function over the past decade, did 
not show any predictive power in the present GA. Both MNA and GFI seem to be 
promising predictive screening tests for outcome when chemotherapy is consid-
ered in elderly patients with cancer.
A limitation of this study is the heterogeneity of patients with a wide 
diversity of types of cancer, different stages of cancer and different treatments. 
Furthermore, it could be that there are unaccounted confounders for example al-
cohol consumption, smoking and socio-economic status. Comparison with other 
studies is difficult because of the paucity of data in the literature. Further re-
search is needed for clarification of the tools available for geriatric assessment. 
In this way, the care for older patients with cancer, treated with chemotherapy 
can result in a more tailor-made approach, aiming for optimal balance between 
efficacy and toxicity of treatment.
Table	  1	  	  
Characteristics	  of	  patients	  (n	  =	  202)	  
years	   SD	  
Age	   Mean	   77	  	   4.22	  
Minimum	   71	  	  
Maximum	   92	  	  
n	   %	  
Gender	   Male	   90	   45	  
Female	   112	   55	  
Number	  of	  chemotherapy	  cycles	   <	  4	   74	   37	  
≥	  4	   118	   58	  
unknown	   10	   5	  
Type	  of	  malignancy	   Upper	  digestive	  tract	   19	   9	  
Colorectal	  cancer	   60	   30	  
Breast	  cancer	   34	   17	  
Ovarian	  cancer	   20	   10	  
Hematological	  malignancies	   36	   18	  
Other	  types*	   28	   14	  
Unknown	   5	   2	  
Purpose	  of	  chemotherapy	   Adjuvant/curative	   80	   40	  
Palliative	   111	   55	  
Unknown	   7	   3	  
Missing	   4	   2	  
*The	  category	  other	  types	  of	  malignancy	  consisted	  mainly	  of	  prostate	  cancer	  (n=12),	  lung	  cancer
(n=7)	  and	  urothelial	  cell	  cancer	  (n=5)	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Table	  2	  	  
Results	  of	  the	  geriatric	  assessments	  at	  baseline	  (n=202)	  	  
Test	   Score	   n	   %	  
MNA	   well	  nourished	  (>12	  pts*	  and	  24-­‐30	  pts§	  )	   131	   65	  
risk	  of	  malnutrition	  (17-­‐23.5	  pts§)	   60	   30	  
malnourished	  assessment	  (less	  than	  17	  pts§)	   5	   3	  
unknown	   6	   2	  
MMSE	   ˃	  24	  pts	   178	   88	  
≤	  24	  pts	   21	   10	  
unknown	   3	   2	  
IQCODE	   > 3.30	  pts 30	   15	  
≤	  3.30	  pts 163	   81	  
Unknown 9	   4	  
GFI	   <4	  pts	   127	   63	  
≥4	  pts	   75	   37	  
*MNA	  screening	  section
§ MNA	  assessment	  section
Table	  3.	  
Baseline	  test	  results	  in	  192	  subjects,	  comparing	  patients	  who	  received	  less	  than	  four	  cycles	  to	  
patients	  who	  received	  four	  or	  more	  cycles	  of	  chemotherapy	  
Number	  of	  cycles	  
<4	  (n=74)	   ≥4	  (n=118)	  
Test	   Score	   n	  	   %	   n	  	   %	   p-­‐	  value	  
MNA:	   well	  nourished	   37	  	   51	   86	  	   75	   0.001	  
risk	  of	  malnutrition/	  
malnourished	   35	  	   49	   29	  	   25	  
missings	   2	   3	  
IQCODE:	   ≥	  3.3	   14	   20	   15	   13	   0.20	  
<	  3.3	   55	   80	   99	   87	  
missings	   5	   4	  
GFI:	   <	  4	   42	   57	   79	   67	   0.15	  
≥	  4	   32	   43	   39	   33	  
MMSE:	   ˃	  24	   64	   89	   113	   97	   0.04	  
≤	  24	   8	   11	   4	   3	  
missings	   2	   1	  
For	  10	  patients	  it	  was	  unknown	  whether	  they	  finished	  4	  cycles	  because	  they	  just	  started	  and	  were	  
ongoing	  with	  chemotherapy.	  
Well	  nourished	  meaning	  >12	  pts	  in	  MNA	  screening	  section	  or	  24-­‐30	  pts	  in	  the	  
MNA	  assessment	  section;	  risk	  of	  malnutrition	  /malnourished	  meaning	  less	  than	  
24	  pts	  in	  the	  MNA	  assessment	  section.	  
P-­‐values	  are	  obtained	  from	  Pearson	  chi-­‐square	  tests	  (missings	  were	  not	  included	  in	  chi-­‐square	  tests).	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Table	  4.	  
Hazard	  ratios	  (95%	  confidence	  intervals)	  for	  mortality	  in	  202	  cancer	  patients	  
Test	   Score	   Crude	   Model	  1	   Model	  2	  
MNA:	   well	  nourished	   1.00	   1.00	   1.00	  
	   risk	  of	  malnutrition	  /	  malnourished	   2.19	  (1.42-­‐3.39)	   2.34	  (1.49-­‐3.66)	   2.54	  (1.55-­‐4.15)	  
	   	   p<0.001	   p<0.001	   p<0.001	  
	   	   	   	   	  
IQCODE:	   ≥	  3.3	   1.00	   1.00	   1.00	  
	   <	  3.3	   0.84	  (0.46-­‐1.53)	   0.86	  (0.47-­‐1.57)	   0.93	  (0.49-­‐1.73)	  
	   	   p=0.57	   p=0.63	   p=0.81	  
	   	   	   	   	  
GFI:	   <	  4	   1.00	   1.00	   1.00	  
	   ≥	  4	   1.80	  (1.17-­‐2.78)	   1.89	  (1.22-­‐2.94)	   2.00	  (1.26-­‐3.17)	  
	   	   p=0.007	   p=0.005	   p=0.004	  
	   	   	   	   	  
MMSE:	   ˃	  24	   1.00	   1.00	   1.00	  
	   ≤	  24	   1.05	  (0.51-­‐2.18)	   0.99	  (0.48-­‐2.07)	   0.92	  (0.44-­‐1.93)	  
	   	   p=0.89	   p=0.87	   p=0.82	  
	   	   	   	   	  
	  
Baseline	  MNA,	  IQCODE,	  GFI	  and	  MMSE	  data	  are	  dichotomized.	  
Well	  nourished	  meaning	  >12	  pts	  in	  MNA	  screening	  section	  or	  24-­‐30	  pts	  in	  the	  
MNA	  assessment	  section;	  risk	  of	  malnutrition	  /	  malnourished	  meaning	  less	  than	  24	  pts	  in	  the	  MNA	  
assessment	  section.	  
Model	  1:	  adjusted	  for	  sex	  and	  age;	  
Model	  2:	  additionally	  adjusted	  for	  purpose	  of	  chemotherapy	  and	  type	  of	  malignancy.	  
	  
Table	  5	  
Differences	  between	  baseline-­‐	  and	  second	  assessment	  (after	  at	  least	  4	  cycli)	  of	  MMSE	  and	  GFI	  (n=51)	  
	   At	  baseline	   	   2e	  assessment	   	   	   	  
	   Median	  	   P25	   P75	   	   Median	   P25	   P75	   Mean	  change	   SE	  	   p-­‐value*	  
MMSE	   30	   28	   30	   	   29	   27	   30	   -­‐0.86	   0.41	   0.041	  
GFI	   2	   1	   3	   	   2	   1	   5	   0.24	   0.33	   0.476	  
	  
*t-­‐test	  for	  paired	  samples	  	  
	  
Figure	  1	  
Kaplan-­‐Meier	  curves	  of	  overall	  survival	  for	  different	  categories	  of	  MNA	  [A],	  IQCODE	  [B],	  GFI	  [C]	  and	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Abstract
Introduction: The prognostic value of geriatric assessment in older patients with 
breast cancer treated with chemotherapy is largely unknown. 
Methods: Fifty-five patients with advanced breast cancer aged 70 years or older 
were assessed by Mini Nutritional Assessment (MNA), Informant Questionnaire 
on Cognitive Decline in the Elderly (IQCODE), Groningen Frailty Indicator (GFI) 
and Mini Mental State Examination (MMSE). Levels of albumin, hemoglobin, cre-
atinine and lactate dehydrogenase were measured. Patients completing at least 
four cycles of chemotherapy were reassessed by GFI and MMSE and mortality 
was evaluated using Cox regression analysis.
Results: The mean age was 76 year (SD 4.8). Inferior MNA and GFI scores were 
associated with increased hazard ratios for mortality: 3.05 (95% confidence in-
terval [CI]: 1.44-6.45; p=0.004) and 3.40 (95% CI: 1.62-7.10; p=0.001), respec-
tively. Physical aspects of frailty worsened during the course of chemotherapy. 
Laboratory values were not associated with assessment scores nor were they 
predictive for mortality.
Conclusions: Malnutrition and frailty, rather than cognitive impairment and lab-
oratory values, were associated with an increased mortality risk in these elderly 
breast cancer patients with advanced breast cancer.
Introduction
In developed countries, breast cancer accounts for nearly one third of all new 
cases of cancer in women [1]. Older age is an important risk factor for breast can-
cer. More than 40% of breast cancer diagnoses and nearly 60% of breast cancer 
deaths occur in women aged 65 years or older [1]. Because older cancer patients 
are hardly represented in randomized clinical trials of chemotherapy, the results 
of these studies cannot predict for outcomes and toxicities of treatment in this 
population. Therefore, population based studies should address outcome- and 
treatment modifying factors in older patients to provide future methods to dis-
tinguish older patients who are likely to benefit from treatment from those who 
are not. 
A comprehensive geriatric assessment (CGA) can be used to systematically 
assess health and functional status in older people [2-4]. A CGA may disclose the 
existence of geriatric syndromes, such as frailty and cognitive dysfunction not 
previously recognized by the treating physician. Several studies use the concept 
of frailty as a hallmark of geriatric syndromes, in accordance with Balducci’s al-
gorithm for the management of elderly cancer patients [5-7]. It has previously 
been shown that psycho-social deficits and comorbidity are associated with poor 
treatment tolerance and mortality, independent of age and stage of disease [8]. 
Also, cognition deficits and frailty predict for toxicity and early treatment with-
drawal in patients treated with chemotherapy [9, 10]. Furthermore, malnutrition 
has been identified as a predictor of increased mortality [11, 12].
The impact of cognitive dysfunction on tolerance of chemotherapy and mor-
tality is largely unknown. The main focus of research on cancer treatment and its 
cognitive side effects have concentrated on adjuvant treatment in breast cancer 
patients [13]. A recently published meta-analysis showed that cognitive deficits 
after chemotherapy in breast cancer patients are small in magnitude and limited 
to the domains of verbal and visiospatial ability [14] and in an accompanying 
editorial the suggestion was made that the effect of chemotherapy on cognition 
is underestimated and that more research is needed [15]. 
Anemia, hypoalbuminemia and renal dysfunction were identified by others 
as risk factors for frailty and chemotherapy toxicity [16, 17]. For example, anemia 
is a powerful prognostic factor for the development of frailty related problems 
such as muscle weakness, reduced performance, falls, and mortality [18-20]. It 
is interesting to know if laboratory measurements are more predictive for the 
number of chemotherapy cycles and mortality than GA. 
We performed a GA that provided combined information on several do-
mains of health and function in older patients: cognition, nutritional status, co-
morbidity, functional-, and psychosocial status. For practical reasons we decided 
to use a limited set of questionnaires and tests instead of a complete CGA. We 
considered this as an effective method to capture a broad spectrum of data and 
at the same time minimizing resources and time spent by health care providers. 
Such a cost-effective choice might broaden the reach of such assessments [10, 
21]. Furthermore, laboratory values of serum albumin, creatinine, lactate dehy-
drogenase (LDH) and hemoglobin were measured
With this variant of an abbreviated GA and selected laboratory tests we studied 
outcome modifying factors in older breast cancer patients treated with chemo-
therapy. In patients who completed at least four cycles of chemotherapy GFI and 
MMSE were repeated in order to examine the effect of chemotherapy on these 
parameters of frailty and cognition.
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 Patients and methods
Study design
This clinical cohort study involved patients aged 70 years or older (n=55) with 
advanced breast cancer for whom chemotherapy was prescribed by their medi-
cal oncologist. Patients were recruited between May 2004 and February 2010 
from the outpatient oncology practices of three general and one university hospi-
tal. Participating hospitals were situated in the western part of the Netherlands: 
Reinier de Graaf Groep in Delft, Groene Hart Hospital in Gouda, HAGA hospital 
in The Hague and the Leiden University Medical Center. Participation of these 
hospitals started at different time points because of time needed for training of 
dedicated nurses in the technique of GA. 
 During the study period all patients aged 70 years or older for whom a 
treatment plan was made that involved chemotherapy were prospectively as-
sessed by trained nurse practitioners using the following tests: Mini Nutritional 
Assessment (MNA) [22], Groningen Frailty Indicator (GFI) [23], Informant Ques-
tionnaire on Cognitive Decline in the Elderly (IQCODE) [24], and Mini Mental 
State Examination (MMSE) [25]. If possible, the IQCODE was filled in by family or 
caregivers. These validated tests were selected to assess in the elderly patients 
the important domains of mobility, physical fitness, polypharmacy, psychosocial 
resources, cognition, weight loss and nutrition, striving for a minimum of overlap 
between the domains. Activities of Daily Living (ADL) and Instrumental Activi-
ties of Daily Living (IADL) were not separately assessed as GFI is considered to 
screen for dependency. Given the fact that many older patients have a time lim-
ited span of attention, we considered 45 minutes the timelimit per interview. For 
patients completing at least four cycles of chemotherapy, assessment by GFI and 
MMSE was repeated at the end of chemotherapy or at six months after start of 
chemotherapy 
   Patients received treatment according to standard of care, therefore, ethi-
cal approval and consent were not considered necessary to be obtained. Patients 
with brain metastases were excluded. 
 For this paper, we selected all women with advanced breast cancer from 
a larger cohort of patients treated with chemotherapy for a variety of cancers. 
A part of this cohort has been previously described [26]. A flow diagram of the 
study is given in figure 1.
Assessment
The used tests have been described in detail [26]. In brief, the MNA makes it pos-
sible to identify patients at risk for malnutrition, before severe changes in weight 
or albumin levels occur [27, 28]. A score of 24-30 points is indicative of being 
well-nourished, 17-23.5 points for being at risk of malnutrition, and a score of 
less than 17 points indicates malnutrition. The GFI consists of items on physical, 
cognitive, social and emotional functioning with a maximum score of 15 points 
(see appendix). Patients with 4 or more points are considered frail. For screen-
ing on cognition we used both the IQCODE and MMSE. The IQCODE screens for 
cognitive decline over the last 10 years by interviewing family members or care 
givers, while with MMSE it is possible to measure deterioration after a short pe-
riod. For IQCODE we used the short Dutch translation IQCODE-N [29]. In clini-
cal settings, a cut-off score of 3.31 reasonably balances between sensitivity and 
specificity on the outcome of cognitive decline, higher scores indicating poorer 
cognition. The MMSE has been tested extensively and is considered to be a stand-
ard test for current cognitive function. The cut-off point for poorer cognition is 
24 points or less [25].
Data collection
Laboratory values, comorbidity, medication history, WHO-performance and rea-
sons for not finishing the planned cycles of chemotherapy were recorded from 
the medical files by a trained registrar. Laboratory values of serum albumin, cre-
atinine, LDH and haemoglobin were registered. Comorbidity was registered by 
using Charlson’s comorbidity scoring system [30]. Performance status was regis-
tered by the scoring system WHO or Karnofsky (KI) [31, 32].
Treatment period and follow-up 
The treatment period was left to the discretion of the medical oncologist. Re-
ceiving less than four cycles of chemotherapy was considered early treatment 
withdrawal. The follow-up was defined as the time between the date of the first 
GA and the date of the last follow-up. The follow-up period varied because of 
different time points of entry in the study and ended after last control in the 
oncology ward. Vital status and last follow-up date were recorded from the pa-
tient’s medical record. Vital status was crosschecked with the municipal registry 
on June 2010. 
 Patients completing at least four cycles of chemotherapy were assessed 
once more by GFI and MMSE at the end of chemotherapy or at six months after 
the start of chemotherapy, and this succeeded in 21 of 39 patients. 
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Statistical analysis
Categorical variables are presented as numbers and percentages and continuous 
variables as means ± standard deviations (SD), with their range, or as medians 
with their interquartile range in case of skewed distributions. Chi-square tests 
were used to compare categorical variables between subgroups. The correlation 
between GA measures was calculated using the non-parametric Spearman’s cor-
relation coefficient and this was also used for correlation between GA and WHO 
performance status. Univariate and multivariate linear regression analysis was 
used to study the associations between GA test results and laboratory measures, 
both crude and after adjustment for age and comorbidity. Standardized regres-
sion coefficients, which are in the case of univariate regression equal to the Pear-
son’s correlation coefficients are reported. Survival probabilities were estimated 
using Kaplan Meier curves and the log-rank test was used to test for difference in 
survival rates among subgroups. 
We also dichotomized MNA (cutoff <24 points in the MNA assessment sec-
tion indicated risk of malnutrition/malnourished); GFI (cutoff ≥4 points indicat-
ed frailty); IQCODE (cutoff ≥3.3 points indicated cognitive decline); MMSE (cutoff 
≤24 points indicated cognitive dysfunction); albumin (cutoff < 35g/L); hemo-
globin (cutoff < 7.5mmol/L); creatinine (cutoff ≥ 100 μmol/L) and LDH (cutoff ≥ 
250 U/L). Logistic regression analysis was used to analyze the associations be-
tween dichotomized variables and receiving more or less than 4 chemotherapy 
cycles with adjustment for confounding variables (age, comorbidity and WHO 
performance status). 
Cox proportional hazard regression was used to calculate mortality risks 
according to categories of the MNA, GFI, IQCODE and MMSE scores. Hazard ratios 
(HRs) were adjusted for age and comorbidities (0, 1, 2 or more). In sensitivity 
analyses, continuous values for the geriatric assessment and laboratory test val-
ues were used. Changes in GA data over time (before chemotherapy and after at 
least 4 cycles) were analyzed using the paired sample t-test. A p value less than 
0.05 was considered significant. SPSS 17.0 for Windows® (SPSS inc. Chicago, IL.) 
was used for statistical analyses.
Results
Table1 shows the baseline characteristics of the 55 included patients with ad-
vanced breast cancer, two of whom were men (4%). Two patients, who had been 
planned for chemotherapy and hence were assessed with basic GA, after all did 
not start chemotherapy. One declined and one unexpectedly died. The mean age 
was 76 years (range70–88). Twenty percent of patients was 80 years or older. 
Median follow-up was 11 months (range 0–57). No comorbidities were docu-
mented in 33% of the patients and 70% of the patients had a WHO-performance 
in categories 0 or 1. Thirteen percent of the patients did not use any (co-)medi-
cation, while 38% used one to three co-medications and 45% four or more co-
medications. 
GA test results and laboratory outcomes were not significantly correlated, 
neither after adjustment for age and comorbidity. The MNA and GFI were in-
versely correlated (r = –0.43; P<0.001), and the IQCODE and MMSE were also in-
versely correlated (r = –0.36; P=0.01). No other significant correlations between 
the GA test results were found. Using Spearman ’s correlation coefficients, more 
disability according to WHO performance status or KI was associated with mal-
nourishment on the MNA and frailty as defined by a score of 4 or more with the 
GFI (r = –0.28; P=0.044 and r = 0.38; P=0.004, respectively). 
Table 3 shows the results of the geriatric assessment and laboratory results 
and the relation between these parameters and either early treatment with-
drawal or treatment with four or more cycles of chemotherapy. Thirty-nine pa-
tients completed at least 4 cycles of chemotherapy. The main reasons for early 
withdrawal were cancer progression, insufficient therapeutic benefit and toxic-
ity. Patients who experienced early withdrawal could not be distinguished from 
patients who received at least 4 cycles of chemotherapy by either GA or labora-
tory parameters, neither after adjustment for age, comorbidity and performance 
status. When geriatric assessment and laboratory test values were analysed as 
continuous variables, the results did not alter (data not shown). 
The MNA indicated that 23 (42%) patients were at risk for malnutrition or 
were malnourished. Frailty as measured by the GFI, was present in 28 (51%) pa-
tients. The IQCODE was indicative of cognitive decline in 10 (18%) patients. Five 
(9%) patients had a MMSE score of 24 points or lower, indicating serious cogni-
tive dysfunction. The majority of patients had normal values for albumin (67%) 
and creatinine (87%), but abnormal values for haemoglobin (decreased in 78% 
of patients) and LDH (elevated in 84% of patients). 
Table 4 shows mortality according to geriatric assessment and labora-
tory test results. After a mean follow-up of 16.0 months (SD 13.7 months) 41 
of 55 (75%) patients had died. Poor MNA and GFI scores were associated with 
increased mortality, with hazard ratios of 3.05 (95% CI: 1.44–6.45; p =0.004) 
and 3.40 (95% CI: 1.62–7.10; p = 0.001), respectively. When MNA and GFI were 
combined in one multivariate Cox regression model, both tests independently 
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contributed to prognostic value (p =0.04 for MNA and p =0.02 for GFI). 
The Kaplan–Meier curves for survival, according to predefined cut-off 
scores for MNA and GFI, are shown in figure 2. Patients scoring lower than 24 
points for MNA and 4 or more points for GFI showed a significantly higher mor-
tality risk (p = 0.004 and p < 0.001, respectively). The median survival difference 
for the MNA (well nourished vs. malnourished) and GFI (not frail vs. frail) was 
more than 12 months for both tests. 
 Due to logistical problems or patient refusal, only 21 of 39 patients, com-
pleting at least 4 cycles of chemotherapy, could be assessed a second time for GFI 
and MMSE. The median time between the first and the second assessment was 
6 months (range 2-26). No significant changes did occur over time, as shown in 
table 5. When we separately considered physical- and psychosocial items of the 
GFI, items representing physical health deteriorated significantly between the 
two assessments (p = 0.05). 
Discussion
This study demonstrates that indicators of frailty and malnutrition, detected 
with the GFI and MNA respectively, were associated with dismal survival in older 
patients with advanced breast cancer selected for treatment with chemotherapy 
by a medical oncologist. In contrast, cognitive deficits or abnormal laboratory 
values at base line did not predict for mortality. Twenty-five patients (46%) were 
part of a previously published study of 202 patients with a diversity of cancers, 
also showing increased mortality risk with an inferior score for MNA and GFI 
[26]. This tumour specific analysis with a larger number of patients with breast 
cancer confirms the previous findings and adds on the meaning of laboratory 
measurements in this cohort.
In this study, 45% of patients was at risk for malnutrition or malnourished. 
This percentage is higher than the 29% (range 15%–44%), described in an over-
view of 7 studies including 2798 community dwelling elderly persons [33]. Ap-
parently, the presence of malnutrition is either not noticed by oncologists or not 
considered to be a reason to withhold chemotherapy. However, our results dem-
onstrate that underweight or malnourished patients with breast cancer, who are 
treated with chemotherapy, have a limited survival and carry a high risk to die 
during or shortly after chemotherapy. Others have also shown that weight loss 
is associated with a decreased response to chemotherapy and reduced survival 
[11]. A cohort of elderly patients in Southwest France with a variety of cancers 
had shortcomings in MNA in 65% of them, predicting early death [12]. However, 
breast cancer patients were not included in this cohort. In a cohort of elderly 
Asian patients, few of whom had breast cancer, malnutrition was a predictor of 
mortality with a hazard ratio of 1.84 [34].
Half of the breast cancer patients that started with chemotherapy had in-
dicators of frailty and again, these patients had a limited survival and carried a 
large risk to die during, or shortly after, chemotherapy. Our results are in agree-
ment with a study of elderly breast cancer survivors, showing that deficits in 
clinical-, functional- and psychosocial domains are associated with poor treat-
ment tolerance and mortality [8]. Although it has been recognized that frailty 
screening tools have insufficient discriminative power in comparison with full 
CGA to detect all aspects of frailty [35], the GFI has a fair negative predictive value 
(specificity 86%) [36].
MNA as well as GFI were strongly and independently associated with an 
increased mortality risk, but were also strongly intercorrelated. It is therefore 
likely that both tests showed some overlap and therefore both identified frailty 
in elderly breast cancer patients. However, the WHO-performance status also 
showed a correlation with inferior scores for MNA and GFI. Nevertheless, with 
MNA and GFI more in depth information is gathered than is obtained with a WHO 
performance score, thereby elaborating the possibilities to interfere with care 
for the elder patient with these relatively simple tests [4].
 Cognitive deficits, screened with MMSE and IQCODE, were rather rare 
among these elderly patients selected for chemotherapy and did not predict for 
early mortality. Moreover, no significant decline in the MMSE was seen after at 
least four cycles of chemotherapy or at 6 months after the start of chemotherapy 
in the 21 patients with complete data. This is in contrast with a prospective pilot 
study, demonstrating a decline in cognitive function in older breast cancer pa-
tients during adjuvant chemotherapy given for 6 months [37].
In the present study abnormal values for hemoglobin and LDH, which were 
present in respectively 78% and 84% of the patients, were unrelated to mortali-
ty. A study among Asian patients (2% breast cancer) showed that serum albumin 
among other factors was a significant predictor for survival [34]. In our study, GA 
test results and laboratory outcome were not significantly correlated. Our find-
ings therefore suggest that the GA has a stronger predictive power than labora-
tory measurements for mortality in patients aged 70 years or older treated with 
chemotherapy.  
In our study, frailty and malnutrition could not predict for early withdrawal 
of treatment, nor could any other item of the assessment or abnormal laboratory 
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early progression, who could tolerate treatment and had no serious toxicity. It 
can be argued that patients with a decline in MMSE or GFI during chemotherapy 
will not continue onto the fourth course. 
We conclude that deficits with MNA and GFI seem strongly associated with 
increased mortality risk in patients with advanced breast cancer treated with 
chemotherapy. Furthermore, in this descriptive study a simplified GA was more 
prognostic for mortality than laboratory parameters. Our findings are of clini-
cal importance to make treatment decisions and to counsel elderly patients with 
breast cancer. Whether interventions directed at the observed deficits may im-
prove outcomes should be investigated in future prospective studies. Already ini-
tiatives have emerged [12].
values. Apparently, in the selection of older breast cancer patients that may toler-
ate at least four cycles of chemotherapy, this limited geriatric assessment did not 
contribute any extra benefit to the clinical judgment of the participating oncolo-
gists. Others have shown that malnutrition as well as elevated LDH was corre-
lated with grade 3-4 non-haematological toxicity in a cohort of elderly patients, 
treated with chemotherapy, 20% of whom had breast cancer [38]. In a cohort of 
500 patients (11% breast cancer patients), eleven risk factors were identified to 
predict chemotherapy toxicity, among which anemia and renal dysfunction [39].
In the present study, frailty scores with GFI were measured before and af-
ter four cycles of chemotherapy and no major changes in these scores were ob-
served. However, when physical and psychosocial aspects of the GFI were studied 
separately, the physical aspects (ADL and IADL elements) showed a significant 
decline (p=0.05) in the course of treatment. The loss of (instrumental) activities 
of everyday living may severely affect well being of elderly patients and an assis-
tance with these activities may improve their quality of life.
The strong association of frailty indicators and malnutrition with a very 
limited lifespan may have important consequences in daily breast cancer prac-
tice. In the present study, it was shown that a limited geriatric assessment can re-
veal deficits that, although they do not predict for early therapy withdrawal, are 
highly predictive for early mortality. Hence, for patients with frailty indicators at 
the start of chemotherapy, a limited life span must be anticipated and therefore, 
patient preferences with regard to chemotherapy near the end of life should spe-
cifically be addressed [40].
Some limitations need to be discussed. First, the study size is relative small. 
However, in view of the paucity of data in the medical literature on outcome of 
elderly patients related to GA, we consider our data important. Second, all pa-
tients had been considered suitable for chemotherapy by an oncologist, hence 
introducing selection bias. These patients were considered fit for treatment, 
hence decreasing the likelihood of functional or health deficits as compared to 
an unselected elderly population. Nevertheless, despite the selection, GA showed 
discriminative power especially with respect to GFI and MNA. Third, we did not 
adjust for severity of metastatic burden and therefore frailty may have reflected 
tumour load. As a consequence, the association between frailty and mortality 
may have been confounded by tumour load. However, the association of high 
GFI score and mortality remains a valid one. Fourth, we only studied the effect 
of treatment on GFI and MMSE in patients that completed 4 or more cycles of 
chemotherapy. After four cycles of chemotherapy, in every day practice tumor 
evaluations are usually planned [41]. We therefore selected patients without 
Table	  1.	  Baseline	  characteristics	  in	  55	  breast	  cancer	  patients.	  
Age	  (yr)	   Mean	   SD	  
76	   4.80	  
n	   %	  
70-­‐74	  yrs	   26	   47	  
75-­‐79	  yrs	   18	   33	  
80+	  yrs	   11	   20	  
Gender	  
Women	   53	   96	  
Men	   2	   4	  
WHO-­‐performance	  /	  Karnofski	  Index	  	  
0	  -­‐	  (KI	  90-­‐100%)	   27	   48	  
1	  -­‐	  (KI	  70-­‐80%)	   12	   22	  
2	  -­‐	  (KI	  50-­‐60%)	   2	   4	  
3	  -­‐	  (KI	  30-­‐40%)	   2	   4	  
	  Unknown	   12	   22	  
Comorbidity	  (Charlson	  index)	  
None	   18	   33	  
One	   21	   38	  
Two	  or	  more	   14	   25	  
Unknown	   2	   4	  
Chemotherapy	  
Mono-­‐chemotherapy	   32	   58	  
Combination	  of	  chemotherapy	   10	   18	  
Chemotherapy	  +	  trastuzumab	   7	   13	  
Chemotherapy	  +	  bevacizumab	   3	   5	  
Trastuzumab	   1	   2	  
None	   2	   4	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Table	  2.	  Correlation	  between	  geriatric	  assessment	  test	  results	  and	  laboratory	  test	  results	  in	  breast	  
cancer	  patients.	  
Albumin	   Hemoglobin	   Creatinine	   LDH	  
MNA	  
	  	  	  	  Crude	   –0.13	  (P=0.38)	   0.05	  (P=0.72)	   –0.14	  (P=0.32)	   –0.15	  (P=0.30)
	  	  	  	  Adjusted	   –0.12	  (P=0.49)	   0.03	  (P=0.85)	   –0.08	  (P=0.62)	   –0.25	  (P=0.09)
GFI	  
	  	  	  	  Crude	   0.24	  (P=0.11)	   0.09	  (P=0.53)	   –0.09	  (P=0.53)	   0.04	  (P=0.77)
	  	  	  	  Adjusted	   0.22	  (P=0.17)	   0.10	  (P=0.48)	   –0.17	  (P=0.26)	   0.11	  (P=0.44)
IQCODE	  
	  	  	  	  Crude	   0.07	  (P=0.66)	   0.14	  (P=0.33)	   –0.03	  (P=0.84)	   0.20	  (P=0.16)
	  	  	  	  Adjusted	   0.08	  (P=0.62)	   0.15	  (P=0.26)	   –0.02	  (P=0.87)	   0.19	  (P=0.16)
MMSE	  
	  	  	  	  Crude	   –0.02	  (P=0.89)	   –0.16	  (P=0.25)	   –0.04	  (P=0.80)	   –0.01	  (P=0.96)
	  	  	  	  Adjusted	   –0.02	  (P=0.86)	   –0.14	  (P=0.33)	   –0.05	  (P=0.71)	   –0.02	  (P=0.90)
Standardized	  regression	  coefficients	  derived	  from	  a	  linear	  regression	  analysis	  are	  reported	  with	  P	  
values.	  Adjusted	  model:	  adjusted	  for	  age	  and	  comorbidity.	  	  
Table	  3.	  Baseline	  geriatric	  assessment	  and	  laboratory	  test	  results	  according	  to	  the	  number	  of	  cycles	  of	  
chemotherapy	  






odds	  ratio	   p	  
Adjusted	  	  
odds	  ratio	   p	  
Geriatric	  assessment:	   n	  (%)	   n	  (%)	  
MNA:	  
	  	  	  	  well	  nourished	   23	  (59)	   7	  (50)	  
	  	  	  	  malnourished	   16	  (41)	   7	  (50) 0.70	  (0.20-­‐2.37)	   0.56	   1.03	  (0.26-­‐4.16)	   0.96	  
	  GFI:	  
	  	  	  	  not	  frail	  <	  4	   21	  (54)	   6	  (38)	  
	  	  	  	  frail	  ≥	  4	   18	  (46)	   10	  (62) 0.51	  (0.16-­‐1.70)	   0.27	   0.73	  (0.16-­‐2.72)	   0.64	  
IQCODE:	  
	  	  	  	  normal	  risk	  <	  3.3	   32	  (84)	   12	  (75)	  
	  	  	  	  cognitive	  decline	  ≥	  3.3	   6	  (16)	   4	  (25) 0.56	  (0.14-­‐2.35)	   0.43	   0.67	  (0.14-­‐3.29)	   0.62	  
MMSE:	  
	  	  	  	  no	  cognitive	  decline	  ˃	  24	   33	  (87)	   16	  (100)	  
	  	  	  	  cognitive	  dysfunction	  ≤	  24	   5	  (13)	   0	  (0)	   –	   –	  
Laboratory	  tests:	  
	  Albumin:	  
	  	  	  	  normal	  (≥35	  g/L)	   8	  (53)	   24	  (73)	  
	  	  	  	  decreased	  (<35	  g/L)	   9	  (27)	   7	  (47) 2.33	  (0.66-­‐8.32)	   0.19	   2.43	  (0.62-­‐9.51)	   0.20	  
	  Hemoglobin:	  
	  	  	  	  normal	  (≥7.5	  mmol/L)	   9	  (24)	   3	  (19)	  
	  	  	  	  decreased	  (<7.5	  mmol/L)	   29	  (76)	   13	  (81) 1.35	  (0.31-­‐5.80)	   0.69	   1.17	  (0.25-­‐5.56)	   0.84	  
	  Creatinine:	  
	  	  	  	  normal	  (<100	  μmol/L)	   33	  (87)	   14	  (87)	  
	  	  	  	  elevated	  (≥100	  μmol/L)	   5	  (13)	   2	  (13) 1.06	  (0.18-­‐6.13)	   0.95	   1.04	  (0.16-­‐6.88)	   0.97	  
	  LDH:	  
	  	  	  	  normal	  (<250	  U/L)	   5	  (13)	   4	  (25)	  
	  	  	  	  elevated	  (≥250	  U/L)	   34	  (87)	   12	  (75) 2.27	  (0.52-­‐9.86)	   0.28	   2.27	  (0.48-­‐10.66)	   0.30	  
Data	  are	  number	  (percentage)	  and	  odds	  ratio	  for	  receiving	  <4	  vs.	  ≥4	  cycles	  (with	  the	  accompanying	  95%	  
confidence	  intervals)	  with	  p-­‐values	  by	  logistic	  regression	  analysis.	  Because	  of	  the	  empty	  cell	  for	  patients	  
with	  a	  low	  MMSE	  and	  receiving	  less	  than	  4	  cycles	  of	  chemotherapy,	  odds	  ratios	  could	  not	  be	  estimated	  
(p-­‐value	  by	  Fisher’s	  exact	  test).	  
Adjusted	  model:	  age,	  comorbidity	  and	  WHO	  performance	  status.	  	  
Patients	  with	  missing	  data	  are	  excluded.	  
Cut-­‐off	  score	  Hb	  for	  woman	  <7.5	  mmol/l,	  for	  men	  <8.5	  mmol/l.	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Table	  4.	  Risk	  for	  overall	  mortality	  according	  to	  geriatric	  assessment	  and	  laboratory	  test	  results.	  
All	  patients	  (n=55)	  
n	  (%)	   Crude	  hazard	  	  ratio	   p-­‐value	  
Adjusted	  hazard	  
ratio	   p-­‐value	  
Geriatric	  assessment:	  
MNA:	  
	  	  	  	  well	  nourished*	   30	  (55)	   1.0	   1.0	  
	  	  	  	  malnourished	   23	  (42)	   2.85	  (1.48-­‐5.50)	   0.002	   3.05	  (1.44-­‐6.45)	   0.004	  
GFI:	  
	  	  	  not	  frail	  <	  4	   27	  (49)	   1.0	   1.0	  
	  	  	  frail	  ≥	  4	   28	  (51)	   3.46	  (1.69-­‐7.10)	   0.001	   3.40	  (1.62-­‐7.10)	   0.001	  
IQCODE:	  
	  	  	  normal	  risk	  <	  3.3	   44	  (80)	   1.0	   1.0	  
	  	  	  cognitive	  decline	  ≥	  3.3	   10	  (18)	   1.11	  (0.51-­‐2.44)	   0.78	   1.07	  (0.49-­‐2.37)	   0.86	  
MMSE:	  
	  	  	  	  no	  cognitive	  decline	  	  ˃	  24	   49	  (89)	   1.0	   1.0	  
	  	  	  	  cognitive	  dysfunction	  ≤	  24	   5	  (9)	   1.12	  (0.34-­‐3.68)	   0.85	   1.68	  (0.49-­‐5.78)	   0.41	  
Laboratory	  tests:	  
Albumin:	  
	  	  	  	  normal	  (≥35	  g/L)	   32	  (58)	   1.0	   1.0	  
	  	  	  	  decreased	  (<35	  g/L)	   16	  (29)	   1.35	  (0.68-­‐2.70)	   0.39	   1.39	  (0.65-­‐2.98)	   0.40	  
Hemoglobin:	  
	  	  	  	  normal	  (≥7.5	  mmol/L)**	   12	  (22)	   1.0	   1.0	  
	  	  	  	  decreased	  (<7.5	  mmol/L)	   42	  (76)	   1.11	  (0.52-­‐2.35)	   0.80	   0.95	  (0.43-­‐2.12)	   0.90	  
Creatinine:	  
	  	  	  	  normal	  (<100	  μmol/L)	   47	  (86)	   1.0	   1.0	  
	  	  	  	  elevated	  (≥100	  μmol/L)	   7	  (13)	   0.63	  (0.22-­‐1.78)	   0.38	   0.63	  (0.20-­‐1.98)	   0.43	  
LDH:	  
	  	  	  	  normal	  (<250	  U/L)	   9	  (16)	   1.0	   1.0	  
	  	  	  	  elevated	  (≥250	  U/L)	   46	  (84)	   1.18	  (0.46-­‐3.02)	   0.73	   1.24	  (0.48-­‐3.23)	   0.66	  
*:	  Being	  well	  nourished	  was	  defined	  as	  a	  score	  of	  >12	  on	  the	  MNA	  screening	  section	  or	  24-­‐30	  pts	  on	  
the	  assessment	  section.	  	  
**:	  A	  cut	  off	  of	  Hb	  <7.5	  mmol/L	  (12	  g/dL)	  for	  women	  was	  used,	  while	  for	  the	  4	  men	  a	  cut	  off	  of	  Hb	  
<8.5	  mmol/L	  was	  used.	  
Data	  are	  hazard	  ratios	  (with	  the	  accompanying	  95%	  confidence	  intervals)	  with	  p-­‐values	  by	  Cox	  
regression	  analysis.	  Adjusted	  model:	  age	  and	  comorbidity.	  	  
Table	  5	  
Differences	  between	  baseline	  and	  second	  assessment	  of	  MMSE	  and	  GFI	  in	  patients	  treated	  with	  at	  
least	  4	  cycles	  of	  chemotherapy	  (n=21)	  
At	  baseline	   2e	  assessment	   Mean	  change	   SE	   p-­‐value*	  
Median	  	   IQR	   Median	   IQR	  
MMSE	   29	   27-­‐30	   29	   27-­‐30	   0.30	   0.70	   0.67	  
GFI	   2	   1-­‐4	   3	   2-­‐6	   0.86	   0.55	   0.14	  
physical	  part	   1.00	   1.00-­‐3.00	   2.00	   1.00-­‐3.00	   0.71	   0.35	   0.05	  
psychosocial	  part	   1.00	   1.00-­‐2.00	   1.00	   0.00-­‐2.50	   0.19	   0.32	   0.56	  
IQR	  indicates	  interquartile	  range;	  SE,	  standard	  error.	  
*:	  p-­‐value	  from	  t-­‐test	  for	  paired	  samples.	  	  
physical	  part:	  (instrumental)	  activities	  of	  everyday	  living	  (ADL	  and	  IADL	  elements).	  
psychosocial	  part:	  memory,	  mood	  and	  anxiety.	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Kaplan–Meier	  curves	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Abstract
Introduction: In general, geriatric assessment (GA) provides the combined in-
formation on comorbidity and functional, nutritional and psychosocial status 
and may be predictive for mortality outcome of cancer patients. The impact of 
geriatric assessment on the outcome of older patients with colorectal cancer 
treated with chemotherapy is largely unknown. 
Methods: In a prospective study, 143 patients with colorectal cancer who were 
70 years and older were assessed before chemotherapy by Mini Nutritional As-
sessment (MNA), Informant Questionnaire on Cognitive Decline in the Elderly 
(IQCODE), Groningen Frailty Indicator (GFI) and Mini Mental State Examination 
(MMSE).
Results: Fifty-four (38%) patients received adjuvant chemotherapy and 89 
(62%) patients received palliative chemotherapy. Malnutrition and frailty were 
prevalent in 39 (27%, assessed by MNA) and 34 (24%, by GFI) patients, respec-
tively; whereas cognitive impairment was prevalent in 19 (13%, by IQCODE) and 
11 (8%, by MMSE) patients, respectively. In patients with palliative chemothera-
py, poor MNA scores were associated with receiving less than 4 cycles of chemo-
therapy (p = 0.008). Poor MNA and GFI scores were associated with increased 
hazard ratios (HRs) for mortality for patients with palliative chemotherapy: HR 
= 2.76 (95% confidence interval [CI]: 1.60-4.77; p < 0.001) and HR = 2.72 (95% 
CI: 1.58–4.69; p < 0.001), respectively, after adjustment for several clinical pa-
rameters. 
Conclusions: Malnutrition and frailty were strongly associated with an increased 
mortality risk in patients who underwent palliative chemotherapy. Furthermore, 
a poor score on MNA was predictive for less tolerance of chemotherapy. Our find-
ings may help the oncologist in future decision making and advice for elderly 
patients with colorectal cancer.
Introduction
Colorectal cancer is one of the most frequent types of cancer in Western coun-
tries, and the incidence and mortality of patients increases with age. In the Neth-
erlands, 54% of patients diagnosed with colorectal cancer and 66% of patients 
who died of colorectal cancer were above 70 years of age [1]. These data are al-
most similar to data from the United States [2]. In the past two decades, patients 
with colorectal cancer showed a substantial improvement in survival, which has 
been attributed largely to the increased administration of chemotherapy. How-
ever, this increased survival – and the increased use of chemotherapy – was less 
pronounced in elderly patients in comparison with younger patients [3–5]. The 
process of aging is associated with a loss of functional reserve of multiple organ 
systems, increased prevalence of chronic diseases and enhanced susceptibility 
to stress [6]. This process occurs at a different pace in individuals resulting in 
a large heterogeneity within the elderly patients with cancer group. For elder-
ly patients, cancer treatments should be adapted to life expectancy and the in-
creased risk of toxicity. Therefore, ‘functional age’ rather than chronological age 
is important for cancer treatment planning. Geriatric Assessment (GA) may be a 
useful tool in the management and follow-up of elderly patients with cancer. A 
GA provides the combined objective and subjective information on comorbidity, 
nutrition, cognition, functional and psychosocial status [6, 7]. Previous studies 
showed that several GA domains were associated with poor treatment tolerance 
and poor survival, independent of age and stage of disease [8, 9]. However, stud-
ies of GA in cohorts comprising of only patients with colorectal cancer are scarce 
[10]. In the present study, we have performed a GA in 143 patients with colorec-
tal cancer aged 70 years and above, with the aim to assess its predictive value for 
tolerance and feasibility of treatment with adjuvant and palliative chemotherapy.
Patients and Methods
Patients
Between May 2004 and February 2010, four hospitals in the western part of the 
Netherlands participated in a geriatric oncology study. Because of time needed 
for training of personnel in the technique of GA, the hospitals started at differ-
ent time points. Patients of 70 years of age and older and regarded eligible for 
chemotherapy treatment by their medical oncologist, were prospectively includ-
ed. Common eligibility criteria used by medical oncologists included adequate 
performance status by Eastern Cooperative Oncology Group (ECOG 0-3), suffi-
cient organ function and absence of severe comorbidity. For the current study 
we selected all patients (n = 143) diagnosed with colorectal cancer and treated 
with chemotherapy. Of these, 60 patients (42%) were also included in a previ-
ous analysis with several types of cancer combined [11]. According to the Dutch 
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national evidence-based guidelines for colon cancer, adjuvant chemotherapy is 
recommended for patients with colon cancer with lymph node metastases (stage 
III) and for patients with high risk stage II colon cancer [12]. Patients with colon
and rectal cancer with distant metastases usually received chemotherapy with
palliative intent and at least four cycles of chemotherapy were considered to be
necessary to reach the palliative goal of treatment. Whether the administration
of chemotherapy was ‘adjuvant’ or ‘palliative’ was left to the discretion of the
oncologist.
Geriatric Assessment (GA) and Clinical Data 
A GA was performed by specially trained nurses before the start of chemother-
apy treatment. The used tests with their accompanying cut-off points have been 
described previously [11]. In brief (Table 1): 
• Mini Nutritional Assessment (MNA) [13], makes it possible to identify
patients at risk for malnutrition, before severe changes in weight or
albumin levels occur [14];
• Groningen Frailty Indicator (GFI) [15] screens on physical, cognitive, social
and emotional items (see Appendix);
• Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) [16],
screens for cognitive decline by interviewing family members or care
givers, for which we used the short Dutch translation IQCODE-N [17];
• Mini Mental State Examination (MMSE) [18] is considered to be a screening
test for detecting current cognitive dysfunction.
Patients completing at least four cycles of chemotherapy were as-
sessed a second time using the GFI and MMSE at the end of chemotherapy or at 
six months after the start of chemotherapy. The number of comorbidities and 
number of regularly used medications, performance status according to the 
Eastern Cooperative Oncology Group (ECOG) and laboratory values (serum-al-
bumin, -creatinine, -lactate dehydrogenase (LDH) and hemoglobin before start 
of chemotherapy) were collected from the medical records of patients, as well 
as chemotherapy regimen, number of cycles, toxicity and mortality. Comorbidity 
was recorded according to the Charlson Index [19]. The vital status of patients 
was cross-checked with the municipal registry at the end of the data collection 
period. 
Statistical Analysis 
Categorical variables are presented as numbers and percentages, and chi-square 
tests were used to compare subgroups. Continuous variables were presented as 
means ± standard deviations (SD) and subgroups were compared by unpaired 
t-tests. In the right-skewed LDH-values, a log-transformation was performed
before analyses. Chi-square and Fisher Exact tests were used to analyze the as-
sociations between dichotomized GA-variables and receiving more or less than
four chemotherapy cycles. In multivariate logistic regression analyses these as-
sociations were adjusted for sex, age, number of co-morbidities and laboratory
values (hemoglobin, serum-creatinine and LDH levels). Patients receiving adju-
vant chemotherapy and those receiving palliative chemotherapy treatment were
analysed separately. Changes in GA-scores over time (before chemotherapy and
after at least four cycles) were analysed using the paired sample t-test. Survival
probabilities were estimated using Kaplan Meier curves and the log-rank test
was used to test for differences in survival rates among subgroups of GA. Cox
proportional hazard analyses were used to estimate hazard ratios for mortality
for each of the four GA tests, adjusted for sex, age, number of co-morbidities and
laboratory values (hemoglobin, serum-creatinine and LDH). The analyses were
repeated for adjustment on performance status, number of medications and al-
bumin values, because of a larger number of missing values for these variables.
A final Cox proportional hazard analysis was performed to assess independent
mortality risks for the MNA and GFI scores. A p-value less than 0.05 was consid-
ered significant. SPSS 17.0 for Windows® (SPSS inc. Chicago, IL) was used for
statistical analyses.
Results
Patient and Tumour Characteristics
Baseline characteristics of all 143 elderly patients with colorectal cancer are 
shown in Table 2. The mean age was 75 years (range 70-92), 12% of patients 
were 80 years and older. Forty-nine percent of patients had multiple comorbidi-
ties (mean = 1.6 ± 1.3). Most common were hypertension (35%), cardiac diseases 
(30%), chronic obstructive pulmonary disease (COPD) (22%), diabetes mellitus 
(20%), vascular diseases (17%), and previous malignancies (13%). With respect 
to polypharmacy, 50% of patients used four or more kinds of medication (mean 
= 3.7 ± 2.8). According to the ECOG functional score, at least one-fifth of patients 
were functionally restricted. However, a functional performance score was not 
documented in 11% of patient records. Seventeen percent of patients had a di-
agnosis of rectal cancer. Fifty-four patients (38%) received chemotherapy with 
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curative intent (adjuvant: stage II-III), of whom 96% were patients with colon 
cancer. Another eighty-nine patients with colorectal cancer (62%) were treated 
with palliative intent (synchronous or metachronous distant metastases). Base-
line characteristics of adjuvant or palliatively treated patients were significantly 
different with respect to sex, hemoglobin- and LDH-values.
Geriatric Assessment 
Assessment showed that 28% of patients were at risk for malnutrition or mal-
nourished (measured by MNA). Frailty, measured by the GFI, was present in 24% 
of patients, 13% of patients were suspect for cognitive decline (IQ-code), and 8% 
had serious cognitive dysfunction (measured by MMSE). Of patients with pallia-
tive chemotherapy, 33% were at risk for malnutrition, versus 20% of patients 
with adjuvant chemotherapy (p = 0.10) (Table 1).
Chemotherapy Treatment 
The majority of elderly patients received poly-chemotherapy, mainly capecit-
abine-oxaliplatin (CapOx; 39%) or fluorouracil-leucovorin-oxaliplatin (FOL-
FOX4; 13%). Forty-two percent of patients received mono-chemotherapy, either 
capecitabine (36%) or fluorouracil-leucovorin (6%). Of adjuvant treated pa-
tients, 48% received poly-chemotherapy, compared to 64% of palliatively treated 
patients (p = 0.06). In addition, 20% of palliatively treated patients received bev-
acizumab. Mean number of chemotherapy cycles was 6.2 (±4.4, range 1-29), and 
were similar for adjuvant and palliatively treated patients (6.2 and 6.3, respec-
tively; p = 0.41). Seventy-three percent of patients received four or more cycles 
of chemotherapy. Fifteen percent of patients received their chemotherapy ac-
cording to protocol. Deviations of protocol included a lower dose or medication 
change (16%), a delay and/or discontinuation of chemotherapy (47%) or both 
(37%). The majority of patients (78%) experienced one or more toxicities due to 
their chemotherapy. Most important toxicities were (poly)neuropathy (29%), di-
arrhoea (23%), and fatigue (14%). Patients treated with adjuvant chemotherapy 
seemed to experience slightly more haematological toxicities (9%) than patients 
treated with palliative intent (2%; p = 0.06). In palliatively treated patients, pa-
tients at risk of malnutrition or who were malnourished (MNA < 24) less fre-
quently completed four or more cycles of chemotherapy than well nourished 
patients (p = 0.008; Table 3). This finding persisted after adjustment for age, 
sex, number of co-morbidities and laboratory values (odds ratio [OR] for ≥4 vs 
<4 cycles = 0.29, 95% Confidence Interval [CI]: 0.11-0.81). In 62 patients, a sec-
ond assessment of MMSE and GFI was performed. Compared to baseline scores, 
there was a significant deterioration in GFI-scores in patients receiving palliative 
chemotherapy (mean change-0.86; standard error [SE] 0.32; p = 0.01). When we 
sub-classified GFI in a physical- and psychosocial part, deterioration was found 
in the physical part (p = 0.001) but not in the psychosocial part (p = 0.85). 
Risk of Mortality 
During a median follow-up of 15 months (range 0.5-62) a total of 76 patients 
(53%) died. Among patients receiving palliative chemotherapy, those with poor 
MNA- and GFI-scores showed significantly higher hazard ratios (HRs) of mortal-
ity (p-values <0.001; Table 4). The median survival difference for the MNA (well 
nourished vs. malnourished) and GFI (not frail vs. frail) was 9 and 10 months, 
respectively (Fig. 1). The increased risk of mortality for palliatively treated pa-
tients with poor baseline MNA- and GFI-scores persisted after adjustment for 
age, sex, number of comorbidities, and laboratory values of hemoglobin, creati-
nine and LDH (hazard ratio [HR] = 2.76, 95% CI: 1.60-4.77 and HR = 2.72, 95% 
CI: 1.58-4.69, respectively; Table 4). In sensitivity analyses, in which we addition-
ally adjusted for performance status, numbers of medications and serum albu-
min, results remained similar (data not shown). In a multivariate model with 
both MNA and GFI, the risk of mortality was significant for patients with poor 
baseline MNA-scores (HR = 2.54, 95% CI: 1.49-4.33), and borderline significant 
for patients with poor GFI-scores (HR = 1.66, 95% CI: 0.94-2.94). No interaction 
effect was found (i.e. MNA*GFI: p for interaction 0.40).
Discussion 
Our study reports the results of GA in 143 patients aged 70 years and older with 
colorectal cancer who received chemotherapy with either adjuvant or palliative 
intent. We found that in palliatively treated patients, poor MNA scores were asso-
ciated with less tolerance of chemotherapy, and GFI-test scores of physical func-
tioning deteriorated over time. Furthermore, poor baseline scores on MNA and 
GFI were associated with an increased mortality risk in case of chemotherapy 
with palliative intent. This tumour specific analysis with a larger number of el-
derly patients with colorectal cancer extends our previous findings among pa-
tients with different kinds of tumours combined [11]. Comorbidity, disability and 
geriatric syndromes were found prevalent in many elderly patients with colorec-
tal cancer [20]. In two recent studies, various geriatric assessment variables were 
identified to be associated with severe chemotherapy toxicity [21, 22], independ-
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ent from laboratory test values, patient, tumour and treatment characteristics. 
Common predictive geriatric parameters seem to encompass decreased physical 
activity, social activity and nutrition status. In a previous study, activities of daily 
living (ADL) impairment and malnutrition were also independently associated 
with changes of the cancer treatment plan [23]. With increasing age, comorbidi-
ties and general aspects of ageing increase the risk of toxicities of chemotherapy 
and competing causes of death gain importance. The majority of elderly patients 
may benefit from chemotherapy treatment, but therapeutic margins are small in 
many of them, and require a careful evaluation of biological and clinical markers 
of aging, aggressiveness of the tumour, the biological and psychosocial costs of 
treatment and its perception by the patient [24]. The administration of chemo-
therapy increases survival in the elderly in the same way as in younger patients 
[25, 26] and there is no evidence that the susceptibility of colon cancer to chemo-
therapy differs in younger and older patients [27]. However, scientific evidence 
from prospective clinical trials taking into account the heterogeneity of elderly 
patients with colorectal cancer is scarce [10, 28] and therefore our knowledge of 
the performance of the appropriate therapeutic strategies in this age group is of-
ten severely limited [10]. Chronological age as an indicator for health risks in the 
elderly is not a very sensitive and specific risk marker. The concept of frailty may 
be more valuable [29]. A geriatric screening should distinguish between fit and 
frail patients, of which the first group of patients should receive standard adult 
chemotherapy treatment [26, 27, 30, 31] while the latter may require a more in-
depth evaluation of their functional reserve and a tailored chemotherapy treat-
ment plan [9, 32, 33].
In two recent studies of the prognostic value of GA in elderly patients with 
cancer, nutritional status was found to be predictive of early mortality and over-
all survival in multivariate models [34,35]. The prevalence of (or risk of) mal-
nutrition in our study was almost similar to an overview of 7 studies with 2798 
community dwelling elderly persons assessed by MNA (29%, range 15%–44%) 
[13]. Our study showed that malnutrition was associated with poor tolerance of 
chemotherapy and increased mortality in elderly patients with colorectal cancer 
treated with palliative intent. Adjustment for several clinical parameters did not 
alter these results. Compared to frailty (by GFI), malnutrition seemed to be the 
stronger predictor of mortality. More research is needed in palliatively treated 
patients concerning the relation between nutritional status, tumour behaviour, 
the type of chemotherapy and mortality. Furthermore, in malnourished patients 
it is unclear whether they benefit more from palliative chemotherapy than from 
comprehensive palliative care. In adjuvant treated patients, the number of pa-
tients appeared too small to show significant associations.
In our study physical and psychosocial frailty (assessed by GFI) was as-
sociated with an about 2.5 times increased mortality risk in patients treated 
with palliative intent. In addition, especially the physical aspects (ADL and in-
strumental activities of daily living [IADL] variables) showed a clear decline af-
ter at least four cycles of chemotherapy. This probably shows that tolerance to 
chemotherapy plays an important role for elderly patients with colorectal can-
cer. A loss of (instrumental) activities of everyday living may have a great im-
pact on their quality of life. Therefore, in future studies of GA a more sensitive 
ADL/IADL test may be used to assess a possible decline of physical functioning 
[36, 37].
The MMSE and IQCODE did not differentiate between patients who under-
went less than four cycles of chemotherapy or four or more cycles and did not 
clearly predict mortality. Moreover, we found no decline in the MMSE-scores after 
at least four cycles of chemotherapy. This is in agreement with a meta-analysis 
of 16 studies in which small to moderate but non-significant negative effects of 
chemotherapy were found in various domains of cognitive function [38]. There 
are some limitations that need to be discussed. First, the patients in our study un-
derwent GA after the oncologist decided they were eligible for receiving chemo-
therapy, which may have introduced some selection bias. The assessed patients 
may have relatively better GA-scores. Compared to an Asian study in an outpa-
tient geriatric oncology clinic, our study comprised of few patients with ECOG 
≥ 2 [35]. Furthermore, population-based studies showed that the proportion of 
elderly patients who received chemotherapy was lower in patients with stage 
III colon cancer than in patients with colorectal cancer with distant metastases 
[4, 5]. Therefore, selection bias may be more apparent in elderly patients with 
adjuvant chemotherapy. Despite this bias, we consider our findings as valid and 
informative. Even after selection by oncologists, the GA revealed considerable 
frailty as assessed with the GFI and MNA. Second, our finding of the increased 
risk of mortality associated with higher levels of frailty at baseline may be partly 
explained by residual confounding factors like alcohol consumption, smoking and 
socio-economic status. Furthermore, we did not screen for geriatric syndromes 
like depression, delirium, incontinence, falls, dizziness and syncope as was done 
by others [9], and unfortunately serum albumin values and performance status 
were lacking in one-tenth of our patients. However, contrary to most studies of 
GA our patient group was homogeneous with respect to tumour type and we per-
formed analyses separately in adjuvant and palliatively treated patients. Third, 
the decline in GA test results was likely underestimated. To minimize the bur-
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den of testing, only patients who completed at least four cycles of chemotherapy 
were re-assessed with GFI and MMSE. However, many patients who received 
four or more chemotherapy cycles refused to complete a second assessment and 
patients with better GA scores were more likely to remain included, leading to 
some attrition bias. Furthermore, the course of the nutritional status of our pa-
tients during chemotherapy treatment was not assessed. At last, MNA as well as 
GFI were independently associated with an increased mortality risk. However, 
MNA and GFI correlated moderately (Sr = 0.43), suggesting that the tests showed 
some construct overlap and therefore partially identified the same group of frail 
patients. However, the ECOG-performance status also showed correlation with 
inferior scores for MNA and GFI. Nevertheless, with MNA and GFI more in depth 
information is gathered than is obtained with ECOG performance score, thereby 
augmenting the possibilities to interfere with care for the elder patient [39]. 
Our findings may help to better identify those patients with colorectal can-
cer with poor prognosis, which is of clinical importance for counselling, psycho-
social support, and management of elderly patients receiving chemotherapy 
for colorectal cancer. Specific and timely nutritional interventions may improve 
nutritional status, tolerability of chemotherapy and survival in some elderly pa-
tients, which is also suggested by other investigators [34].
Conclusion
In conclusion, poor scores for MNA and GFI were independently associated with 
increased hazard ratios for mortality, and poor MNA-scores were predictive for a 
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Table	  2	  –	  Baseline	  characteristics	  of	  143	  patients	  with	  colorectal	  cancer.	  
Total	   Adjuvant	   Palliative	  
N	  =	  143	  (%)	   N	  =	  54	  (%)	   N	  =	  89	  (%)	   p-­‐value	  
Sex	  –	  No.	  (%)	   0.02	  
male	   84	  (59)	   25	  (46)	   59	  (66)	  
Female	   59	  (41)	   29	  (54)	   30	  (34)	  
Age	  –	  No.	  (%)	   0.28	  
70-­‐74	  years	   68	  (48)	   29	  (54)	   39	  (44)	  
75-­‐79	  years	   57	  (40)	   21	  (39)	   36	  (40)	  
≥	  80	  years	   18	  (12)	   4	  (7)	   14	  (16)	  
ECOG	  Performance	  Status	  –	  No.	  
(%)	  
0.15#	  
0	   98	  (69)	   38	  (84)	   60	  (73)	  
1	   26	  (18)	   7	  (16)	   19	  (23)	  
2	  +	   3	  (2)	   0	   3	  (4)	  
Unknown	   16	  (11)	   9	  (-­‐)	   7	  (-­‐)	  
No.	  of	  Comorbid	  Organ	  Systems	  –	  
No.	  (%)	  
0.66	  
0	   31	  (22)	   12	  (22)	   19	  (21)	  
1	   42	  (29)	   18	  (33)	   24	  (27)	  
2	  +	   70	  (49)	   24	  (44)	   46	  (52)	  
Number	  of	  Medications	  –	  No.	  (%)	   0.65#	  
0	   20	  (14)	   9	  (18)	   11	  (12)	  
1-­‐3	   49	  (34)	   18	  (35)	   31	  (35)	  
4	  +	   71	  (50)	   24	  (47)	   47	  (53)	  
Unknown	   3	  (2)	   3	  (-­‐)	   0	  
Tumour	  Location	  –	  No.	  (%)	   0.001	  
Colon	   119	  (83)	   52	  (96)	   67	  (75)	  
Rectum	   24	  (17)	   2	  (4)	   22	  (25)	  
Albumin	  (g/L)$	  –	  Mean	  ±	  SD	   37.1	  ±	  9.9	   37.2	  ±	  6.9	   37.1	  ±	  11.5	   0.18	  
Hemoglobin	  (Hb,	  mmol/L)	  –	  Mean	  ±	  
SD	  
7.6	  ±	  0.87	   7.4	  ±	  0.79	   7.7	  ±	  0.89	   0.02	  
Creatinine	  (μmol/L)	  –	  Mean	  ±	  SD	   87.2	  ±	  22.0	   86.7	  ±	  17.5	   87.5	  ±	  24.6	   0.64	  
LDH	  (U/L)&	  –	  Median	  (P25-­‐P75)	   319	  (208-­‐402)	   239	  (174-­‐367)	   357	  (250-­‐489)	   <	  0.001	  
Data	  are	  presented	  as	  numbers	  and	  percentages.	  ECOG	  denotes	  Eastern	  Cooperative	  Oncology	  
Group.	  LDH	  denotes	  lactate	  dehydrogenase.	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Figure	  1.	  
Fig.	  1	  –	  Kaplan–Meier	  curves	  of	  overall	  survival	  in	  143	  patients	  with	  colorectal	  cancer	  
according	  to	  categories	  of	  [A]	  Mini	  Nutritional	  Assessment	  (MNA)	  and	  [B]	  Groningen	  Frailty	  
Indicator	  (GFI).	  P-­‐values	  by	  log-­‐rank	  tests	  separately	  for	  patients	  undergoing	  
adjuvant/curative	  chemotherapy	  (n	  =	  54)	  and	  palliative	  chemotherapy	  (n	  =	  89).	  MNA	  data	  
was	  missing	  for	  7	  patients	  at	  baseline,	  whereas	  there	  were	  no	  missing	  data	  for	  the	  GFI.	  
Months






























Adjuvant 50 47 40 32 27
Palliative 87 64 42 20 12
No. at risk
Adjuvant 54 51 44 35 30
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Abstract
The age-adjusted International Prognostic Index (IPI) is an important prog-
nostic factor for patients with non-Hodgkin lymphoma (NHL). We investigated 
whether a geriatric assessment (GA) is of additional prognostic value in NHL. 
In this prospective cohort study of 44 patients aged 70 years or older with NHL 
receiving R-CHOP, a GA was administrated before the start of chemotherapy. GA 
was composed of Mini Nutritional Assessment (MNA), Groningen Frailty Indica-
tor (GFI), Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE), 
Mini Mental State Examination (MMSE) and levels of albumin, creatinine, lactate-
dehydrogenase (LDH) and hemoglobin. Multivariate analyses were performed 
using logistic regression and the cox regression model. After adjustment for sex, 
age, comorbidity and univariate laboratory values with p ≤ 0.1, abnormal MNA 
and GFI scores and low hemoglobin level were associated with not being able 
to complete the intended chemotherapy: odds ratio (OR) 8.29 (95% confidence 
interval [CI]: 1.24-55.6; p = 0.03), 9.17 (95% CI: 1.51-55.8; p = 0.02) and 5.41 
(95% CI: 0.99-29.8; p = 0.05), respectively. Adjusted for sex, age, comorbidity, 
age-adjusted IPI and univariate laboratory values with p ≤ 0.1, frailty by GFI and 
low hemoglobin were associated with worse survival with hazard ratio (HR) of 
mortality of 2.55 (95% CI: 1.07-6.10; p = 0.04) and 4.90 (95% CI: 1.76-13.7; p = 
0.002), respectively. We conclude that (risk of) malnutrition, measured with the 
MNA, frailty, measured with the GFI, and low hemoglobin level had additional 
predictive value for early treatment withdrawal, and GFI and hemoglobin were, 
independent of the age-adjusted IPI, predictive for an increased mortality risk.
Introduction
Non-Hodgkin lymphomas (NHL) form the largest group of malignancies (40-
50%) within the range of hemato-oncological diseases [1, 2]. The median ages 
of diagnosis and death are 66 and 75 years, respectively [3, 4]. Aggressive B-cell 
NHL is the most common lymphoid tissue neoplasm in adults and occurs fre-
quently in elderly patients [5]. The incidence steadily increases with age [6]. 
Since the 1970s the first generation chemotherapy regimen with cyclo-
phosphamide, doxorubicin, vincristine and prednisone (CHOP) remains the best 
available treatment after comparison with second generation regimens, as was 
shown in a randomized trial of patients with advanced stage aggressive B-cell 
NHL [7]. Rituximab has been added to the standard treatment since more than 
ten years (R-CHOP) [8]. In patients over 80 years old a reduced dose of CHOP 
with rituximab (R-miniCHOP) has been suggested as new standard treatment 
[9].
The process of aging is associated with increasing functional impairment 
and increasing comorbidity [10] and age is a well-established prognostic factor 
for NHL. In 1993, the International NHL Prognostic Factors Project developed the 
International Prognostic Index (IPI) with the risk factors age, stage, performance 
status, lactate dehydrogenase (LDH) and extranodal sites of disease. The age-
adjusted IPI, originally developed for patients of 60 years and younger but also 
shown to be applicable for older age groups, is defined by the risk factors stage, 
performance status and LDH [11]. 
A comprehensive geriatric assessment (GA) can be a useful tool in the man-
agement and follow-up of elderly patients [12-14]. A comprehensive GA provides 
information on the functional status of older cancer patients with the combined 
objective and subjective information on comorbidity, functional-, nutritional-, 
and psychosocial status. Several studies have been published underscoring the 
usefulness of some form of GA [9, 15-18]. Application of GA in a cohort of 143 
patients with NHL demonstrated the importance of instrumental activity of daily 
living (IADL) score and comorbidity as prognostic variables for survival [18]. The 
R-miniCHOP study showed that a decreased serum albumin was an important
risk factor for survival [9] and this was also found in a study among NHL patients
over 90 years of age [19]. In a cohort of 348 elderly patients, among whom 105
patients with non-Hodgkin lymphoma, male sex, advanced stage, poor MNA score
and a prolonged timed get up and go (GUG) test were associated with a higher
risk of mortality [16]. Tailored treatment based on GA identified three groups
in a study of 91 elderly patients with diffuse large B-cell lymphoma (DLBCL): fit
patients, patients with comorbidity, and frail patients. The overall survival of fit
patients was significant better in comparison with the other two groups [17].
Finally, in a study of 100 elderly NHL patients, three subgroups could be char-
acterized by GA: fit, unfit and frail. They received R-CHOP mitigated in dose and
drugs according to co-morbidity, activities of daily living (ADL) and IADL scores,
resulting in manageable toxicity and excellent outcome [15].
The aim of the present prospective study is to investigate the prognostic 
value of GA in addition to the age-adjusted IPI for patients aged 70 years and 
older diagnosed with non-Hodgkin lymphoma and treated with R-CHOP. 
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Patients and Methods
Study design
This prospective cohort study involved patients aged 70 years or older (n = 90) 
with non-Hodgkin lymphoma who were considered fit to be treated with chemo-
therapy by their hematologist. Patients were recruited between May 2004 and 
February 2010 from three general and one university hospital. To investigate a 
homogeneous patient population we selected all patients with DLBCL and fol-
licular lymphoma grade III who were treated with R-CHOP (n = 44). The exclud-
ed 46 patients (of whom 12 patients with DLBCL) who were treated with other 
schemes than the R-CHOP regimen were comparable for the following baseline 
characteristics compared to the included patients: male gender (53% vs 43%; P 
= 0.39), age (mean = 77 yr vs 78 yr, P = 0.48), Karnofsky Index (median = 0, vs 
median = 0; p = 0.56), age-adjusted IPI of 2 to 3 (55% vs 46%; p = 0.47) 
and 2 or more comorbidities (53% vs 46%; p = 0.82), see figure 1. We in-
cluded follicular lymphoma grade III patients, because usually these pa-
tients receive the same treatment regimens as patients with DLBCL, re-
sulting in improved survival [20, 21]. One patient was assessed twice, at 
the first manifestation of DLBCL and at a relapse three-and-a-half years 
later. In the survival analysis only data on the first manifestation was used 
(n = 43). Ten patients were included in a previous analysis with several types of 
cancer combined [22].
Geriatric Assessment
Before participating in the study, informed consent was obtained. At baseline, the 
patients were prospectively assessed by trained nurses using the following tests: 
Mini Nutritional Assessment (MNA) [23], Groningen Frailty Indicator (GFI) [24], 
Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) [25], and 
Mini Mental State Examination (MMSE) [26]. There were data missing for MNA 
(n = 2), but these could be reliable categorized based on the available data. The 
GFI, IQCODE, MMSE and MNA tests were pragmatically selected for performing a 
GA with a minimum of overlap between the domains and a maximum of 45 min-
utes to complete the interview. The MNA combines anthropometric measures 
with risk factors for malnutrition (disease, mental health and functional depend-
ency, ingestive behaviour and subjective health) [27]. The MNA is a stepwise test 
and is comprised of two sections. First, there is the screening section (6 items). 
When the score is less than 12 points, indicating the possibility of malnutrition, 
the assessment section (12 items) is filled in. The GFI has been developed as 
a simple screening instrument for frailty and a case finder for elderly patients 
who would benefit from integrated (geriatric) care. The GFI consists of items on 
physical, cognitive, social and emotional functioning with a maximum score of 15 
points. Patients scoring 4 or more points are considered to be frail (appendix). 
The IQCODE screens for cognitive decline over the last 10 years by interviewing 
family members or care givers, for which we used the short Dutch translation 
IQCODE-N [28]. The 16 items are rated on 5-point Likert scales, ranging from 
much improved to much worsened, and the average score is used in the analyses. 
In clinical settings, a cut-off score of 3.31 reasonably balances between sensitiv-
ity and specificity on the outcome of cognitive decline with higher scores indicat-
ing poorer cognition. The MMSE has been tested extensively and is considered 
to be a standard test for current cognitive function. Sensitivity of the MMSE for 
cognitive dysfunction is 88%, the specificity is 93% [29]. The cut-off point for 
poor cognition is 24 points or less. If indicated by the test results, a dietician or 
a geriatrician was consulted because of the importance of corrective action [30].
Laboratory values and other variables 
Laboratory assessment before start of chemotherapy included serum albumin 
(cut-off < 35g/L); hemoglobin (cut-off < 6.8 mmol/L); creatinine (cut-off ≥ 100 
μmol/L) and LDH (cut-off ≥ 250 U/L). These laboratory values were recorded 
retrospectively from the medical files by a trained registrar. Co-morbidity was 
registered by Charlson’s comorbidity scoring system [31]. Another way of reg-
istration for comorbidity is possible with the Cumulative Illness Rating Scale 
for Geriatrics (CIRS-G), but we did not choose for this system because it is more 
time consuming. Of course, we did not count NHL as comorbidity to calculate the 
Charlson comorbidity index, because NHL was the index disease. Performance 
status was registered by the scoring system ECOG/WHO or Karnofsky (KI) [32, 
33]. Toxicity of chemotherapy in patients with early treatment withdrawal was 
retrospectively retrieved from the medical files and was scored according to the 
Common Terminology Criteria of Adverse Events (CTCAE) v. 4.03 [34]. 
Treatment and follow-up
According to current guidelines, patients with stage I (Ann Arbor stage [35]) 
were planned to be treated with at least three cycles of R-CHOP and patients with 
stages II-IV at least six cycles (according to scheme). When less than the number 
of cycles according to scheme were administered, this was considered as early 
treatment withdrawal.
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The duration of follow-up was defined as the time between the date of the 
first GA until 1st January 2013 or the date of death. Vital status was checked with 
the nationwide population registries network at the end of the study period. 
These registries provide complete coverage of all deceased Dutch citizens. The 
cause of death was retrospectively retrieved from the medical files. Repeated as-
sessment by GFI and MMSE was scheduled at the end of chemotherapy or at six 
months after start of chemotherapy.
Statistical analysis
Categorical variables are presented as numbers with percentages, chi-square 
tests were used to compare subgroups. We dichotomized stage in stage I and 
stage II-IV. Because of the small numbers of patients with an age-adjusted IPI of 
low risk and high risk we dichotomized the age-adjusted IPI in two categories: 
0 and 1 risk factor (n = 24) versus 2 and 3 risk factors (n = 20). We also dichoto-
mized MNA, GFI, IQ-code, MMSE, albumin, hemoglobin, creatinine and LDH ac-
cording to the given cut-off scores.
To assess the association between GA scores and early treatment with-
drawal, odds ratios (ORs) with 95% confidence intervals (CI) with p-values were 
estimated by univariate- and multivariate logistic regression analysis. Survival 
probabilities were estimated using Kaplan Meier curves and the log-rank test 
was used to test for differences in survival rates among subgroups of MNA, GFI, 
serum albumin, hemoglobin, serum creatinine, serum LDH and age-adjusted IPI. 
Association between baseline geriatric assessment scores and survival were es-
timated by hazard ratios (HRs) by univariate- and multivariate Cox proportional 
hazard analysis. Multivariate logistic regression models were adjusted for sex, 
age, comorbidity and univariate laboratory values with p ≤ 0.1. The multivariate 
Cox regression models were adjusted for sex, age, comorbidity, age-adjusted IPI 
and univariate laboratory values with p ≤ 0.1. Changes in GA-scores over time 
were analysed using the paired sample t-test. A p-value lower than 0.05 was con-
sidered significant. IBM-SPSS statistics 21 for Windows® (IBM-SPSS inc. Chicago, 
IL.) was used for statistical analyses.
Results
Characteristics and scores of the geriatric assessment are shown in table 1. The 
mean score (± SDs) of the MNA screening was 10.5 ± 2.6 and for the MNA assess-
ment 13.6 ± 1.8. The mean scores of GFI, IQCODE and MMSE were 3.10 ± 0.14, 3.6 
± 2.7 and 27.7 ± 1.9 respectively. 
Table 2 shows the baseline characteristics of the 44 patients treated with 
R-CHOP chemotherapy, of whom 43% were men. The mean age was 78 years
(range 70–86), 46% were 80 years or older. The majority of patients either be-
longed to the low-intermediate risk category of the age-adjusted IPI (one risk
factor) or to the high-intermediate risk category (two risk factors). No co-mor-
bidities were documented in 11 (22%) patients. Most patients had diffuse large
B-cell lymphoma (91%). The median follow-up was 46 months (range 0–101).
At baseline, 15 patients (34%) were at risk for malnutrition or were mal-
nourished and 19 patients (43%) had a GFI score of four or more points. Albu-
min was low in 14 (32%) patients and low hemoglobin was seen in 11 (25%) 
patients. There were only a few patients with cognitive impairment by IQ-CODE 
and MMSE, 11% and 5% respectively. Creatinine and LDH were elevated in 13 
(30%) and 38 (86%) patients respectively (Table 3).
Thirty-two (73%) patients received chemotherapy according to the proto-
col. Twelve (27%) patients failed to complete the intended number of chemo-
therapy cycles: 11 with stage II-IV and 1 with stage I. The most important reasons 
for early withdrawal were toxicity of chemotherapy (50% of cases), insufficient 
response, worsening of comorbidity and general condition.
Table 4 shows the association between geriatric assessment scores and lab-
oratory variables for early treatment withdrawal. In the univariate analysis poor 
MNA and GFI scores, and a decreased value of hemoglobin were associated with 
early treatment withdrawal. In multivariate analysis, after adjustment for sex, 
age, comorbidity and univariate laboratory values with p ≤ 0.1, poor MNA and 
GFI scores and low hemoglobin level maintained association with early treat-
ment withdrawal: ORs 8.29 (95% CI: 1.24-55.6; p = 0.03), 9.17 (95% CI: 1.51-
55.8; p = 0.02) and 5.41 (95% CI: 0.99-29.8; p = 0.05), respectively. According 
to the CTCAE, half of the patients with early treatment withdrawal (n = 12) had 
hematological toxicity grade 3 to 4. All 12 patients suffered from nonhemato-
logical toxicities such as mucositis, lung infection, depression, renal insufficiency, 
bad condition, atrial flutter, dysphagia, nausea, colonic- or gastric hemorrhage, 
and sepsis, see table 5. In a separate analysis, also adjusting for MNA and GFI, 
the MNA was no longer significantly associated with early treatment withdrawal, 
possibly reflecting that impaired nutritional status results in frailty (data not 
shown).
With respect to survival, 28 (65%) patients had died at the date of last 
follow-up. The Kaplan-Meier curves for survival, according to predefined cut-off 
scores, are shown in figure 2. Patients with abnormal MNA and GFI score, low 
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hemoglobin and elevated creatinine showed a significantly higher mortality risk. 
In univariate Cox regression analysis the age-adjusted IPI with 2-3 risk factors 
versus 0-1 risk factor showed a HR of 1.57 (95% CI: 0.74-3.31; p=0.24). In multi-
variate analysis (adjusted for sex, age, comorbidity, univariate laboratory values 
with p ≤ 0.1 and age-adjusted IPI) abnormal GFI score and low hemoglobin pre-
dicted for mortality with HRs of 2.55 (95% CI: 1.07-6.10; p = 0.04) and 4.90 (95% 
CI: 1.76-13.7; p = 0.002), respectively, shown in table 6.
Most common cause of death was progression of NHL (50%). Four patients 
(15%) died because of toxicity of chemotherapy. Other causes were cardiovascu-
lar problems (12%), infectious problems (12%) or unknown (11%).
GFI and MMSE were repeated in only 13 patients at the end or 6 months 
after the start of chemotherapy; therefore meaningful analyses could not be per-
formed.
Discussion 
This prospective cohort study demonstrates that early treatment withdrawal 
after start of R-CHOP was associated with poor scores for MNA and GFI, and de-
creased levels of hemoglobin at the start of chemo-immunotherapy. An abnormal 
score for GFI and decreased level of hemoglobin were significantly associated 
with the risk of death, both in univariate and multivariate analyses. As the num-
ber of patients with cognitive impairment, measured by IQ-code and MMSE, was 
limited, no meaningful analyses could be performed in this regard. 
It is important to realize that in this cohort of patients the hematologist 
decided to treat the patient with systemic therapy before GA was performed. 
The patients were considered fit enough for treatment with R-CHOP on clini-
cal grounds. This probably explains the low number of patients with cognitive 
dysfunction as assessed by MMSE and IQ-CODE. The hematologist quite likely se-
lected on the absence of obvious cognitive problems. Nevertheless, GA revealed 
considerable shortcomings in the test results of MNA and GFI, respectively in 
34 and 43% of the patients. It is well accepted nowadays that a GA provides ad-
ditional information to judgment by performance status and is predictive for the 
functional outcome in the elderly patient with cancer [12, 14].
Poor scores for MNA, GFI and anemia were associated with early withdraw-
al of systemic chemotherapy (inability to be treated according to scheme) and 
this pertains especially for the GFI and anemia. Most probably a poor score with 
MNA also reflects frailty. The GFI, a 15-items questionnaire (9 on physical func-
tioning and 6 on psychosocial functioning), is an indicator for frailty, exempli-
fied for example by a decline in self-management abilities [36]. Alternatively, the 
ADL and IADL questionnaires could be used. However, GFI also reflects nourish-
ment, cognition, feelings of anxiety and depression. When frailty, defined by GFI 
or ADL/IADL, results in the inability to receive optimal chemo-immunotherapy, 
reduced survival can be expected as has been demonstrated in several studies 
[9, 15, 17, 37, 38). Shortcomings in IADL have been demonstrated to result in 
increased hematologic toxicity [39], overall grade 3-5 toxicity [40], early func-
tional decline [41] and shorter survival [18]. The predictive model of Hurria et 
al on grade 3-5 toxicity also identified anemia as a risk factor [40] and moreover, 
anemia is part of the FLIPI risk score, albeit this score has been developed for 
follicular lymphomas [42, 43]. The present study showed that early treatment 
withdrawal was associated with toxicity of the R-CHOP regimen in 50% of the 
cases. Early withdrawal of systemic chemotherapy could be responsible for the 
reduced survival in this patients category, as also has been demonstrated in the 
analysis of a population-based cohort of patients aged 75 years or older with 
DLBCL [44]. Finally, shortcomings in MNA was found a risk factor for non-hema-
tologic toxicity [39] as well as for early death [16]. 
To date, the most important prognostic value for survival is obtained by 
using the age-adjusted IPI [11], even in the present era in which a lot of immune-
histochemical biomarkers have been investigated for additional prognostic sig-
nificance [45]. Fine-tuning of the application of the IPI in the post rituximab era 
resulted in the so-called R-IPI [46] and for patients older than 70 years of age 
the E-IPI has been demonstrated to give more discriminative power in the low 
and low-intermediate risk groups [47]. Nevertheless, in other patient cohorts 
the standard IPI remained a valid predictor of outcome [48]. Others showed the 
absolute lymphocyte count to be an independent risk factor besides the R-IPI, 
ALC/R-IPI [49], or the comorbidity [50]. Especially in elderly patients, of whom 
the majority is not entered into clinical trials [51], population-based data [44] 
may provide additional insights for proper treatment decisions in this fast grow-
ing number of patients, as has been shown for comorbidity and IPI [50]. There-
fore, the present study emphasizes the importance of a GA by showing that frailty 
by the GFI and low hemoglobin were predictive for the risk of early withdrawal 
of R-CHOP and mortality of patients over 70 years of age treated with R-CHOP. 
Notably, almost half of the patients (46%) in our study were 80 years or older 
and the median follow-up was 46 months, thereby augmenting the value of the 
data for elderly patients.
Some limitations have to be taken into account. Firstly, the cohort is small, 
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resulting in relatively wide confidence intervals. Secondly, a limited number of 
tests were selected to perform a GA, striving for a minimum need of time and a 
minimum of overlapping items between tests. We did not assess the response 
criteria standardized by Cheson [52], and therefore we could not analyze wheth-
er GA predicted for response. Thirdly, the selected patients underwent a GA after 
they were considered to be fit to undergo chemotherapy by their hematologist, 
thereby introducing selection bias. Despite these limitations the GA results re-
vealed some interesting associations with early withdrawal of chemotherapy 
and mortality. 
In conclusion, we found additional prognostic factors. MNA, GFI and hemo-
globin were associated with early treatment withdrawal and GFI and hemoglobin 
were, independent of the age-adjusted IPI, predictive for an increased mortal-
ity risk. Further research in larger cohorts of elderly patients with non-Hodgkin 
lymphoma is needed for proper fine-tuning of prognostic factors besides the well 
known IPI. The value of GA to identify risk factors, suitable and elderly patients 
confined, is demonstrated with this study and practical judgment alone falls 
short in this regard. Whether appropriate interventions, based on identified risk 
factors by GA, can result in better outcome of treatment, should be investigated 
in future prospective studies. So far, the identification of GA-associated risk fac-
tors should be helpful for caution in the management strategy of the hematolo-
gist. 
Table	  1.	  Domains	  and	  measures	  of	  the	  Geriatric	  Assessment	  
Domain	   Measure	   No.	  of	  items	   Description	   Range	  of	  scores	   Mean	  (SD)	   Min-­‐Max	  
Nutrition	   MNA	   6	  (screening)	  
12	  (assessment)	  
Identify	  patients	  at	  risk	  for	  
malnutrition	  
0-­‐14	  (S)	  





Cognition	   IQCODE	   16	   Screens	  for	  cognitive	  decline	  over	  the	  
last	  10	  years	  by	  interviewing	  family	  
members	  or	  care	  givers	  
1-­‐5	  (lower	  score:	  less	  cognitive	  decline)	  	   3.10	  (0.14)	   3.00-­‐3.63	  
MMSE	   20	   Screens	  for	  cognitive	  dysfunction	   0-­‐30	  (Higher	  score:	  better	  cognitive	  function)	   27.7	  (1.9)	   23-­‐30	  
Frailty	   GFI	   15	   Screens	  for	  deterioration	  on	  physical,	  
cognitive,	  and	  psycho-­‐social	  items	  
0-­‐15	  (Higher	  score:	  more	  frailty)	   3.6	  (2.7)	   0-­‐11	  
Abbreviations:	  MNA,	  Mini	  Nutritional	  Assessment,	  a	  stepwise	  test:	  when	  the	  score	  in	  the	  screening	  section	  (S)	  is	  less	  than	  12	  points,	  indicating	  
the	  possibility	  of	  malnutrition,	  the	  assessment	  section	  (A)	  is	  completed.	  With	  the	  assessment	  section,	  a	  total	  score	  of	  24-­‐30	  points	  is	  indicative	  of	  being	  well-­‐nourished,	  
17-­‐23.5	  points	  for	  being	  at	  risk	  of	  malnutrition,	  and	  a	  score	  of	  less	  than	  17	  points	  for	  being	  malnourished.;	  IQCODE,	  Informant	  Questionnaire	  on	  Cognitive	  Decline,	  
ranging	  from	  much	  improved	  to	  much	  worsened,	  and	  the	  average	  score	  is	  used	  in	  the	  analyses;	  GFI,	  Groningen	  Frailty	  Indicator,	  with	  a	  maximum	  score	  of	  15	  points.	  
Patients	  scoring	  4	  or	  more	  points	  are	  considered	  to	  be	  frail.	  MMSE,	  Mini	  Mental	  State	  Examination,	  where	  the	  cut-­‐off	  point	  for	  poor	  cognition	  is	  24	  points	  or	  less.	  SD,	  
standard	  deviation.	   
Table	  2	  Baseline	  characteristics	  of	  patients	  with	  NHL	  receiving	  R-­‐CHOP	  regimen	  (n=44)*	  	  
n	  (%)	  
Sex	  	  
	  	  	  Male	  




	  	  	  70-­‐74	  years	  
	  	  	  75-­‐79	  years	  




WHO-­‐performance	  /	  Karnofski	  Index	  	  
	  	  	  0	  -­‐	  (KI	  90-­‐100%)	  
	  	  	  1	  -­‐	  (KI	  70-­‐80%)	  




Age-­‐adjusted	  IPI	  	  
	  	  	  0	  -­‐	  Low	  risk	  	  
	  	  	  1	  -­‐	  Low-­‐intermediate	  risk	  
	  	  	  2	  -­‐	  High-­‐intermediate	  risk	  





Comorbidity	  (Charlson	  index)	  
	  	  	  0	  
	  	  	  1	  
	  	  	  ≥	  2	  






	  	  	  Diffuse	  large	  B-­‐cell	  lymphoma	  (DLBCL)	  




	  	  	  Stage	  I	  
	  	  	  Stage	  II	  
	  	  	  Stage	  III	  





*One	  patient	  presented	  with	  stage	  I	  and	  three-­‐and-­‐a-­‐half	  years	  later	  with	  stage	  II	  DLBCL	  and	  thus
was	  registered	  twice.	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Table	  3.	  Abnormal	  baseline	  geriatric	  and	  laboratory	  assessment	  results	  (n=44)	  
Test	   n	  (%)	  
MNA	  (Risk	  of)	  malnutrition* 15(34)	  
GFI	  (risk	  of)	  frailty	  (>4	  points)	   19	  (43)	  
IQ-­‐code	  Cognitive	  decline**	  (<3.31	  points))	   5	  (11)	  
MMSE	  Cognitive	  dysfunction	  (<24	  points)	   2	  (5)	  
Albumin	  Low	  (<35g/l)	   14	  (32)	  
Hemoglobin	  Low	  (<6.8mmol/L)	   11	  (25)	  
Creatinine	  Elevated	  (≥100	  μmol/L)	   13	  (30)	  
LDH	  Elevated	  (≥250	  U/L)	   38	  (86)	  
*:(Risk	  of)	  malnutrition	  defined	  as	  a	  score	  of	  ≤	  11	  on	  the	  MNA	  screening	  section	  or	  less	  than	  24	  pts	  








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table	  5.	  Treatment	  related	  adverse	  events	  of	  12	  patients	  with	  early	  treatment	  withdrawal.	  	  
Toxicity	  type*	  
Grade	  3-­‐5	   Grade	  3	   Grade	  4	   Grade	  5	  
no	  (%)	   no	  (%)	   no	  (%)	   no	  (%)	  
	  	  	  Hematologic	  
	  	  	  	  	  	  	  Leukocytopenia	   5	  (42)	   4	  (25)	   1	  (8)	  
	  	  	  	  	  	  	  Anemia	   2	  (17)	   2	  (17)	  
	  	  	  	  	  	  	  Trombocytopenia	   2	  (17)	   1	  (8)	   1	  (8)	  
	  	  	  Nonhematologic	  
	  	  	  	  	  	  	  Mucositis	   2	  (17)	   2	  (17)	  
	  	  	  	  	  	  	  Lung	  infection	   3	  (25)	   3	  (25)	  
	  	  	  	  	  	  	  Renal	  insufficiency	   1	  (8)	   1	  (8)	  
	  	  	  	  	  	  	  General	  condition	  (fragility)	   1	  (8)	   1	  (8)	  
	  	  	  	  	  	  	  Atrial	  flutter	   1	  (8)	   1	  (8)	  
	  	  	  	  	  	  	  Dysphagia	   1	  (8)	   1	  (8)	  
	  	  	  	  	  	  	  Nausea	   2	  (17)	   2	  (17)	  
	  	  	  	  	  	  	  Colonic	  hemorrhage	   1	  (8)	   1	  (8)	  
	  	  	  	  	  	  	  Gastric	  hemorrhage	   1	  (8)	   1	  (8)	  
	  	  	  	  	  	  	  Sepsis	   3	  (25)	   1	  (8)	   2	  (17)	  
	  	  	  	  	  	  	  Ileus	   1	  (8)	   1	  (8)	  
*	  According	  to	  the	  Common	  Terminology	  Criteria	  for	  Adverse	  Events	  (CTCAE)	  Version	  4.03	  (34)
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Figure	  1.	  Flow-­‐diagram	  of	  the	  study	  
Eligible	  patients	  
with	  non-­‐Hodgkin	  Lymphoma	  (NHL)	  
aged	  ≥	  70	  yr
(n=90)
Included	  patients	  
for	  whom	  a	  hematologist	  prescribed	  R-­‐CHOP
(n=44)
Baseline	  data	  collection:
	  	  -­‐	  Geriatric	  Assessment:	  MNA,	  GFI,	  IQCODE,	  MMSE
	  	  -­‐	  Laboratory	  values:	  Alb,	  Hb,	  Creat,	  LDH
Follow-­‐up	  data	  collection:
	  	  -­‐	  Chemotherapy	  according	  to	  scheme	  (toxicity)
	  	  -­‐	  Mortality
46 (51%) Excluded 
19 Indolent lymphoma
12 Diffuse large B-cell lymphoma 
11 Mantle-cell lymphoma
2 Follicular lymphoma grade II
1 Follicular lymphoma grade III
1	  Burkitt	  lymphoom
Figure	  2.	  
Kaplan–Meier	  curves	  of	  overall	  survival	  during	  up	  to	  60	  months	  (i.e.	  4	  yr,	  until	  31	  December	  2012)	  
follow-­‐up	  in	  patients	  with	  NHL	  according	  to	  categories	  of:	  [A]	  MNA,	  [B]	  GFI,	  [C]	  age-­‐adjusted	  IPI,	  [D]	  
albumin,	  [E]	  hemoglobin,	  [F]	  creatinine,	  and	  [G]	  LDH.	  	  
P-­‐values	  by	  log-­‐rank	  tests.	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Abstract
Background: Comprehensive geriatric assessment (CGA) is a multidimensional 
method to detect frailty in elderly patients. Time saving could be accomplished 
by identifying those individual items that classify elderly cancer patients at risk 
for feasibility of chemotherapy and for mortality.
Material and methods: Patients older than 70 years of age were assessed be-
fore the first chemotherapy administration. Geriatric assessment (GA) consisted 
of the Mini Nutritional Assessment (MNA), Informant Questionnaire on Cogni-
tive Decline in the Elderly (IQCODE), Groningen Frailty Indicator (GFI) and Mini 
Mental State Examination (MMSE). Predictive individual items for feasibility of 
chemotherapy and mortality were entered in the multivariable logistic regres-
sion and Cox-regression models, and a three-item sum scale was constructed: the 
Geriatric Prognostic Index (GPI). 
Results: The 494 patients had a median age of 75 years (range 70-92 years). The 
majority of the patients had malignancies of the digestive tract (41.7%) followed 
by haematological tumors (22.3%). Three items of the MNA (‘psychological dis-
tress or acute disease in the past three months’, ‘neuropsychological problems’ 
and ‘using > 3 prescript drugs’) independently predicted for feasibility of chemo-
therapy. Two items of the MNA and one of the GFI (‘declining food intake in past 3 
months’, ‘using >3 prescript drugs’, and ‘dependence in shopping’) independently 
predicted for mortality. In comparison with patients without any positive item 
on the three-item GPI, patients with one, two or three positive items had hazard 
ratios (HRs) of 1.58, 2.32, and 5.58, respectively (all p < 0.001). 
Conclusions: With only three items of the MNA, feasibility of chemotherapy can 
be predicted. The three-item GPI may help to identify elderly cancer patients at 
elevated risk for mortality.
Background
The majority of persons with cancer is older than 65 years of age, and 70% of 
cancer mortality occurs in this age cohort [1]. As a result of demographic chang-
es, the demand for care and treatment of older people with cancer will strongly 
increase in the coming decades.
Comprehensive geriatric assessment (CGA) is a multidimensional method 
to provide objective information on comorbidity, functional status, social sup-
port, polypharmacy, nutritional- and psychosocial status [2]. As geriatric prob-
lems increase sharply after 70 years of age in cancer patients, the guidelines of 
the International Society of Geriatric Oncology (SIOG) recommend that all pa-
tients with cancer and an age above 70 years should undergo some form of GA 
[3]. However, to conduct a full CGA is time consuming and associated with high 
costs. Therefore, a two-step approach could be a pragmatic alternative by using 
a brief screening tool. Well known examples of screening tools are formed by ab-
breviated CGA (aCGA) [4], Vulnerable Elders Survey (VES-13) [5], the Geriatric 
8 (G8) [6], Groningen Frailty Indicator (GFI) [7], Flemish version of the Triage 
Risk Screening Tool (fTRST) [8] and others [9]. Nevertheless, further time sav-
ing might be accomplished by identifying the essential items of such screening 
tools. For example, this has been shown to be applicable for the Mini Nutritional 
Assessment (MNA) [10]. The study of osteoporotic fractures (SOF) index was de-
veloped from frequently cited physiologic domains in the frailty literature [11, 
12] and appeared accurate in comparison with CGA for the detection of frailty in
cancer patients [13]. The geriatric vulnerability score (GVS) appeared applicable
for elderly patients with advanced ovarian cancer treated with carboplatin [14].
The present cohort of elderly cancer patients, collected in the region of the 
Comprehensive Cancer Center West in the Netherlands, offered the opportunity 
to analyze and determine which elements of the chosen geriatric screening pro-
gram were independently predictive for feasibility of chemotherapy and mortal-
ity.
Material and methods
Patients older than 70 years of age with various types of cancer (N = 520) were 
prospectively assessed before chemotherapy administration with either curative 
or palliative intent. The decision for treatment with chemotherapy had already 
been made by the treating (hemato)-oncologist on clinical grounds. The patients 
had been considered to be fit enough to receive chemotherapy. The collection 
of data was accomplished between May 2004 and February 2010 in three gen-
eral and one university hospital: the hospital of the Reinier de Graaf Groep in 
Delft, Groene Hart hospital in Gouda, Haga hospital in The Hague, and the Leiden 
University Medical Center in Leiden. After February 2010 no more funding was 
available for data management, thus prohibiting further inclusion of patients in 
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this prospective registration cohort. We excluded 25 patients because they did 
not start with chemotherapy and one patient because of age.
GA consisted of the MNA, Informant Questionnaire on Cognitive Decline in 
the Elderly (IQCODE), GFI and Mini Mental State Examination (MMSE). These 
tests were selected for performing a GA with a minimum of overlap between the 
domains, and a maximum duration of 45 minutes to complete the interview. The 
tests have been described in detail previously [15]. The appendices provide de-
tails on these tests. Patients scoring 4 or more points on the GFI were considered 
to have a moderate to severe frailty. The IQCODE screens for cognitive decline 
over the last 10 years by interviewing family members or caregivers. We used 
the short 16 items Dutch translation IQCODE-N [16]. The MMSE has been tested 
extensively and is considered to be a standard test for current cognitive function.
Feasibility of chemotherapy was defined by the inability to complete the 
intended number of cycles of chemotherapy: at least four cycles. This number 
was arbitrarily chosen as a surrogate endpoint, realizing that four cycles cannot 
be considered as the standard number of cycles. It was considered likely, that if 
at least four cycles could be administered, then patients could be treated with the 
intended total dose of chemotherapy. The small group of patients with aggressive 
non-Hodgkin lymphoma stage I who were treated with the intended number of 
three cycles of chemo(-immuno)therapy and involved field radiotherapy, were 
grouped under the heading of four or more cycles of chemotherapy.
The duration of the follow-up was defined as the difference between the 
date of the first GA and 1st January 2013 or the date of death. Vital status and last 
follow-up date were recorded from the patient’s medical record. If indicated by 
the test results, a dietician or a geriatrician was consulted. 
Statistical analysis 
To identify the most relevant individual items of the MNA, GFI, IQ-CODE and 
MMSE, every single item was dichotomized. Details are given in addendum 1. 
Categorical variables are presented as numbers with percentages and con-
tinuous variables as medians with their range. Logistic regression analysis and 
Cox regression analysis on (items of) the MNA, GFI, IQCODE and MMSE for the 
prediction of feasibility of chemotherapy and mortality obtained odds ratios 
(ORs) and hazard ratios (HRs), respectively. To avoid type I errors in multiple 
testing, a p-value < 0.01 was considered statistically significant. All multivariable 
models were adjusted for sex, age, purpose of treatment, and type of malignancy. 
Those questionnaires of the MNA, GFI, IQCODE and MMSE that independently 
predicted for feasibility of chemotherapy or mortality (p < 0.01) were used in 
further analyses with the dichotomized composite items. When individual items 
were predictive for feasibility of chemotherapy and mortality (p<0.01), these 
were included in multivariable logistic regression and Cox-regression models. 
Forward stepwise procedures were used in both the logistic and Cox regression 
models, with an entry criterion of p<0.01 and the removal criterion of p>0.10. As 
sensitivity analysis, the variable selection procedures were rerun using backward 
stepwise selection. Subsequently, the independent predictive items for mortality 
were summed, and this sum score was analyzed using the multivariable adjusted 
Cox regression model. In stratified analyses, the predictors for mortality were 
tested separately in the palliative treated and adjuvant/curative treated groups. 
The models were internally validated by calculating c-statistics, which are meas-
ures for the discriminative performance of the models, using bootstrapping to 
take into account that the models were developed and validated on the same 
data [17]. For logistic regression the c-statistic is equal to the area under the 
curve of a ROC curve. Statistical tests and analyses were performed using SPSS 
21 for Windows® (SPSS inc. Chicago, IL. USA) and R 3.1.0 [18] using package rms 
(Regression Modeling Strategies) [19]. 
Results
A total of 494 patients with various types of cancer were evaluated. Table 1 
shows the baseline characteristics of the patients.
The scores of the GA are shown in table 2. Roughly one-third of the patients 
showed shortcomings with the MNA and the GFI, and some 10% of the patients 
had cognitive problems. In total 353 patients were treated with four or more 
cycles of chemotherapy, of whom 61% were treated with full dose and 39% with 
an adapted dose. A total of 141 patients (29%) could not complete at least four 
cycles of chemotherapy. In this group, 69% of the patients were treated with full 
dose, and 31% received an adapted dose (a decision of the treating oncologist). 
The reasons for early treatment withdrawal were complications of chemothera-
py (50%), deteriorating general condition (11%), ineffectiveness of chemother-
apy (10%), worsening comorbidity (2%) and others (27%). Addendum 2 gives 
information on applied chemotherapy regimens. Of course, this shows a large 
variety in this cohort of patients. 
The median follow-up was 17 months (range 1-101) for all patients, and 61 
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months (range 44-101) for the 99 survivors. The most common cause of death 
was cancer progression (84.0%). Other causes were treatment related (3.1%), 
cardiovascular mortality (2.3%), or unknown causes (10.6%). 
 The effect of the MNA, GFI, IQCODE and MMSE on feasibility of chemotherapy 
and mortality are given in table 3. Patients with adverse scores on 
the MNA and GFI had a higher odds to stop chemotherapy before the 
4th cycle with ORs of 2.21 (95% confidence interval [CI]: 1.48-3.31; 
p < 0.001) and 1.71 (95% CI: 1.13-2.58; p = 0.01), respectively. After adjusting for 
gender, age, purpose of treatment and type of malignancy only the MNA was sig-
nificantly related to feasibility with a p value < 0.01: OR 2.30 (95% CI: 1.48-3.58; 
p < 0.001). The MNA remained a significant predictor after additional adjustment 
for GFI (OR 2.12 (95% CI: 1.33-3.39; p = 0.002). With respect to mortality, an 
adverse score for MNA and GFI was associated with increased HRs for mortality 
of 1.68 (95% CI: 1.37-2.06; p < 0.001) and 1.47 (95% CI: 1.19-1.82; p < 0.001), 
respectively. After adjustment for gender, age, purpose of treatment and type of 
malignancy, these HRs remained significant (1.86; 95% CI: 1.48-2.34; p < 0.001; 
and 1.77; 95% CI: 1.41-2.22; p < 0.001, respectively). 
 Table 4 shows the univariable significant individual items (with p < 0.01) 
of MNA for feasibility of chemotherapy and of the GFI and MNA for mortality. In 
the stepwise selection procedure, three items of the MNA independently predict-
ed feasibility [‘psychological distress’ (MNA-D), ‘neuropsychological problems’ 
(MNA-E) and ‘using > 3 prescript drugs’ (MNA-H)], with ORs of 2.10 (95% CI: 
1.31-3.38; p = 0.002), 3.44 (95% CI: 1.50-7.90; p = 0.004) and 1.96 (95% CI: 1.27-
3.03; p = 0.002), respectively. Two items of the MNA [‘declining food intake in 
past 3 months’ (MNA-A) and ‘using > 3 prescript drugs’ (MNA-H)] and one item 
of the GFI [‘dependence in shopping’ (GFI-Q1)] independently predicted for mor-
tality, with HRs of 1.82 (95% CI: 1.47-2.24; p < 0.001), 1.38 (95% CI: 1.12-1.71; 
p = 0.003) and 1.77 (95% CI: 1.31-2.40; p < 0.001), respectively. In sensitivity 
analyses a backward stepwise selection procedure resulted in the same three 
items. Table 5 shows the c-statistic of the different models. For mortality the out-
come increased from 0.66 to 0.70 when adding MNA(A), MNA(H) and GFI(Q1) to 
the model. This indicates that these three dichotomous variables gave additional 
predictive value to the model. Similarly, the items MNA(D), MNA(E), and MNA(H) 
added predictive value to the outcome variable feasibility, increasing the c-statis-
tic from 0.61 to 0.69. 
 A sum score, the Geriatric Prognostic Index (GPI), was constructed using 
the three items with increased HRs for mortality. With one positive item the 
HR was 1.58 (95% CI: 1.24-2.02; p < 0.001), with two positive items 2.32 (95% 
CI: 1.76-3.06; p < 0.001), and with all three items 5.58 (95% CI: 3.48-8.61; p < 
0.001), in comparison with no positive item. The median survival with the GPI 
was 2.26 years with score 0, 1.34 years with score 1, 0.95 years with score 2 and 
0.56 years with score 3 (figure 1). 
 The effect of the three predictive items for mortality was studied separately 
in the palliative (N = 288) and adjuvant/curative (N = 206) treated patients. The 
three items (MNA-A, MNA-H and GFI-Q1) remained significant in the palliative 
treated group with HRs of 2.02 (95% CI: 1.54-2.65; p < 0.001), 1.54 (95% CI: 
1.19-2.00; p = 0.001) and 1.89 (95% CI: 1.30-2.74; p = 0.001), respectively. In the 
adjuvant/curative treated group the GFI-Q1 remained associated with mortality 
(HR 2.22 [95% CI: 1.28-3.83; p = 0.004]), but the effect of MNA-A and MNA-H was 
smaller (HR 1.31 [95% CI: 0.90-1.93; p = 0.17] and 1.30 [95% CI: 0.89-1.92; p = 
0.18], respectively). 
Discussion
In this study among 494 elderly cancer patients the result of the MNA test was 
predictive for the risk of premature discontinuation of chemotherapy. Further-
more, a three-item Geriatric Prognostic Index (GPI) was constructed, that pre-
dicted for mortality. It has to be stressed that these 494 patients were considered 
to be fit for treatment with chemotherapy before the GA was performed.
 CGA is an evidence-based method to evaluate deficits and frailty in elderly 
cancer patients [3]. This diagnostic tool provides information for the process 
leading up to the treatment plan and may recognize previously unaddressed 
problems, creating opportunities to improve functional status and resources of 
old cancer patients [3]. It may even contribute to prolonged survival and may 
help to weigh the benefits against the risks of chemotherapy and identify pa-
tients that may be too frail to profit from this demanding form of treatment [3].
 Already, the literature of geriatric oncology highlighted scoring systems for 
the toxicity of chemotherapy [20, 21]. Hurria et al. identified three risk strata 
for grade 3-5 toxicity, with 11 risk factors [21], while the CRASH score of Ex-
termann et al. identified four risk factors for hematologic and nonhematologic 
toxicity each, discerning four risk categories for grade 4 hematologic toxicity and 
grade 3-4 nonhematologic toxicity [20]. Hoppe et al. identified depression and 
dependence for instrumental activity of daily living (IADL) as risk factors for ear-
ly functional decline during chemotherapy [22]. The GVS showed increased tox-
icity with three or more risk factors of albumin, lymphocyte count, and scores of 
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Activity of Daily Living (ADL), IADL and Hospital Anxiety and Depression Scale, 
for patients with advanced ovarian cancer and treatment with carboplatin [14]. 
The present study concentrated on the inability to complete at least four cycles of 
chemotherapy and showed that in the case of (risk of) malnutrition by MNA the 
chance not to complete chemotherapy increased more than two-fold. The large 
variety of chemotherapy regimens, shown in addendum 2, precluded analyses 
of specific schedules. However, for all schedules given adequate dose intensity 
is essential, whether it is given for palliative or curative reasons. The reasons for 
early treatment withdrawal in our study form common reasons in general oncol-
ogy practice to decide on stopping chemotherapy. And of course it is legitimate 
to ask the question, whether one should have started chemotherapy at all, when 
this only results in toxicity and early treatment withdrawal [2, 3, 23, 24].
Others concentrated in their research on risk factors for mortality [24, 25]. 
Kanesvaran et al. developed a Clinical Scoring System (CSS) in an Asian popula-
tion, consisting of the factors age, albumin, ECOG performance status, depres-
sion, stage of disease and nutritional index. A nomogram predicted overall sur-
vival rate [25]. Soubeyran et al. identified male gender, advanced stage, poor 
MNA and decreased mobility as risk factors for early death [24]. The GVS showed 
significantly worse survival with the same risk factors as shown for toxicity [14]. 
As previously shown in a smaller cohort [15], the present study identified poor 
MNA and poor GFI as risk factors for mortality. In general, CGA contains com-
ponents that predict for mortality [23]. These data show the importance of the 
nutritional status and frailty score as part of pre-treatment assessment to select 
patients who might benefit from interventions.
Screening tests have been developed to help for the identification of 
frailty and select the patients who might benefit from extensive CGA [9]. How-
ever, screening tools still contain 5 - 15 items [4, 8], which may lead to a barrier 
against broad usage in clinical care. Many health workers aim for a balance be-
tween optimal health-care and a minimal burden to patients and caregivers [5, 
6]. To improve pretreatment assessment it is not always necessary to complete a 
full version of a (self-reported) questionnaire. The aCGA used seven of 16 ADL/
IADL items for detection of shortcomings [4]. The three-item SOF index showed 
a sensitivity and specificity of 89.0 and 81.1, respectively, for the detection of dis-
abilities in comparison with CGA [13]. The GVS score was developed for elderly 
patients with advanced ovarian cancer and treatment with carboplatin [14].
Regarding feasibility of chemotherapy, this study shows that three items of 
the MNA were predictive in multivariable analysis: “psychological stress or acute 
disease in the past three months”, “neuro psychological problems” and “using 
more than three prescript drugs”. These items seem comparable with items used 
by Hurria et al: “decreased social activity because of physical/emotional health, 
limited at least sometimes” and “taking medications with some help/unable” 
[21]. Depression was one of the risk factors for early functional decline, as shown 
by Hoppe et al [22], and was also a risk factor of the GVS [14]. The MNA-score as a 
whole was one of the risk factors for nonhematologic toxicity, identified with the 
CRASH score [20].
The present study introduces the GPI as instrument for the prediction of 
mortality. Two items of the MNA (MNA-A and MNA-H) and one item of GFI (GFI-
Q1) proved to be highly predictive for mortality. In comparison with no positive 
items the patients with all three items positive showed a HR for mortality of 5.58 
(95% CI 3.48-8.61; p < 0.001). This holds especially for the palliative treated pa-
tients. The GPI cannot be compared with the SOF index [13], which has not been 
correlated with mortality, nor with the CSS [25] (developed in an Asian popula-
tion), nor with the GVS [14] (tumor- and treatment specific score). The GPI con-
centrates on decreased food intake, polypharmacy and dependence in shopping. 
Poor score of MNA was identified as risk factor of early death by Soubeyran et al, 
but this study was not analyzed which factor(s) of the MNA contributed mostly 
[24]. Dependence in shopping was also identified by others as important risk fac-
tor for detection of disabilities [4]. 
The GPI could support the use of chemotherapy in patients with score 0-1, 
whereas a more thorough CGA would be warranted for those patients scoring 
2 (median survival in this cohort almost one year) and the use of chemother-
apy should be questioned in patients with score 3 (median survival of only six 
months). A potential form of bias exists for MNA-H, due to the fact that all pa-
tients with a normal screening score on the MNA were given score 1 (see appen-
dix). Therefore the GPI should be validated in an independent study population 
of elderly cancer patients.
Some limitations have to be mentioned. First, a variety of cancer types were 
included. However, we adjusted for cancer type in our multivariable models. An-
other source of heterogeneity may have been the fact that different chemothera-
py regimens were given of which not all were given in the full doses. Second, the 
selected patients underwent a GA after they were considered to be fit to undergo 
chemotherapy by their oncologist, thereby introducing selection bias. Neverthe-
less, considerable shortcomings appeared to be present at baseline regarding GFI 
and MNA. Third, we tested the individual items of the MNA, GFI, IQCODE and MMSE 
resulting in a three-item GPI. Type I errors occurs in multiple testing and therefore 
we selected only individual items that were predictive in crude models with a p 
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value < 0.01 and in forward stepwise regression models with an entry criterion of 
p < 0.01. Fourth, models were developed and validated on the same dataset. The 
GPI therefore needs to be validated in future studies of elderly cancer patients. 
A strength of the study is that we did analyze separately the adjuvant/curatively 
and the palliatively treated patients for the effect of the GPI on mortality.
 In conclusion, our results show that a poor MNA score was predictive for 
not completing four cycles of chemotherapy and poor MNA- and GFI scores were 
predictive for mortality of elderly patients with various types of cancer. ‘Psycho-
logical stress’, ‘neuropsychological problems’ and ‘number of drugs taken’ were 
predictive items of MNA for feasibility of chemotherapy. ‘Declining food intake’, 
‘number of drugs taken’ and ‘dependence in shopping’ were the three predictive 
items for a higher risk of mortality, resulting in the GPI. Hazard ratios for mortal-
ity increased linearly with sum scores increasing from 0 to 3 points. The GPI can 
help to identify the elderly patient at increased risk for mortality, who before-
hand is considered to be fit enough to receive treatment with chemotherapy.
Table	  1.	  Baseline	  characteristics	  of	  494	  elderly	  cancer	  patients.	  
	   Median	  
(range)	  
N	  (%)	  
Age	   75	  (70-­‐92)	   	  
70-­‐74	  years	   	   237	  (48.0)	  
75-­‐79	  years	   	   170	  (34.4)	  
≥	  80	  years	   	   87	  (17.6)	  
Male	  gender	   	   246	  (49.9)	  
Type	  of	  malignancy:	   	   	  
Upper	  digestive	  tract	   	   64	  (13.0)	  
Lower	  digestive	  tract	   	   142	  (28.7)	  
Haematological	   	   110	  (22.3)	  
Breast	   	   61	  (12.3)	  
Gynaecological	   	   38	  (7.7)	  
Prostate	   	   29	  (5.9)	  
Lung	   	   21	  (4.3)	  
Urinary	  tract	   	   11	  (2.2)	  
Other	   	   18	  (3.6)	  
Purpose	  of	  treatment:	   	   	  
Adjuvant/	  curative	   	   206	  (41.7)	  




Table	  2.	  Results	  of	  the	  geriatric	  assessments	  of	  494	  elderly	  cancer	  patients.	  




well	  nourished	  	  





GFI	   <	  4	  pts	  





IQCODE	   ≤	  3.30	  pts	  





MMSE	   >	  24	  pts	  





*(Risk	  of)	  malnutrition	  defined	  as	  a	  score	  of	  ≤	  11	  on	  the	  MNA	  screening	  section	  or	  less	  than	  
24	  pts	  on	  the	  assessment	  section	  (see	  appendix).	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Table	  5.	  	  
	  
C-­‐statistic	  coefficients	  of	  the	  different	  additional	  models	  for	  feasibility	  of	  chemotherapy	  and	  
mortality.	  
	  
Model	   Feasibility	   Mortality	  
	  	  	  Gender,	  age,	  purpose	  of	  treatment,	  and	  type	  of	  malignancy	   0.61	   0.66	  
	  	  	  MNA	  +	  GFI,	  dichotomized	   0.65	   0.69	  
	  	  	  MNA-­‐D	  +	  MNA-­‐E	  +	  MNA-­‐H	   0.69	   -­‐-­‐	  
	  	  	  MNA-­‐A	  +	  MNA-­‐H	  +	  GFI-­‐Q1	   -­‐-­‐	   0.70	  
	  	  	  GPI	  score	   -­‐-­‐	   0.70	  
	  
MNA-­‐A:	  Declining	  food	  intake	  in	  past	  3	  months;	  MNA-­‐D:	  Psychological	  stress	  or	  acute	  disease	  in	  past	  
3	  months;	  





Kaplan–Meier	  curves	  of	  overall	  survival	  in	  494	  elderly	  patients	  with	  various	  types	  of	  cancer	  according	  
to:	  [A]	  MNA	  item	  A,	  [B]	  MNA	  item	  H,	  [C]	  GFI	  question	  1	  and	  [D]	  sum	  score	  of	  these	  three	  items.	  	  























































A	  	  	  	  MNA	  item	  A B	  	  	  	  MNA	  item	  H
D	  	  	  	  Sum	  scoreC	  	  	  GFI	  question	  1
c 2	  (1)	  =	  23.4
P	  <	  0.001
c 2	  (1)	  =	  20.2
P	  <	  0.001
c 2	  (1)	  =	  23.8
P	  <	  0.001





	  Declining	  food	  intake	  in	  past	  3	  months	  	  (n=217)
No	  declining	  food	  intake	  in	  past	  
3	  months	  	  (n=273)
Using	  >	  3	  prescription	  drugs	  (n=181)






Has	  food	  intake	  declined	  over	  the	  past	  three	  months?	  
(due	  to	  loss	  of	  appetite,	  digestive	  problems,	  chewing	  or	  swallowing	  difficulties)
MNA(A) Any	  decrease	  =	  1
MNA(H) Does	  the	  patient	  take	  more	  than	  3	  prescription	  drugs	  per	  day? Yes	  =	  1
Is	  the	  patient	  able	  to	  carry	  out	  shopping	  without	  any	  help?




Score	  1 1.58	  (1.24-­‐2.02)	  	  	  	  P	  <	  0.001
Score	  2 2.32	  (1.76-­‐3.06)	  	  	  	  P	  <	  0.001
Score	  3 5.58	  (3.48-­‐8.61)	  	  	  	  P	  <	  0.001
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Addendum 2 
Chemotherapy of malignancies  
Type of malignancy Chemotherapy N (%) 
Upper digestive tract (N=64) Platina combination therapy 47 (73.5) 
Gemcitabine 13 (20.3) 
Capecitabine 2 (3.1) 
Platina mono therapy 2 (3.1) 
Lower digestive tract (N=142) 5-fluoropyrimidine combination therapy 82 (57.8) 
5-fluoropyrimidine mono therapy 54 (38.0) 
Irinotecan mono therapy 4 (2.8) 
Platina combination therapy 2 (1.4) 
Haematological (N=110) Combination chemotherapy (mostly rituximab, 
cyclophosphamide, hydroxydaunomycin, oncovin, 
prednisone (R-CHOP)) 82 (74.5) 
Multiple myeloma directed therapies (vincristin-
adriamycin-dexamethasone (VAD), bortezomib and 
combinations, melphalan and combinations) 18 (16.4) 
Mono therapy (chloorambucil, fludarabine, methotrexate, 
decitabine, rituximab) 10 (9.1) 
Breast (N=61) Capecitabine mono therapy 16 (26.1) 
Anthracycline mono therapy 9 (14.8) 
Anthracycline combination therapy 9 (14.8) 
Paclitaxel 6 (9.8) 
Docetaxel 3 (4.9) 
Taxane combination therapy 4 (6.6) 
CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil) 4 (6.6) 
Vinorelbine 4 (6.6) 
Anthracyclines + Taxane 4 (6.6) 
Herceptin 1 (1.6) 
Gemcitabine 1 (1.6) 
Gynaecological (N=38) Platina combination therapy 25 (65.8) 
Platina mono therapy 12 (31.6) 
Melphalan 1 (2.6) 
Prostate (N=29) Docetaxel 28 (96.6) 
Mitoxantrone 1 (3.4) 
Lung (N=21) Platina combination therapy 17 (81) 
CDE (cyclophosphamide, doxorubicin, etoposide) 4 (19) 
Urinary tract (N=11) Platina combination therapy 8 (72.7) 
M-VAC (methotrexate, vinblastin, adriamycin, cisplatin) 2 (18.2) 
Platina mono therapy 1 (9.1) 
Addendum 1. 
Dichotomized items of the screening tests. 
With MNA the individual items were dichotomized as follows; 
− item A: score 0/1 vs score 2  
− item B:  score 0/1 vs score 2/3 
− item C:  score 0/1 vs score 2
− item E: score 0/1 vs score 2 
− item F: score 0/1/2 vs score 3 
− item J: score 0 vs score 1/2 
− item K: score 0.0/0.5 vs score 1.0 
− item M:  score 0.0/0.5 vs score 1.0
− item N:  score 0/1 vs score 2
− item O:  score 0/1 vs score 2
− item P: score 0.0/0.5 vs score 1.0/2.0 
− item Q:  score 0.0/0.5 vs score 1.0
The cut-off score for the items of the IQ-CODE was between ‘nothing changed’ and ‘worse’. 
The cut-off score for the items of the MMSE according to Small et al.* were; 
− ‘immediate memory’: ≥ 2 points, 
− ‘serial sevens’:   ≥ 3 points, 
− ‘delayed memory’:   ≥ 2 points  
− ‘follow commands’: ≥ 2 points, 
* From: Small, B.J. et al., Mini-Mental State Examination item scores as predictors of Alzheimer's
disease: incidence data from the Kungsholmen Project, Stockholm. J Gerontol A Biol Sci Med Sci, 
1997. 52(5): p. M299-304.	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of chemotherapy, while patients with unfavourable MNA and GFI scores showed 
increased mortality rates.
 Chapter 3 concentrates on the results of the outcome of GA in 55 patients 
with breast cancer, who had a mean age of 76 years (range 70–88 years, 20% 
were older than 80 years). Apart from the above mentioned GA, also the re-
sults of laboratory tests at baseline for serum albumin, haemoglobin, creatinine 
and lactate dehydrogenase (LDH) were taken into consideration in relation to 
the outcome of palliative chemotherapy. Twenty-one patients underwent post-
chemotherapy evaluation by GFI and MMSE. Abnormal test results were present 
in 42% patients for MNA, 51% for GFI, 18% for IQCODE and 9% for MMSE. Labo-
ratory tests were abnormal in 13%, 33%, 78% and 84% of the patients, respec-
tively for creatinin, albumin, haemoglobin and LDH. Besides the inverse correla-
tion of MNA and GFI (r = –0.43; P < 0.001) and the inverse correlation of IQCODE 
and MMSE (r = –0.36; P = 0.01), no significant correlations between the GA tests 
results and laboratory tests results were found. However, disability according to 
WHO-performance status was correlated with an inferior test result of MNA (r 
=-0.28, p = 0.04) and GFI (r = 0.38, p = 0.004).
 There was no significant difference between the number of patients (n 
= 39) who underwent at least 4 cycles of chemotherapy compared to patients 
who underwent less than 4 cycles (n = 16) with regard to GA and laboratory 
parameters (neither after adjusting for age, comorbidity and WHO performance 
status). Inferior MNA and GFI scores were associated with increased mortality, 
with HRs of 3.05 (95% CI: 1.44–6.45; p = 0.004) and 3.40 (95% CI: 1.62–7.10; p 
= 0.001), respectively. When MNA and GFI were combined in one multivariate 
Cox regression model, both GA parameters independently contributed to early 
mortality (p = 0.04 for MNA and p = 0.02 for GFI). The median survival difference 
between normal versus abnormal MNA (well nourished vs. malnourished) and 
normal versus abnormal GFI (not frail vs. frail) was more than 12 months for 
both tests. The post-chemotherapy evaluation by GFI and MMSE showed wors-
ening of the physical aspects of the GFI (p = 0.05). In conclusion, neither GA tests 
nor laboratory tests were predictive for the chance to complete chemotherapy in 
this cohort of patients. However, abnormal baseline results of MNA and/or GFI 
were strongly associated with an increased mortality risk, which could not be 
demonstrated for abnormal laboratory tests.
 The analysis of the role of GA in 143 patients with colorectal cancer for its 
predictive value on the feasibility of treatment with chemotherapy and survival, 
separately for patients treated with adjuvant intent (n = 54) or palliative intent 
(n = 89), is described in Chapter 4. Mean age was 75 years (range 70-92 years), 
Summary and general discussion
The decision to treat elderly patients with cancer aged 70 years or older with 
chemotherapy is generally based on clinical judgment of the clinician, in com-
bination with the evidence obtained from clinical studies performed in younger 
age groups. This clinical judgment often falls short to characterize the actual con-
dition of the elderly in full details. The instrument of geriatric assessment (GA) 
might be helpful to detect these hidden shortcomings and may aid clinical deci-
sion making with regard to the feasibility of treatment with chemotherapy and 
prediction of survival in the elderly patients with cancer. This thesis is the result 
of clinical research on certain elements of GA that might be useful for routine 
daily oncology practice, in order to select the proper patients and improve the 
outcome of treatment with chemotherapy. 
Summary
Chapter 2 describes the role of GA on 202 patients with a mean age of 77 years 
(range 71-92 years), all treated at the Reinier de Graaf hospital in Delft. The ma-
jority were women (55%), and most of the patients had colorectal cancer (30%) 
followed by haematological malignancies (18%) and breast cancer (17%). The 
GA consisted of the Mini Nutritional Assessment (MNA), Informant Question-
naire on Cognitive Decline in the Elderly (IQCODE), Groningen Frailty Index (GFI) 
and Mini Mental State Examination (MMSE). Furthermore, among 51 patients 
the assessment by MMSE and GFI was repeated after at least four cycles of chem-
otherapy or at six months after start of treatment with the aim to assess the im-
pact of the given chemotherapy. At baseline, adversities were detected in 33% of 
patients on the MNA, in 37% on the GFI, in 10% on the MMSE and in 15% on the 
IQCODE. The percentage of patients who could not complete at least four cycles 
of chemotherapy was significantly different in comparison with patients who un-
derwent four or more cycles with respect to the average scores on the MNA and 
MMSE (p = 0.001 and p = 0.04, respectively). The mortality rate after the start of 
chemotherapy was higher for patients with low (vs. high) MNA scores and high 
(vs. low) GFI scores, with hazard ratios (HRs) of 2.19 (95% confidence interval 
[CI]: 1.42-3.39; p < 0.001) and 1.80 (95% CI: 1.17-2.78; p = 0.007), respectively. 
After adjustment for sex, age, purpose of chemotherapy and type of malignancy, 
the increased HRs for mortality persisted. The post-chemotherapy evaluation by 
GFI and MMSE showed a significant deterioration for the MMSE (p = 0.041) but 
not for the GFI (p = 0.476). In conclusion, inferior test results of MNA, and for a 
lesser extent of the MMSE, were predictive for the inability to complete 4 cycles 
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to survival probabilities, frailty by abnormal GFI and low haemoglobin showed 
increased HRs for mortality, 2.55 and 4.90 respectively (adjusted for sex, age, 
comorbidity, age-adjusted IPI and univariate laboratory values with p < 0.10). In 
conclusion, this cohort of patients with aggressive NHL showed, that (risk of) 
malnutrition, measured with the MNA, frailty, measured with the GFI, and low 
haemoglobin level were predictive for early treatment withdrawal, and abnor-
mal GFI and haemoglobin were, independent of the age-adjusted IPI, predictive 
for an increased mortality risk. 
A detailed analysis on the question, which elements of the chosen geriatric 
screening program were independently predictive for feasibility of chemothera-
py and mortality in the whole cohort of 494 patients forms the subject of Chap-
ter 6. Men and women were almost equally divided. The mean age was 75 years 
(range 70-92 years). Most of the patients had cancer of the lower digestive tract 
(29%), followed by haematological malignancies (22%), upper digestive tract 
cancers (13%) and breast cancer (12%). Fifty-eight percent of the patients were 
treated with palliative intent. The GA showed shortcomings on the MNA in 36%, 
on the GFI in 30%, on the IQCODE in 13% and on the MMSE in 9% of the patients. 
In multivariable adjusted models, the MNA proved to be predictive for feasibility 
of chemotherapy with an odds ratio of 2.30 (95% CI: 1.48-3.58; p<0.001). With 
respect to survival, abnormal tests for MNA and GFI were independently predic-
tive for mortality with HRs of 1.86 (95% CI: 1.48-2.34; p<0.001) and 1.77 (95% 
CI: 1.41-2.22; p<0.001), respectively. Concerning the individual items of the MNA 
and the GFI, three items of the MNA were predictive for feasibility of chemo-
therapy: ‘psychological distress and/or acute disease in the past three months’, 
‘dementia or depression’ and ‘using >3 prescript drugs’ with odds ratios of 2.10, 
3.44 and 1.96, respectively. Two items of the MNA and one item of the GFI: ‘de-
clining food intake in past 3 months’, ‘using >3 prescript drugs’, and ‘dependent 
shopping’, were independently predictive for mortality with HRs of 1.82, 1.38 
and 1.77, respectively. Subsequently, the independent predictive items for mor-
tality were summed, and this sum score was analyzed using the multivariable 
adjusted Cox regression model. In comparison with patients without any positive 
item, patients with one, two or three positive item showed HRs for mortality of 
1.58, 2.32 and 5.58, respectively. This sum score was called the Geriatric Prog-
nostic Index (GPI). The median survival by application of the GPI was 2.26 years 
with score 0, 1.34 years with score 1, 0.95 years with score 2 and 0.56 years with 
score 3. In conclusion, a poor MNA score was predictive for not completing four 
cycles of chemotherapy (feasibility of chemotherapy), while poor MNA and GFI 
scores were predictive for an increased risk for mortality in this cohort of 494 
12% of patients were 80 years and older, 59% were men. At baseline, 28% of the 
patients showed abnormalities on the MNA, 24% on the GFI, 13% on the IQCODE 
and 8% on the MMSE. The mean scores of the GA tests were not significantly dif-
ferent between adjuvant and palliatively treated patients. Mean number of chem-
otherapy cycles was similar for adjuvant and palliatively treated patients (6.3 
and 6.2, respectively; p = 0.41). With respect to the probability of receiving less 
than four cycles of chemotherapy, only the result of the MNA test was significant-
ly predictive (p = 0.008) and only for palliatively treated patients. This finding 
persisted after adjusting for age, sex, number of co-morbidities and laboratory 
values. Patients with poor MNA- and GFI-scores had a higher risk of mortality 
with HRs of 2.95 (95% CI: 1.79-4.85; p < 0.001) and 2.38 (95% CI: 1.41-4.02; 
p = 0.001), respectively, again only when treated in palliative setting. This per-
sisted after adjustment for age, sex, number of comorbidities, and laboratory 
values of haemoglobin, creatinine and LDH (HRs 2.76 and 2.72, both p<0.001, 
respectively). In addition, adjusting for performance status, number of medica-
tions and serum albumin showed similar results in sensitivity analyses. The me-
dian survival differences between normal versus abnormal MNA test (i.e. well 
nourished vs. malnourished) and between normal versus abnormal GFI test (i.e. 
not frail vs. frail) were 9 and 10 months, respectively. Longitudinal follow-up by 
GFI and MMSE tests showed significant deterioration in GFI scores, especially of 
the physical elements limited to the palliatively treated group. In conclusion, 
poor MNA scores were predictive for the chance to receive less than four cycles 
of chemotherapy, and poor scores for MNA and GFI showed independently in-
creased HRs for mortality for palliatively treated patients only.
Chapter 5 describes the prognostic value of the used GA in relation to the 
age-adjusted IPI for patients with a mean age of 78 years (range 70-86 years; n 
= 44) diagnosed with aggressive non-Hodgkin lymphoma (91% had diffuse large 
B-cell lymphoma (DLBCL)) and treatment with R-CHOP. Fifty-seven percent were
women and 46% were 80 years or older. The majority of patients either belonged
to the low-intermediate risk category of the age-adjusted IPI (one risk factor, n =
21) or to the high-intermediate risk category (two risk factors, n = 18). At base-
line, 34% of the patients showed shortcomings on the MNA, 43% on the GFI,
11% on the IQCODE and 5% on the MMSE. Laboratory tests showed low albu-
min in 32%, low haemoglobin in 25%, elevated creatinine in 30% and elevated
LDH in 86% of the patients. Abnormal results of the MNA and GFI tests, and low
haemoglobin levels were associated with not being able to complete the intend-
ed chemotherapy, adjusted for sex, age, comorbidity and univariate laboratory
values with p ≤ 0.1 (odds ratio 8.29, 9.17 and 5.41, respectively). With respect
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3. Will GA predict complications? 4. What is the impact of GA on overall survival?
5. What is the impact of GA on treatment decisions? 6. What should be covered
by GA? and 7. How should GA be organized and implemented? [9]. An extensive
review of the literature provided answers on these questions. GA can detect rel-
evant health care problems in older patients with cancer that are under- or un-
recognized with a standard history and physical examination [13], and which el-
ements have significant effects on complications of treatment [14-17], change of
treatment plan [18, 19] and survival outcomes [20-22]. The domains that should
be covered by GA comprise: demography and social status, comorbidity, func-
tional status, cognition, depression, nutrition, fatigue, polypharmacy, and preva-
lent geriatric syndromes [9]. An international expert panel considered functional
status, comorbidity and cognition as the most important domains [12]. A recent
survey among haematologists in the Netherlands showed, that in daily practice
geriatric assessments are rarely carried out, and that especially comorbidity and
shortcomings with ADL are considered important for the decision to treat with
curative intent or not [23]. Furthermore, cardiovascular comorbidity, cognitive
disorders (especially dementia) and untreated depression formed common rea-
sons for dose-reductions in advance or palliative treatment only, especially in the 
over-eighties [24].
An instrument mentioned by the SIOG-consensus is the MNA, which measures 
nutritional status in a broad sense. The MNA screens on eighteen items, of which 
eleven items are directly related to nutrition while seven items cover other as-
pects of well-being: two items on IADL, three items on comorbidity, one item on 
polypharmacy and one item on psychological health. Roughly one-third of the 
patients included in our studies showed shortcomings on the MNA (ranging from 
28 to 42%). In case of such shortcomings, risks were increased for not completing 
four cycles of chemotherapy (except for 55 patients with breast cancer) as well 
as for overall mortality. The Eastern Cooperative Oncology Group found weight 
loss before the start of chemotherapy to have a negative impact on survival in a 
group of 3047 patients [25]. More recent studies confirmed the meaning of the 
nutritional status for mortality [20, 21]. An example that gives support for the 
MNA to predict the risk of severe non-hematologic toxicity after chemotherapy in 
older patients is shown with the Chemotherapy Risk Assessment Scale for High-
Age Patients (CRASH-score) [15]. This thesis, together with several reports in the 
literature, underscores the importance of the MNA as a risk profiling tool before 
chemotherapy is offered to the older patient with cancer, both with respect to 
toxicity and mortality risk.
patients with a variety of malignancies and treatments. The GPI can help to iden-
tify the elderly patient at increased risk for mortality. This instrument offers the 
oncologist an opportunity for fine-tuning of the treatment plan. We would like to 
advice that patients scoring 0-1 can be offered chemotherapy, a more thorough 
CGA might be of help for patients scoring 2, and the use of chemotherapy is ques-
tionable in patients scoring 3 points. 
General discussion
In the Netherlands, the life expectancy for men increased from 76 years to 79 
years and for women from 81 years to 83 years during the decade 2000-2010. 
In this decade, the chance for a 65 years old man to reach the age of 80 years 
increased from 52% to 63% and for a woman from 71% to 75%. For a large part, 
this may be explained by declining cancer deaths, as the incidence and mortality 
of patients with cancer increases with age. Sixty percent of all cancers and 70% 
of cancer mortality is found above 65 years of age [1]. Therefore, adult oncolo-
gists are, in fact, geriatric oncologists [2]. The estimated life expectancy and how 
treatment might affect function and quality of life is of utmost importance, as 
stated recently by Hyman Muss in an interview for the ASCO Post [3]. There are 
several tools to predict the life expectancy of elders [3-6]. An example of an online 
tool for the estimated life expectancy is given by ePrognosis [3, 7, 8]. However, 
these tools have not yet been studied and validated specifically within the oncol-
ogy population, and they should be explored in uniform cancer populations [9]. 
Nevertheless, by using the information of ePrognosis, one aspect for fine-tuning 
of the treatment plan can be covered. To cover other aspects, a geriatric-focused 
assessment is mandatory in order to avoid both undertreatment and excessive 
toxicity of the treatment plan [2]. Because of the heterogeneity in the aging pro-
cess, a cut-off score of age for the use of geriatric assessment before (and dur-
ing!) treatment of the elderly patients with cancer is not well defined [9]. How-
ever, the prevalence of age-related changes (e.g. dementia, decline of visual and 
hearing function, congestive heart failure etc.) increases sharply after 70 years of 
age [10, 11] and therefore we used a cut-off score of  ≥ 70 years. An international 
expert panel reached consensus, that GA should be performed in patients of 70 
years and over, and in younger patients with special issues or concerns [12]. 
The International Society of Geriatric Oncology (SIOG) formulated a con-
sensus statement on the role for geriatric assessment in older patients with 
cancer [9]. The consensus concentrated on the answers for seven questions, in 
short: 1. What is the rationale for GA? 2. What extra information is given by GA? 
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 One might suppose that patients who have been treated with chemother-
apy before, would show more signs of frailty and therefore would have a worse 
prognosis in comparison with patients without previous chemotherapy. Among 
the 494 patients with various types of cancer described in chapter six, there were 
74 patients who had already received chemotherapy before inclusion in the pro-
tocol comprising geriatric assessment. The groups of 420 and 74 patients did not 
differ significantly with respect to age-groups and gender. However, significantly 
more patients were treated with curative intent in the group of 420 patients who 
did not receive any chemotherapy in the past versus the group who did receive 
chemotherapy before (46% versus 20%, p < 0.001). This may explain that Cox re-
gression analysis showed an increased HR for mortality of 1.35 (95% confidence 
interval: 1.03-1.75; p = 0.03) in the previous chemotherapy group. Anyhow, the 
percentages of patients with an adverse score for GA at baseline were not signifi-
cantly different among the two groups, as shown in table 1. Moreover, previous 
chemotherapy was not an effect modifier for the predictive effect of the GPI on 
mortality (p=0.44 for interaction term), as shown in table 2. From this analysis 
we conclude that there was no significant difference in the GPI as a predictor for 
mortality, whether or not chemotherapy was given previously.
 The GFI is an instrument considered to assess frailty and contains two ADL 
items, two IADL items, one on polypharmacy, cognition and nutrition each, three 
physical fitness items, and five psycosocial items. The GFI may aid as a case finder 
for elderly patients who would benefit from integrated (geriatric) care [26]. As a 
screening test for frailty the GFI has been tested in elderly patients both without 
cancer [26, 27] and with cancer [27-30]. The threshold for frail vs. non-frail is ≥ 4 
points. However, in patients with cancer a cut-off value of ≥ 3 points seems more 
sensitive for the detection of frailty in comparison with a full comprehensive ger-
iatric assessment [28]. Abnormal scores of the GFI (≥ 4 points) were identified 
in 30% of the patients investigated in the studies of this thesis (ranging from 24 
to 51% for the different cohorts). Patients with shortcomings showed a higher 
risk for mortality after start of treatment with chemotherapy. Similarly, an ele-
vated risk of mortality was found in patients after surgery for gastric cancer [30]. 
Thus, the studies in this thesis emphasize the importance of the GFI to identify 
elderly patients at increased risk for mortality after the start of chemotherapy. 
A more detailed comprehensive geriatric assessment with the help of a geriatri-
cian might be helpful for these patients, in order to identify frailty as precise as 
possible. Further studies should explore whether intervention aimed at specific 
domains of frailty and malnutrition may help to improve outcome.
 The MMSE is often used to screen for cognitive problems in elderly patients 
with cancer. Screening for cognition is also mentioned as an important domain 
by consensus panels [9, 12]. The patients in the studies of this thesis showed 
cognitive problems in 5-10% on the MMSE and 11-18% on the IQCODE. Some of 
the analyses reported in this thesis showed a correlation with the risk of mortal-
ity, but these relationships were generally less strong than the relationships with 
the above mentioned GFI and MNA. Only the cohort study described in Chapter 
2, showed statistically significant association between a low MMSE score and 
the risk of not completing the intended chemotherapy. Moreover, the MMSE 
worsened significantly during chemotherapy in this cohort. It has to be stressed, 
that the patients underwent screening after the decision for the start of chemo-
therapy had been made by their (hemato-)oncologist, which choice would most 
likely be affected by overt symptoms of cognitive dysfunction. As included pa-
tients were therefore unlikely to have obvious cognitive problems, our findings 
may be prone to some selection bias. Nevertheless, a previous study also found 
evidence for an abnormal MMSE test to be predictive of non-hematologic toxicity 
in the CRASH score [15]. Findings therefore suggest that patients with cognitive 
impairment may require a modification of their treatment regimen or increased 
supervision during their treatment [31, 32].
Table	  1.	  Base-­‐line	  characteristics	  according	  to	  previous	  chemotherapy	  in	  494	  patients.	  	  








Male	  gender	   213	  (50.7%)	   33	  (44.6%)	   0.33	  
Age	  groups:	   	   	   	  
	  	  	  70-­‐74	  yr	   200	  (47.6%)	   37	  (50.0%)	   0.67	  
	  	  	  75-­‐79	  yr	   145	  (34.5%)	   25	  (33.8%)	   	  
	  	  	  ≥	  80	  yr	   75	  (17.9%)	   12	  (16.2%)	   	  
Curative	  intent	  	   191	  (45.5%)	   15	  (20.3%)	   <	  0.001	  
Adverse	  base-­‐line	  score	  of	  GA	   	   	   	  
	  	  	  MNA	   153	  (36.8%)	   21	  (28.4%)	   0.16	  
	  	  	  GFI	   131	  (31.3%)	   18	  (24.3%)	   0.23	  
	  	  	  IQCODE	   52	  (12.6%)	   10	  (14.7%)	   0.64	  
	  	  	  MMSE	   40	  (9.6%)	   4	  (5.5%)	   0.26	  
	  
	  
The role of geriatric assessment prior to chemotherapy in elderly patients with cancer Chapter 7  |  Summary and general discussion138 139
Flowchart	  
	  Patient	  with	  cancer
age	  ≥	  70	  yr
considering	  chemotherapy
Geriatric	  Prognostic	  Index	  (GPI)	  screening
-­‐	  ‘declining	  food	  intake	  in	  past	  3	  months’
-­‐	  ‘using	  >3	  prescript	  drugs’
-­‐	  ‘dependent	  shopping’
Consider:





·∙ 	   repeat	  compromised	  assessment
·∙ 	   change	  of	  schedule,	  dose	  
reduction,	  tailored	  medication
·∙ 	   revision	  of	  supportive	  care





·∙ 	   Social	  status,	  comorbidity,	  functional	  status,	  
cognition,	  depression,	  nutrition,	  polypharmacy,	  
existence	  of	  geriatric	  syndromes9
·∙ 	   Consultance	  of	  geriatrician	  (team)
Consider:
·∙ 	   supportive	  care:	  physical	  therapist,	  
occupational	  therapist,	  social	  worker,	  
pharmacist,	  nutritionist33
·∙ 	   change	  of	  schedule,	  	  dose	  reduction,	  tailored	  
medication	  
·∙ 	   Longitudinal	  follow-­‐up	  by	  CGA	  
	  Patient	  with	  cancer	  
starting	  chemotherapy
Comprehensive	  geriatric	  assessment:
·∙ 	   Social	  status,	  comorbidity,	  functional	  status,	  
cognition,	  depression,	  nutrition,	  polypharmacy,	  
existence	  of	  geriatric	  syndromes9
·∙ 	   Consultance	  of	  geriatrician	  (team)
Consider:
·∙ 	   supportive	  care:	  physical	  therapist,	  
occupational	  therapist,	  social	  worker,	  
pharmacist,	  nutritionist33
·∙ 	   change	  of	  schedule,	  	  dose	  reduction,	  tailored	  
medication	  








Table 2. Risk of mortality in relation to the GPI score according to previous chemotherapy. 









No Previous Chemotherapy (n=420) 
 Score 0 (n=154) 29 Ref. < 0.001 0.44 
 Score 1 (n=152) 15 1.58 (1.21-2.08) 
 Score 2 (n=90) 10 2.40 (1.76-3.24) 
 Score 3 (n=21) 5 5.20 (3.18-8.49) 
Previous Chemotherapy (n=74) 
 Score 0 (n=34) 16 Ref. 0.09 
 Score 1 (n=23) 14 1.04 (0.54-2.01) 
 Score 2 (n=14) 9 1.39 (0.69-2.81) 
 Score 3 (n=3) 7 7.60 (1.94-29.7) 
Hazard ratios (with 95% confidence intervals [CI]) were calculated using Cox regression analysis, and 
models were adjusted for sex, age, purpose of treatment, and type of malignancy.  
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3. Understand the impact of oncology therapeutics in the general population
of older cancer patients.
4. Identify and test interventions to improve symptoms and maintain quality
of life of older cancer patients.
The clinical research described in this thesis focused on the roles of the 
MNA and the GFI, both for feasibility of treatment with chemotherapy and as pre-
dictors for overall survival. Whether intervention strategies, after having identi-
fied specific shortcomings, will lead to better outcomes and will help to maintain 
quality of life, form challenging questions that still need to be resolved. On the 
basis of the results described in this thesis and in view of the current literature, 
we propose the following recommendations as is depicted in the flow chart be-
low when chemotherapy is considered in an elderly patient with cancer.
The elderly patients with cancer, increasing rapidly in numbers in the 
coming decades, deserve nothing less than an optimal inventory of coexisting 
geriatric problems which predict the feasibility of certain therapeutic strategies, 
of which chemotherapy is an important part. Furthermore, this gives a better 
insight in the overall life expectancy in order to choose the proper treatment-
plan without the risk of over- or under treatment [2]. Elderly-specific studies 
on intervention strategies, based on GA, to improve the outcome of treatment 
should be developed and the elderly should be encouraged to participate herein. 
These kind of studies have been performed in younger age groups with positive 
outcome for an exercise related program in breast cancer patients [36] and, cur-
rently, a study protocol on the effect of physical exercise in elderly breast cancer 
survivors is running in the Netherlands (the Climb Every Mountain study) [37]. 
Thus, the research is evolving, although much effort still lies ahead in the coming 
decade on the development of tumor-specific studies. The studies of this thesis 
can be used for background information, upon which these developments can be 
built. We hope that this thesis may contribute to the development of standard-
ized instruments and may help to let the GA become part of routine care in the 
elderly oncology patient. The use of computerized measurements may facilitate 
this incorporation.
Our in-depth analysis that included all items of the MNA and the GFI on the 
risk for mortality after the start of chemotherapy identified two items of the MNA 
and one item of the GFI as independent risk factors. On the basis of these three 
items the Geriatric Prognostic Index (GPI) was constructed to help the medical 
(hemato-)oncologist in identifying the elderly patient with cancer at increased 
risk for mortality before chemotherapy is started. Just by asking the following 
three questions important prognostic information may be uncovered: ‘declining 
food intake in past 3 months’, ‘using > 3 prescript drugs’, and ‘dependence in 
shopping’. In case of a high score, a more elaborate comprehensive geriatric as-
sessment by a geriatrician is warranted to tailor a more detailed treatment plan 
before chemotherapy should be considered. The meaning of these findings and 
recommendations for clinical practice should be investigated in future research. 
However, so far these recommendations are only applicable for patients of whom 
the clinician decided for treatment with chemotherapy on clinical grounds and 
furthermore, need to be validated in other cohorts.
How should the knowledge, obtained by a geriatric assessment in clinical 
oncology be incorporated into clinical practice? In the ideal situation the elderly 
patient’s needs are covered by a geriatric oncologist. However, both the fields 
of geriatrics and oncology are evolving rapidly and therefore, in practice, coop-
erative actions of oncologists (trained in the basic principles of geriatrics) and 
geriatricians (trained in applying cancer-specific geriatric assessments) will be 
necessary to optimize the care for the elderly with cancer [33]. This can be ac-
complished in so-called geriatric oncology units or by a geriatric consultation 
team (GCT) [9, 33]. The advantage of the model with a GCT is, that the direct 
relationship between the patient and the oncologist is not interrupted and that 
the onco-geriatric team is available for guidance if further geriatric-related is-
sues occur. A possible disadvantage might be the organization for longitudinal 
follow-up of geriatric issues [9]. GCT’s (consisting of a geriatrician and geriatrics-
trained nurse practitioner or physician’s assistant) should be embedded into an 
existing oncology clinic, and should participate actively in a multidisciplinary 
team [9, 33]. Recently, the role of the pharmacist in the multidisciplinary team 
was advised to further explore the potential adverse effects of polypharmacy, 
complex drug-drug interactions, and potentially inappropriate medication [34].
Mohile et al defined four goals for research in geriatric oncology [35]:
1. Incorporate geriatric assessment tools into clinical trials that predict
adverse outcomes for older adults with cancer.
2. Test the ability of a geriatric assessment model of care for improving
outcomes of older cancer patients.
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Samenvatting en algemene discussie
Het besluit om patiënten met kanker van 70 jaar en ouder te behandelen met 
chemotherapie is grotendeels gebaseerd op het klinische oordeel van de behan-
delend arts, welke in belangrijke mate gebaseerd is op wetenschappelijk onder-
zoek van jongere patiëntengroepen. Het klinische oordeel schiet vaak te kort om 
gedetailleerd de actuele conditie van de oudere patiënt te typeren. Het instru-
ment geriatrisch assessment (GA) kan helpen om verborgen problemen op te 
sporen en de besluitvorming met betrekking tot de haalbaarheid van de behan-
deling met chemotherapie en de overleving van de oudere patiënt met kanker 
te onderbouwen. Dit proefschrift is het resultaat van onderzoek met de gekozen 
onderdelen van het GA die van belang zouden kunnen zijn in de oncologische 
praktijk van alledag, teneinde de uitkomst van de behandeling met chemothera-
pie te verbeteren.
Samenvatting
Hoofdstuk 2 beschrijft de rol van het GA bij 202 patiënten met een gemiddel-
de leeftijd van 77 jaar (met een spreiding van 71-92 jaar) die allen behandeld 
werden in het Reinier de Graafgasthuis in Delft. De meerderheid was vrouw 
(55%) en de meesten hadden darmkanker (30%) gevolgd door hematologische 
maligniteiten (18%) en borstkanker (17%). Het GA bestond uit de ‘Mini Nutri-
tional Assessment’ (MNA), ‘Informant Questionnaire on Cognitive Decline in the 
Elderly’ (IQCODE), ‘Groningen Frailty Index’ (GFI) en ‘Mini Mental State Exami-
nation’ (MMSE). Bovendien werden bij 51 patiënten de MMSE en de GFI herhaald 
na tenminste 4 kuren of 6 maanden na de start van de chemotherapie met het 
doel de gevolgen van de chemotherapie op de testscores te kunnen beoordelen. 
Voor aanvang van de chemotherapie werden de volgende percentages tekort-
komingen geregistreerd: met de MNA bij 33% van de patiënten, met de GFI bij 
37%, met de MMSE bij 10%, en met de IQCODE bij 15%. Het percentage van de 
patiënten die 4 kuren niet konden afmaken verschilde significant van de groep 
die wel 4 of meer kuren hadden gekregen ten aanzien van de gemiddelde uitkom-
sten van de MNA (p = 0.001) en MMSE (p = 0.04). Het sterftecijfer na de start van 
de chemotherapie was verhoogd bij patiënten met een lage (versus hoge) MNA 
score en een hoge (versus lage) GFI score, met ‘hazard ratios’ (HRs) van respec-
tievelijk 2.19 (95% ‘confidence’ interval [CI]: 1.42-3.39; p < 0.001) en 1.80 (95% 
CI: 1.17-2.78; p = 0.007). De verhoogde HR’s persisteerden na correctie voor ge-
slacht, leeftijd, doel van de chemotherapie en soort maligniteit. De evaluatie van 
de MMSE en GFI na de chemotherapie liet een significante verslechtering zien 
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de voorspellende waarde van de haalbaarheid van de behandeling met chemo-
therapie en voor de overleving, afzonderlijk voor adjuvant (n = 54) en palliatief 
(n = 89) behandelde patiënten wordt beschreven in hoofdstuk 4. De gemiddelde 
leeftijd was 75 jaar (met een spreiding van 70-92 jaar van wie 12% ouder was 
dan 80 jaar). Voor aanvang van de chemotherapie werden tekortkomingen ge-
constateerd bij 28% van de patiënten met de MNA, bij 24% met de GFI, bij 13% 
met de IQCODE en bij 8% met de MMSE. De gemiddelde scores van de GA testen 
waren niet significant verschillend tussen de adjuvant en de palliatief behandel-
de patiënten. Het gemiddelde aantal chemotherapie cycli was gelijk voor de ad-
juvant en de palliatief behandelde patiënten, respectievelijk 6.3 en 6.2 (p = 0.41). 
Ten aanzien van de mogelijkheid om minder dan 4 chemotherapie cycli te krijgen 
bleek alleen het resultaat van de MNA significant voorspellend (p = 0.008), en 
wel alleen voor de palliatief behandelde patiënten. Deze bevinding persisteerde 
na correctie voor leeftijd, geslacht, aantal comorbiditeiten en laboratorium 
waarden. Patiënten met een slechte MNA- en GFI-score hadden een hoger mor-
taliteitsrisico met HRs van respectievelijk 2.95 (95% CI: 1.79-4.85; p < 0.001) en 
2.38 (95% CI: 1.41-4.02; p = 0.001), wederom alleen in de palliatief behandelde 
groep. Dit bleef ook zo na multivariabele adjustering (HRs van respectievelijk 
2.76 en 2.72, beide p < 0.001). Na additioneel geadjusteerd te hebben voor PS, 
aantal medicamenten en serum albumine lieten sensitiviteits-analyses soortgeli-
jke uitkomsten zien. Het verschil in mediane overleving met de MNA (normaal 
versus (kans op) ondervoeding) en de GFI (niet kwetsbaar versus kwetsbaar) 
was respectievelijk 9 en 10 maanden. Longitudinaal vervolgonderzoek met de 
GFI en MMSE liet alleen een in de palliatief behandelde patiënten een significante 
achteruitgang zien in de GFI score, en wel met betrekking tot de fysieke aspecten 
van de GFI. Samenvattend bleek een slechte MNA scores voorspellend te zijn 
voor de kans op minder dan 4 cycli chemotherapie en slechte scores van de MNA 
en GFI toonden, onafhankelijk van elkaar, toegenomen HR’s voor sterfte, alleen in 
de palliatief behandelde groep.
Hoofdstuk 5 beschrijft de prognostische waarde van het gebruikte GA in 
relatie tot de ‘age-adjusted-International Prognostic Index’ (age-adjusted-IPI) bij 
patiënten met een gemiddelde leeftijd van 78 jaar (met een spreiding van 70-
86 jaar; n = 44) gediagnosticeerd met agressief non-Hodgkin lymfoom (NHL). 
Van hen had 91% een diffuus grootcellig B-cel lymfoom (DLBCL) en allen waren 
behandeld met R-CHOP. De meerderheid van de patiënten behoorde of tot de 
laag-intermediaire risico groep (1 risico factor, n = 21) of tot de hoog-intermedi-
aire risico groep (2 risico factoren, n = 18). Voor aanvang van de chemotherapie 
werden tekortkomingen geconstateerd bij 34% van de patiënten met de MNA, bij 
bij de MMSE (p = 0.04), maar niet bij de GFI (p = 0.48). Samenvattend bleken 
slechtere resultaten bij de MNA, en in mindere mate met de MMSE, voorspellend 
voor het niet afronden van tenminste 4 chemotherapiekuren, terwijl patiënten 
met tekortkomingen met de MNA en GFI een verhoogd sterfterisico lieten zien. 
Hoofdstuk 3 concentreert zich op de resultaten van de uitkomst van het 
GA bij 55 patiënten met borstkanker met een gemiddelde leeftijd van 76 jaar 
(met een spreiding van 70-88 jaar en van wie 20% ouder dan 80 jaar was). Naast 
de hierboven genoemde GA testen zijn ook de uitgangswaarden van serum albu-
mine, hemoglobine, creatinine en lactaat dehydrogenase (LDH) in beschouwing 
genomen in relatie tot de uitkomst van palliatieve chemotherapie. Bij 21 patiënt-
en werd de MMSE en de GFI herhaald na tenminste 4 kuren of 6 maanden na de 
start van de chemotherapie. Met de MNA waren afwijkende testresultaten aan-
wezig bij 42% van de patiënten, met de GFI bij 51%, met de IQCODE bij 18% en 
met de MMSE bij 9%. Afwijkende laboratoriumtesten van creatinine, albumine, 
hemoglobine en LDH waren aanwezig bij respectievelijk 13%, 33%, 78% en 84% 
van de patiënten. Behalve de inverse correlatie tussen de MNA en GFI (r = -0.43; p 
< 0.001) en tussen de IQCODE en MMSE (r = -0.36; p = 0.01), werden er geen sig-
nificante correlaties tussen de GA- en laboratoriumtesten gevonden. Echter, een 
verminderde ‘WHO-performance status’ (PS) was wel gecorreleerd met slechtere 
uitkomsten van de MNA (r = -0.28, p = 0.04) en GFI (r = 0.38, p = 0.004). Er waren 
geen statistisch significante verschillen tussen het aantal patiënten (n = 39) die 
ten minste 4 kuren kregen vergeleken met de patiënten (n = 16) die minder dan 4 
kuren kregen met betrekking tot het GA en de laboratorium parameters (ook niet 
na correctie voor leeftijd, comorbiditeit en PS). Slechtere MNA en GFI uitkomsten 
waren geassocieerd met een verhoogde mortaliteit met HRs van respectievelijk 
3.05 (95% CI: 1.44–6.45; p = 0.004) en 3.40 (95% CI: 1.62–7.10; p = 0.001). Wan-
neer de MNA en de GFI werden gecombineerd in één multivariabel Cox-regressie 
model, hadden beide GA-parameters een onafhankelijke bijdrage (p = 0.04 voor 
de MNA en p = 0.02 voor de GFI). Het verschil van de mediane overleving met de 
MNA (normaal versus (kans op) ondervoeding) en de GFI (niet kwetsbaar versus 
kwetsbaar) was meer dan 12 maanden voor beide testen. De evaluatie van de 
MMSE en GFI na de chemotherapie liet een verslechtering zien van de fysieke 
aspecten van de GFI (p = 0.05). Samenvattend bleken noch de GA-testen, noch 
de laboratoriumtesten voorspellend te zijn voor de kans om de chemotherapie 
af te ronden in dit patiëntencohort. Echter, abnormale uitgangswaarden van de 
MNA en/of GFI verhoogden het mortaliteitsrisico, terwijl dit niet kon worden 
aangetoond voor abnormale laboratoriumtesten. 
De analyse van de rol van het GA bij 143 patiënten met darmkanker voor 
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samengenomen en werd de score geanalyseerd door middel van een multivari-
abel gecorrigeerd Cox regressie-model. In vergelijking met patiënten zonder één 
enkel positief item lieten de patiënten met één, twee of drie positieve items HR’s 
zien van respectievelijk 1.58, 2.32 en 5.58. Deze score werd de ‘Geriatric Prog-
nostic Index’ (GPI) genoemd. De mediane overleving met toepassing van de GPI 
was 2.26 jaar met score 0, 1.34 jaar met score 1, 0.95 jaar met score 2 en 0.56 
jaar met score 3. Samenvattend bleek een slechte MNA-score voorspellend voor 
de haalbaarheid van chemotherapie, terwijl slechte MNA- en GFI- scores voor-
spellend waren voor mortaliteit in dit cohort van 494 patiënten met een versc-
heidenheid aan maligniteiten en behandelingen. De GPI kan behulpzaam zijn om 
oudere patiënten te identificeren met een verhoogd mortaliteitsrisico. Dit instru-
ment biedt de oncoloog de mogelijkheid om het behandelplan af te stellen op de 
noden van de patiënt. We zouden willen adviseren om patiënten met een score 
van 0-1 standaard chemotherapie aan te bieden, terwijl een uitgebreider GA van 
nut kan zijn bij een score van 2. Het is discutabel of chemotherapie aangeboden 
moet worden bij een score van 3. 
Algemene discussie
In Nederland is de levensverwachting in de jaren 2000-2010 voor mannen geste-
gen van 76 jaar naar 79 jaar en voor vrouwen van 81 jaar naar 83 jaar. De kans 
om 80 jaar te worden voor een 65-jarige man laat in dit decennium een stijging 
zien van 52% naar 63% en voor een vrouw van 71% naar 75%. Voor een groot 
gedeelte is dit te verklaren door een daling van de sterfte ten gevolge van kanker, 
immers, met stijgende leeftijd nemen de incidentie en de mortaliteit ten gevolge 
van kanker toe. Zestig procent van alle kankers en 70% van de mortaliteit ten 
gevolge van kanker wordt gezien na de leeftijd van 65 jaar [1]. Daarom zijn on-
cologen in feite geriater-oncologen [2]. De geschatte levensverwachting en de 
wijze waarop de behandeling het functioneren en de kwaliteit van leven beïn-
vloedt, is uitermate belangrijk, zoals benadrukt door Hyman Muss in een inter-
view voor de ASCO Post [3].
Er zijn verschillende hulpmiddelen om de levensverwachting van ouderen 
te schatten [3-6]. Een voorbeeld van een ‘online’ hulpmiddel voor de geschatte 
levensverwachting betreft ‘ePrognosis’ [3, 7, 8]. Echter, dergelijke hulpmiddelen 
zijn nog niet bestudeerd binnen de oncologische populatie en behoren verder te 
worden onderzocht per tumorsoort [9]. Desalniettemin, door gebruik te maken 
van de informatie van ePrognosis kan één aspect voor een goed afgestemd be-
handelplan worden meegenomen. Voor het wegen van andere aspecten is een 
43% met de GFI, bij 11% met de IQCODE en bij 5% met de MMSE. Laboratorium 
testen toonden laag albumine bij 32% van de patiënten, laag hemoglobine bij 
25%, verhoogd creatinine bij 30%, en verhoogd LDH bij 86%. 
Afwijkende resultaten van de MNA en GFI en een laag hemoglobine waren 
geassocieerd met het niet afronden van de voorgenomen chemotherapie, in 
multivariabele modellen (odds ratio van respectievelijk 8.29, 9.17 en 5.41). Een 
afwijkende GFI en een laag hemoglobine lieten een onafhankelijk verhoogd risico 
op mortaliteit zien met HRs van respectievelijk 2.55 en 4.90. Samenvattend liet 
dit cohort van patiënten met agressief NHL zien dat (de kans op) ondervoed-
ing, gemeten met de MNA, kwetsbaarheid, gemeten met de GFI, en een verlaagd 
hemoglobine voorspellend waren voor voortijdig staken van de behandeling en 
een afwijkende GFI en hemoglobine waren, onafhankelijk van de ‘age-adjusted-
IPI’, voorspellend voor een verhoogd mortaliteitsrisico. 
Een gedetailleerde analyse van de vraag, welke onderdelen van het 
gekozen geriatrisch screenings programma onafhankelijk voorspellend waren 
voor de haalbaarheid van chemotherapie en welke voor mortaliteit in het gehele 
cohort van 494 patiënten, vormt het onderwerp van hoofdstuk 6. Mannen en 
vrouwen waren zo goed als gelijk verdeeld. De gemiddelde leeftijd was 75 jaar 
(met een spreiding van 70-92 jaar). De meeste patiënten hadden maligniteiten 
van de lage tractus digestivus (29%), gevolgd door hematologische malignitei-
ten (22%), hoge tractus digestivus maligniteiten (13%) en borstkanker (12%). 
Achtenvijftig procent van de patiënten werd behandeld met palliatieve intentie. 
Het GA liet tekortkomingen zien bij 36% van de patiënten met de MNA, bij 30% 
met de GFI, bij 13% met de IQCODE, en bij 9% met de MMSE. In multivariabele, 
gecorrigeerde modellen bleek de MNA voorspellend voor de haalbaarheid van 
chemotherapie met een odds ratio van 2.30 (95% CI: 1.48-3.58; p < 0.001). Ten 
aanzien van de overleving waren afwijkende testuitslagen van de MNA en GFI on-
afhankelijk voorspellend voor mortaliteit met HRs van respectievelijk 1.86 (95% 
CI: 1.48-2.34; p < 0.001) en 1.77 (95% CI: 1.41-2.22; p < 0.001). Met betrekking 
tot de individuele items van de MNA en GFI bleken drie items van de MNA on-
afhankelijk voorspellend voor de haalbaarheid van chemotherapie: ‘mentale 
stress en/of acute ziekte in de afgelopen drie maanden’, ‘dementie of depressie’, 
en ‘dagelijks meer dan drie voorgeschreven medicijnen’ met een odds ratio van 
respectievelijk 2.10, 3.44 en 1.96. Twee items van de MNA (‘verminderde eet-
lust in de afgelopen drie maanden’ en ‘dagelijks meer dan drie voorgeschreven 
medicijnen’) en één item van de GFI (‘afhankelijkheid voor boodschappen doen’) 
waren onafhankelijk voorspellend voor mortaliteit met HRs van respectievelijk 
1.82, 1.38 and 1.77. Vervolgens werden de onafhankelijk voorspellende items 
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geriatrisch georiënteerde beoordeling vereist, teneinde onderbehandeling en 
bovenmatige toxiciteit van het behandelplan te vermijden [2]. Vanwege de heter-
ogeniteit van het verouderingsproces is een afkapwaarde voor de leeftijd, vanaf 
welke een geriatrische beoordeling (‘geriatric assessment’ (GA)) moet worden 
gebruikt vóór (en tijdens!) de behandeling van de oudere patiënt met kanker 
niet goed gedefinieerd [9]. Echter, de prevalentie van leeftijdsgebonden aandoe-
ningen (zoals dementie, achteruitgang van visus en gehoor, hartfalen, etc.) stijgt 
fors na de leeftijd van 70 jaar [10, 11] en daarom gebruikten wij deze afkap-
waarde. Een internationaal panel van deskundigen kwam ook tot consensus, dat 
GA uitgevoerd moet worden bij patiënten van zeventig jaar en ouder, alsmede bij 
jongere patiënten met speciale problemen of zorgvragen [12].
 De ‘International Society of Geriatric Oncology’ (SIOG) formuleerde con-
sensus over de rol van het GA bij oudere patiënten met kanker [9]. De consensus 
concentreerde zich op de antwoorden van zeven vragen, in het kort: “1. Wat is 
de rationale voor het GA? 2. Welke extra informatie wordt verstrekt door het 
GA? 3. Kan het GA complicaties voorspellen? 4. Wat betekent het voor de totale 
overleving? 5. Wat betekent het voor de besluitvorming van de behandeling? 6. 
Wat moet meegenomen worden bij het GA? en 7. Hoe moet het GA georganiseerd 
en geïmplementeerd worden?” [9]. Een uitgebreid overzicht van de literatuur 
geeft antwoorden op deze vragen. GA kan bij oudere patiënten met kanker rel-
evante gezondheidsproblemen vaststellen die niet onderkend of niet herkend 
zijn bij standaard anamnese en lichamelijk onderzoek [13] en die significante 
effecten hebben op complicaties van de behandeling [14-17], wijziging van het 
behandelplan [18, 19] en uitkomst van de overleving [20-22]. De domeinen die 
meegenomen behoren te worden bij het GA omvatten: demografische en sociale 
status, comorbiditeit, functionele status, cognitie, depressie, voeding, vermoeid-
heid, polyfarmacie en bestaande geriatrische syndromen [9]. Een internationaal 
panel van deskundigen beschouwde functionele status, comorbiditeit en cog-
nitie als de meest belangrijke domeinen [12]. Een enquête onder Nederlandse 
hematologen liet zien, dat in de dagelijkse praktijk GA’s zelden worden uitgevo-
erd en dat met name comorbiditeit en tekortkomingen bij de ADL van belang 
werden geacht ten aanzien van de intentie om wel of niet curatief te behandelen 
[23]. Bovendien vormden cardiovasculaire comorbiditeit, cognitieve stoornissen 
(vooral dementie) en onbehandelde depressie veel voorkomende redenen om 
op voorhand dosis-reductie toe te passen of alleen palliatief te behandelen, met 
name bij 80-plussers [24].
 Eén van de instrumenten, aangegeven in de SIOG consensus, betreft de 
MNA, waarmee de voedingsstatus in brede zin gemeten wordt. De MNA screent 
op achttien items, waarvan elf items direct gerelateerd zijn aan voeding en zeven 
items aan andere aspecten van welzijn: twee items over IADL, drie items over 
comorbiditeit , één item over polyfarmacie, en één item over psychische gezond-
heid. Ongeveer een derde van de patiënten (variërend van 28% tot 42%) in onze 
studies lieten tekortkomingen zien bij de MNA. Bij zulke tekortkomingen was er 
een verhoogd risico zowel om vier chemotherapie cycli niet af te maken (met 
uitzondering van 55 patiënten met borstkanker) als voor de totale sterfte. De 
‘Eastern Cooperative Oncology Group’ vond in een groep van 3047,patiënten, dat 
gewichtsverlies voor de start van de chemotherapie een negatief effect had op de 
overleving [25]. Recentere studies bevestigden het belang van de voedingsstatus 
met betrekking tot mortaliteit [20, 21]. Een voorbeeld, dat steun geeft aan de 
MNA als voorspellende factor voor het risico van ernstige niet-hematologische 
toxiciteit na chemotherapie bij oudere patiënten, betreft de ‘Chemotherapy Risk 
Assessment Scale voor High-Age Patients (CRASH-score)’ [15]. Al met al onder-
steunt dit proefschrift, samen met verscheidene rapportages in de literatuur, het 
belang van de MNA als risicoprofiel voor chemotherapie bij de oudere patiënt 
met kanker, zowel voor wat betreft toxiciteit als mortaliteit.
 De GFI is een instrument met het doel kwetsbaarheid te beoordelen en bev-
at twee items over de ADL, twee items over de IADL, één item over respectievelijk 
polyfarmacie, cognitie en voeding, drie items over fysieke fitheid, en vijf psycho-
sociale items. De GFI kan helpen bij het identificeren van oudere patiënten die 
zouden kunnen profiteren van geïntegreerde (geriatrische) zorg [26]. De GFI is 
als screenings instrument voor kwetsbaarheid getest bij oudere patiënten, zow-
el zonder [26, 27] als met kanker [27-30]. De drempelwaarde voor kwetsbaar 
versus niet-kwetsbaar is ≥ 4 punten. Echter, bij patiënten met kanker lijkt een 
afkapwaarde van ≥ 3 punten gevoeliger voor de detectie van kwetsbaarheid in 
vergelijking met een volledig uitgevoerd CGA [28]. Tekortkomingen met de GFI (≥ 
4 punten) werden gevonden in 30% van de patiënten in de studies van dit proef-
schrift (variërend van 24% tot 51% in de verschillende cohorten). Patiënten met 
tekortkomingen vertoonden een verhoogd risico op mortaliteit na aanvang van 
de behandeling met chemotherapie. Evenzo werd er een verhoogd sterfte-risico 
gevonden na operatie bij patiënten met maagkanker [30]. Aldus benadrukken 
de studies in dit proefschrift het belang van de GFI om oudere patiënten met een 
verhoogd risico op mortaliteit te identificeren na de start van de chemotherapie. 
Een gedetailleerd CGA, met behulp van een geriater, kan nuttig zijn voor deze 
patiënten om kwetsbaarheid zo precies mogelijk te identificeren. Vervolgstudies 
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tussen de twee groepen, zie tabel 1. Bovendien bleek eerdere chemotherapie niet 
van invloed op de voorspellende waarde van de GPI voor mortaliteit (p = 0.44 
voor interactie), zie tabel 2. Concluderend: er was geen significant verschil voor 
de GPI als risicofactor voor mortaliteit, of nu wel of niet eerder chemotherapie 
was gegeven.
moeten onderzoeken of interventie, gericht op specifieke domeinen van kwets-
baarheid en ondervoeding, kunnen helpen bij het verbeteren van de uitkomsten. 
De MMSE wordt vaak gebruikt voor de screening op cognitieve problemen 
bij oudere patiënten met kanker. Screening van cognitie wordt ook genoemd als 
belangrijk domein door de consensus-panels [9, 12]. De patiënten in de studies 
van dit proefschrift lieten cognitieve problemen zien in 5%-10% met de MMSE 
en in 11%-18% met de IQCODE. Sommige van de gerapporteerde analyses in 
dit proefschrift laten een correlatie zien met het sterfterisico, maar deze relat-
ies waren minder sterk en minder consistent dan de relaties met de hiervoor 
genoemde GFI en MNA. Alleen de beschreven cohort-studie van hoofdstuk 2 laat 
een significante associatie zien tussen een lage MMSE-score en het risico om de 
beoogde chemotherapie niet af te maken. Bovendien was er een significante ver-
slechtering geobserveerd met de MMSE tijdens chemotherapie in dit cohort. Het 
moet worden benadrukt dat de patiënten de screening ondergingen nadat de 
beslissing was genomen om te starten met chemotherapie door hun (hemato-) 
oncoloog. Hierbij is het waarschijnlijk dat de keuze werd beïnvloed door duideli-
jke symptomen van cognitieve dysfunctie. Omdat het onwaarschijnlijk geacht 
werd dat de geïncludeerde patiënten duidelijke cognitieve problemen hadden, 
kunnen onze bevindingen beïnvloed zijn door selectie bias. Desalniettemin 
werden er in een eerdere studie ook aanwijzingen gevonden dat een afwijkende 
MMSE-test voorspellend was voor niet-hematologische toxiciteit in de CRASH 
score [15]. Deze bevindingen suggereren dan ook dat patiënten met cognitieve 
achteruitgang baat kunnen hebben bij aanpassing van hun behandelplan of een 
intensiever toezicht tijdens de behandeling [31, 32].
Men kan veronderstellen dat patiënten, die eerder met chemotherapie 
zijn behandeld meer tekenen van kwetsbaarheid tonen en daarom een slechtere 
prognose hebben, in vergelijking met patiënten die niet eerder met chemothera-
pie zijn behandeld. Onder de in hoofdstuk 6 beschreven 494 patiënten met een 
verscheidenheid aan kanker bevonden zich 74 patiënten, die chemotherapie 
hadden gehad vóór deelname aan het protocol met GA. De groepen van 420 en 
74 patiënten verschilden niet significant met betrekking tot leeftijdscohorten en 
geslacht. Echter, in de groep van 420 patiënten zonder eerdere chemotherapie 
werden significant vaker patiënten in opzet curatief behandeld, in vergelijking 
met de groep waarin eerder chemotherapie was toegediend (41% versus 20%, 
p < 0.001). Dit kan de verklaring zijn dat Cox regressie analyse een verhoogde 
HR voor mortaliteit liet zien van 1.35 (95% BI: 1.03-1.75; p = 0.03) in de groep 
die eerder met chemotherapie was behandeld. Hoe dan ook, het aandeel van 
patiënten met een afwijkende uitgangsscore van GA verschilde niet significant 
Tabel 2. Mortaliteitsrisico voor de GPI score in relatie tot eerdere chemotherapie. 












Geen	  eerdere	  chemotherapie (n=420) 
 0 punten (n=154) 29 Ref. < 0.001 0.44 
 1 punt (n=152) 15 1.58 (1.21-2.08) 
 2 punten (n=90) 10 2.40 (1.76-3.24) 
 3 punten (n=21) 5 5.20 (3.18-8.49) 
Eerder	  chemotherapie (n=74) 
 0 punten (n=34) 16 Ref. 0.09 
 1 punt (n=23) 14 1.04 (0.54-2.01) 
 2 punten (n=14) 9 1.39 (0.69-2.81) 
 3 punten (n=3) 7 7.60 (1.94-29.7) 
Hazard ratios (met 95% BI) zijn berekend dmv Cox regressie analyse, en de modellen werden 
gecorrigeerd voor geslacht, leeftijd, doel van de behandeling en soort maligniteit. 








Mannelijk	  geslacht	   213	  (50.7%)	   33	  (44.6%)	   0.33	  
Leeftijdsgroepen:	  
	  	  	  70-­‐74	  jr	   200	  (47.6%)	   37	  (50.0%)	   0.67	  
	  	  	  75-­‐79	  jr	   145	  (34.5%)	   25	  (33.8%)	  
	  	  	  ≥	  80	  jr	   75	  (17.9%)	   12	  (16.2%)	  
In	  opzet	  curatieve	  behandeling	  	   191	  (45.5%)	   15	  (20.3%)	   <	  0.001	  
Afwijkende	  uitgangsscore	  GA:	  
	  	  	  MNA	   153	  (36.8%)	   21	  (28.4%)	   0.16	  
	  	  	  GFI	   131	  (31.3%)	   18	  (24.3%)	   0.23	  
	  	  	  IQCODE	   52	  (12.6%)	   10	  (14.7%)	   0.64	  
	  	  	  MMSE	   40	  (9.6%)	   4	  (5.5%)	   0.26	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In onze gedetailleerde analyse, waarbij alle items werden meegenomen 
van de MNA en de GFI met betrekking tot het sterfterisico na de start met chemo-
therapie, werden twee items van de MNA en één item van de GFI als onafhanke-
lijke risico factor geïdentificeerd. Op basis van deze drie items werd de ‘Geriatric 
Prognostic Index (GPI)’ samengesteld om de drukbezette (hemato-)oncoloog te 
helpen bij het identificeren van de oudere patiënt met kanker met een verhoogd 
sterfterisico. Alleen al door het stellen van de volgende drie vragen kan belangri-
jke prognostische informatie worden onthuld: ‘Heeft u een verminderde eetlust 
in de afgelopen drie maanden?’, ‘Gebruikt u dagelijks meer dan drie voorgeschre-
ven medicijnen?’ en ‘Bent u afhankelijk van anderen voor boodschappen doen?’. 
In het geval van een hoge score is een meer uitgebreid CGA geïndiceerd voor het 
nauwkeurig afstemmen van het behandelplan dat nodig kan zijn bij het streven 
naar een betere uitkomst. De betekenis van deze bevindingen en adviezen voor 
de klinische praktijk zal in de toekomst nader onderzocht moeten worden. Ech-
ter, momenteel zijn deze aanbevelingen alleen van toepassing bij patiënten voor 
wie de clinicus behandeling met chemotherapie op klinische gronden wenselijk 
achtte. Bovendien moeten de bevindingen gevalideerd worden in een ander co-
hort.
Hoe moet de kennis, tot nu toe verkregen door het GA in de geriatrische 
oncologie, in de klinische praktijk worden toegepast? In de ideale situatie zal in 
de behoeften van de oudere patiënt voorzien worden door geriater-oncologen. 
Echter, zowel het vakgebied van de geriatrie als de oncologie ontwikkelt zich snel 
en daarom zal, praktisch gesproken, samenwerking van oncologen (getraind in 
de basisprincipes van de geriatrie) en geriaters (getraind in het toepassen van 
kanker specifieke GA’s) noodzakelijk zijn om de zorg voor ouderen met kanker te 
optimaliseren [33]. Dit kan worden gerealiseerd op geriatrische oncologie afde-
lingen of door een geriatrisch consultatie team (GCT) [9, 33]. Het voordeel van 
het model met een GCT is dat de directe relatie tussen de patiënt en de oncoloog 
niet wordt verstoord en dat het team beschikbaar is voor begeleiding als later 
geriatrie-gerelateerde problemen optreden. Een mogelijk nadeel betreft de or-
ganisatie voor longitudinaal vervolgen van de geriatrische problemen [9]. Een 
GCT (bestaande uit een geriater en geriatrisch opgeleide ‘nurse practitioner’ of 
‘physician’s assistant’) zou zelfs kunnen worden ingebed in een bestaande oncol-
ogische kliniek en zou actief moeten participeren in een multidisciplinair team 
[9, 33]. Recent werd de rol voor de apotheker benadrukt binnen het multidisci-
plinaire team, voor het in kaart brengen van de mogelijk nadelige gevolgen van 
polyfarmacie, gecompliceerde interacties tussen geneesmiddelen en potentieel 
ondoelmatige medicatie [34]. 
Stroomdiagram	  
	  Patiënten	  met	  kanker
leeftijd	  ≥	  70	  jaar
overweging	  chemotherapie
Geriatric	  Prognostic	  Index	  (GPI)	  screening
-­‐	  ‘verminderde	  eetlust	  in	  de	  afgelopen	  drie	  maanden’
-­‐	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·∙ 	   Aanpassing	  schema,	  verlaging	  dosering,	  
medicatie	  op	  maat	  
·∙ 	   Longitudinale	  follow-­‐up	  dmv	  CGA	  
	  Patiënt	  met	  kanker	  
start	  chemotherapie
Comprehensive	  geriatric	  assessment:
·∙ 	   Sociale	  status,	  comorbiditeit,	  functionele	  status,	  
cognitie,	  depressie,	  voeding,	  polyfarmacie,	  
bestaan	  van	  geriatrische	  syndromen9
·∙ 	   Consultatie	  van	  geriater	  (team)
Overweeg:
·∙ 	   Aanvullende	  zorg:	  fysiotherapeut,
ergotherapeut,	  sociaal	  werker,	  apotheker,	  
diëtist33
·∙ 	   Aanpassing	  schema,	  verlaging	  dosering,	  
medicatie	  op	  maat	  








The role of geriatric assessment prior to chemotherapy in elderly patients with cancer Chapter 7  |  Summary and general discussion156 157
een routine onderdeel wordt van de zorg bij de oudere patiënt met kanker. Het 
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 Mohile en anderen definieerden vier doelen voor verder onderzoek in geri-
atrische oncologie [35]:
1. Incorporeer GA instrumenten in klinisch onderzoek die nadelige 
 uitkomsten voorspellen voor de oudere volwassenen met kanker; 
2. Onderzoek de mogelijkheid van een GA zorgmodel om de uitkomst van de 
 oudere patiënt met kanker te verbeteren; 
3. Verkrijg meer inzicht op de invloed van de oncologische behandeling in de 
 algemene populatie van de oudere patiënt met kanker;
4. Identificeer en onderzoek interventies om de symptomen te verbeteren en 
 de kwaliteit van leven van ouderen patiënten met kanker te behouden. 
 Het klinisch onderzoek zoals beschreven in dit proefschrift richtte zich 
op de prognostische rol van de MNA en de GFI, voor zowel de haalbaarheid van 
de behandeling met chemotherapie als voor de overleving. Of interventie strat-
egieën, na opsporing van specifieke tekortkomingen, zullen resulteren in betere 
uitkomsten en of deze zullen helpen om de kwaliteit van leven te behouden, zijn 
uitdagende vragen die nu nog niet zijn beantwoord. Op grond van de in dit proef-
schrift beschreven resultaten en met in achtneming van de huidige literatuur 
worden de volgende aanbevelingen voor de behandeling met chemotherapie bij 
oudere patiënten met kanker in het stroomdiagram weergegeven. 
 
 De oudere patiënten met kanker, in aantal snel toenemend de komende 
decennia, verdienen niets minder dan een optimale inventarisatie van reeds 
bestaande geriatrische problemen welke nadelige uitkomsten voorspellen en 
aangepakt moeten worden [2]. Onderzoek naar interventiestrategieën die speci-
fiek gericht zijn op ouderen, op basis van GA, zullen verder ontwikkeld moeten 
worden om de uitkomst van de behandeling te verbeteren en  ouderen moeten 
worden aangemoedigd om aan deze onderzoeken deel te nemen. Dit type onder-
zoek werd verricht met positief resultaat door middel van fysieke training bij 
patiënten met borstkanker in jongere leeftijdsgroepen [36] en momenteel is er 
een lopend onderzoek naar het effect van fysieke training bij oudere patiënt-
en met borstkanker (de ‘Climb Every Mountain’-studie) [37]. De onderzoeken 
zijn dus in ontwikkeling, maar in het komend decennium zal nog veel inspan-
ning geleverd moeten worden voor het uitvoeren van tumorspecifieke studies. 
De onderzoeken in dit proefschrift kunnen gebruikt worden als achtergrond-
informatie en een eerste stap vormen waarop deze ontwikkelingen gebaseerd 
kunnen worden. We hopen dat dit proefschrift een bijdrage kan leveren aan het 
ontwikkelen van gestandaardiseerd instrumentarium en daarmee, dat het GA 
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Appendices Mini	  Nutritional	  Assessment	  (MNA)*	  
(From: Guigoz et.al. Identifying the elderly at risk for malnutrition. The Mini Nutritional Assessment. 
Clin Geriatr Med, 2002. 18(4): p.737-57). 
* http://www.mna-elderly.com/forms/MNA_MNenglish.pdf.
SCREENING	  
A Has	  food	  intake	  declined	  over	  the	  past	  3	  months	  due	  
to	  loss	  of	  appetite,	  digestive	  problems,	  chewing	  or	  
swallowing	  difficulties?	  
0	  =	  severe	  decrease	  in	  food	  intake	  
1	  =	  moderate	  decrease	  in	  food	  intake	  
2	  =	  no	  decrease	  in	  food	  intake	  
B Weight	  loss	  during	  the	  last	  3	  months	  
0	  =	  weight	  loss	  greater	  than	  3kg	  (6.6lbs)	  
1	  =	  does	  not	  know	  
2	  =	  weight	  loss	  between	  1	  and	  3kg	  (2.2	  and	  6.6	  lbs)	  
3	  =	  no	  weight	  loss	  
C Mobility	  
0	  =	  bed	  or	  chair	  bound	  
1	  =	  able	  to	  get	  out	  of	  bed	  /	  chair	  but	  does	  not	  go	  out	  
2	  =	  goes	  out	  
D Has	  suffered	  psychological	  stress	  or	  acute	  disease	  in	  
the	  past	  3	  months?	  
0	  =	  yes	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	  =	  no	  
E Neuropsychological	  problems	  
0	  =	  severe	  dementia	  or	  depression	  
1	  =	  mild	  dementia	  
2	  =	  no	  psychological	  problems	  
F Body	  Mass	  Index	  (BMI)	  (weight	  in	  kg)	  /	  (height	  in	  m2)	  
0	  =	  BMI	  less	  than	  19	  
1	  =	  BMI	  19	  to	  less	  than	  21	  
2	  =	  BMI	  21	  to	  less	  than	  23	  
3	  =	  BMI	  23	  or	  greater	  
Screening	  score	  (subtotal	  max.	  14	  points)	  	  
12-­‐14	  points:	  	  	  	  	  	  
8	  -­‐	  11	  points:	  	  	  	  	  	  
0	  -­‐7	  points:	  	  	  	  	  	  	  	  	  
Normal	  nutritional	  status	  
At	  risk	  of	  malnutrition	  
Malnourished	  
ASSESSMENT	  (if	  screening	  <	  12	  points)	  
G Lives	  independently	  (not	  in	  nursing	  home	  or	  hospital)	  
1	  =	  yes	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0	  =	  no	  
H Takes	  more	  than	  3	  prescription	  drugs	  per	  day	  
0	  =	  yes	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  =	  no	  
I Pressure	  sores	  or	  skin	  ulcers	  
0	  =	  yes	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  =	  no	  
J How	  many	  full	  meals	  does	  the	  patient	  eat	  daily?	  
0	  =	  1	  meal	  
1	  =	  2	  meals	  
2	  =	  3	  meals	  
K Selected	  consumption	  markers	  for	  protein	  intake	  
•	  At	  least	  one	  serving	  of	  dairy	  products
(milk,	  cheese,	  yoghurt)	  per	  day	  
• Two	  or	  more	  servings	  of	  legumes	  or	  eggs	  per	  week
•	  Meat,	  fish	  or	  poultry	  every	  day
0.0	  =	  if	  0	  or	  1	  yes	  
0.5	  =	  if	  2	  yes	  
1.0	  =	  if	  3	  yes	  
L Consumes	  two	  or	  more	  servings	  of	  fruit	  or	  vegetables	  per	  
day?	  
0	  =	  no	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  =	  yes	  
M How	  much	  fluid	  (water,	  juice,	  coffee,	  tea,	  milk...)	  is	  
consumed	  per	  day?	  
0.0	  =	  less	  than	  3	  cups	  
0.5	  =	  3	  to	  5	  cups	  
1.0	  =	  more	  than	  5	  cups	  
N Mode	  of	  feeding	  
0	  =	  unable	  to	  eat	  without	  assistance	  
1	  =	  self-­‐fed	  with	  some	  difficulty	  
2	  =	  self-­‐fed	  without	  any	  problem	  
O Self	  view	  of	  nutritional	  status	  
0	  =	  views	  self	  as	  being	  malnourished	  
1	  =	  is	  uncertain	  of	  nutritional	  state	  
2	  =	  views	  self	  as	  having	  no	  nutritional	  problem	  
P In	  comparison	  with	  other	  people	  of	  the	  same	  age,	  how	  
does	  the	  patient	  consider	  his	  /	  her	  health	  status?	  
0.0	  =	  not	  as	  good	  
0.5	  =	  does	  not	  know	  
1.0	  =	  as	  good	  
2.0	  =	  better	  
Q Mid-­‐arm	  circumference	  (MAC)	  in	  cm	  
0.0	  =	  MAC	  less	  than	  21	  
0.5	  =MAC	  21	  to	  22	  
1.0	  =	  MAC	  22	  or	  greater	  
R Calf	  circumference	  (CC)	  in	  cm	  
0	  =	  CC	  less	  than	  31	  
1	  =	  CC	  31	  or	  greater	  
Assessment	  score	  (max.	  16	  points)	  
Total	  (Screening	  +	  Assessment)	  
24	  to	  30	  points:	  
17	  to	  23.5	  points:	  
Less	  than	  17	  points:	  
Normal	  nutritional	  status	  
At	  risk	  of	  malnutrition	  
Malnourished	  
The role of geriatric assessment prior to chemotherapy in elderly patients with cancer Chapter 7  |  Summary and general discussion162 163
Informant	  questionnaire	  on	  cognitive	  decline	  in	  the	  elderly	  (IQCODE)	  
Hoe	  is	  mevrouw/meneer,	  vergeleken	  met	  10	  jaar	  geleden,	  bij:	  
1	   2	   3	   4	   5	  
1. Feiten	  herinneren	  over	  familie-­‐	   Veel	   Iets	   Niet	   Iets	   Veel	  
leden	  en	  vrienden,	  zoals	   beter	   beter	   veranderd	   slechter	   slechter	  
beroepen,	  verjaardagen	  of	  adressen.
2. Herinneren	  wat	  er	  pas Veel	   Iets	   Niet	   Iets	   Veel	  
geleden	  is	  gebeurd.	   beter	   beter	   veranderd	   slechter	   slechter	  
3. Gesprekken	  herinneren	   Veel	   Iets	   Niet	   Iets	   Veel	  
van	  een	  paar	  dagen	  geleden. beter	   beter	   veranderd	   slechter	   slechter	  
4. Onthouden	  van	  zijn/haar	  adres Veel	   Iets	   Niet	   Iets	   Veel	  
en	  telefoonnummer. beter	   beter	   veranderd	   slechter	   slechter	  
5. Onthouden	  welke	  dag	  en	  maand	   Veel	   Iets	   Niet	   Iets	   Veel	  
het	  is. beter	   beter	   veranderd	   slechter	   slechter	  
6. Onthouden	  waar	  	  normaal Veel	   Iets	   Niet	   Iets	   Veel	  
gesproken	  ligt. beter	   beter	   veranderd	   slechter	   slechter	  
7. weten	  te	  vinden	  dat Veel	   Iets	   Niet	   Iets	   Veel	  
	  op	  z'n	  gewone	  plek	  ligt. beter	   beter	   veranderd	   slechter	   slechter	  
8. Omgaan	  met	  bekende	   Veel	   Iets	   Niet	   Iets	   Veel	  
huishoudelijke	  apparaten. beter	   beter	   veranderd	   slechter	   slechter	  
9. Leren	  omgaan	  met	  nieuwe Veel	   Iets	   Niet	   Iets	   Veel	  
huishoudelijke	  apparaten. beter	   beter	   veranderd	   slechter	   slechter	  
10. Nieuwe	  dingen	  leren	  in	  het Veel	   Iets	   Niet	   Iets	   Veel	  
algemeen. beter	   beter	   veranderd	   slechter	   slechter	  
11. Het	  verhaal	  kunnen	  volgen	   Veel	   Iets	   Niet	   Iets	   Veel	  
in	  een	  boek	  of	  op	  televisie. beter	   beter	   veranderd	   slechter	   slechter	  
12. Beslissingen	  nemen	  over Veel	   Iets	   Niet	   Iets	   Veel	  
alledaagse	  dingen. beter	   beter	   veranderd	   slechter	   slechter	  
13. Omgaan	  met	  geld	  voor Veel	   Iets	   Niet	   Iets	   Veel	  
de	  boodschappen. beter	   beter	   veranderd	   slechter	   slechter	  
14. Geldzaken	  regelen,	  zoals Veel	   Iets	   Niet	   Iets	   Veel	  
het	  pensioen,	  bankzaken. beter	   beter	   veranderd	   slechter	   slechter	  
15. Andere	  alledaagse	  rekenproblemen	   Veel	   Iets	   Niet	   Iets	   Veel	  
oplossen,	  zoals	  hoe	  eten	   beter	   beter	   veranderd	   slechter	   slechter	  
er	  gekocht	  moet	  worden,	  weten	  
wanneer	  familieleden	  of	  vrienden	  
voor	  het	  laatst	  op	  bezoek	  zijn	  geweest.	  
16. Het	  gezonde	  verstand	  gebruiken	   Veel	   Iets	   Niet	   Iets	   Veel	  
om	  te	  begrijpen	  wat	  er	  gebeurt beter	   beter	   veranderd	   slechter	   slechter	  
en	  de	  zaken	  op	  een	  rijtje	  te	  zetten.
Totaal	  
(From: Jorm	  AF.	  A	  short	  form	  of	  the	  Informant	  Questionnaire	  on	  Cognitive	  Decline	  in	  the	  Elderly	  (IQCODE):	  development	  
and	  cross-­‐validation.	  Psychological	  Medicine	  1994;24:145-­‐153.	  
Groningen	  Frailty	  indicator	  (GFI)	  
Mobility	  
Is	  the	  patient	  able	  to	  carry	  out	  these	  tasks	  single	  handed	  without	  any	  help?	  (The	  use	  of	  help	  resources	  such	  as	  
walking	  stick,	  walking	  frame,	  wheelchair,	  is	  considered	  independent)	  
1.	  Shopping
2.	  Walking	  around	  outside	  (around	  the	  house	  or	  to	  the	  neighbors)	  
3.	  Dressing	  and	  undressing
4.	  Going	  to	  the	  toilet
Physical	  Fitness	  
5.	  What	  mark	  does	  the	  patient	  give	  himself/herself	  for	  physical	  fitness?	  (scale	  0	  to	  10)
Vision	  
6.	  Does	  the	  patient	  experience	  problems	  in	  daily	  life	  due	  to	  poor	  vision?
Hearing	  
7.	  Does	  the	  patient	  experience	  problems	  in	  daily	  life	  due	  to	  being	  hard	  of	  hearing?
Nourishment	  
8.	  During	  the	  last	  6	  months	  has	  the	  patient	  lost	  a	  lot	  of	  weight	  unwillingly?	  (3	  kg	  in	  1	  month	  or	  6	  kg	  in	  2
months)	  
Morbidity	  
9.	  Does	  the	  patient	  take	  4	  or	  more	  different	  types	  of	  medicine?
Cognition	  (Perception)	  
10.	  Does	  the	  patient	  have	  any	  complaints	  about	  his/her	  memory	  or	  is	  the	  patient	  known	  to	  have	  a
dementia	  syndrome?	  
Psychosocial	  
11.	  Does	  the	  patient	  sometimes	  experience	  emptiness	  around	  him/her?
12.	  Does	  the	  patient	  sometimes	  miss	  people	  around	  him/her?
13.	  Does	  the	  patient	  sometimes	  feel	  abandoned?
14.	  Has	  the	  patient	  recently	  felt	  downhearted	  or	  sad?
15.	  Has	  the	  patient	  recently	  felt	  nervous	  or	  anxious?
Scoring:	  
Questions	  1–4:	   	  Independent	  =	  0;	  dependent	  =	  1	  
Question	  5:	   	  0–6	  =	  1;	  7–10	  =	  0	  
Questions	  6–9:	   	  No	  =	  0;	  yes	  =	  1	  
Question	  10:	   	  No	  and	  sometimes	  =	  0;	  yes	  =	  1	  
Questions	  11–15:	   	  No	  =	  0;	  sometimes	  and	  yes	  =	  1	  
(From:	  Slaets	  JP.	  Vulnerability	  in	  the	  Elderly:	  frailty.	  Med	  Clin	  North	  Am	  2006;90:593-­‐601)	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Sluit	  uw	  ogen	  
(from:	  Folstein	  MF,	  Folstein	  SE,	  McHugh	  PR.	  Mini-­‐mental	  state:	  A	  practical	  method	  for	  grading	  the	  cognitive	  state	  of	  
patients	  for	  the	  clinician.	  Journal	  of	  psychiatric	  research	  1975;	  12:189-­‐198).	  
Mini-­‐Mental	  State	  Examination	  (MMSE)	  
Ik	  ga	  u	  nu	  enkele	  vragen	  stellen	  en	  geef	  u	  enkele	  problemen	  om	  op	  te	  lossen.	  Wilt	  u	  alstublieft	  uw	  best	  doen	  om	  zo	  goed	  
mogelijke	  antwoorden	  te	   geven.	  
noteer	  antwoord	   score:	  
1. a.	  Welk	  jaar	  is	  het?
b. Welk	  seizoen	  is	  het?
c. Welke	  maand	  van	  het	  jaar	  is	  het?
d. Wat	  is	  de	  datum	  vandaag?
e. Welke	  dag	  van	  de	  week	  is	  het?
2. a.	  In	  welke	  provincie	  zijn	  we	  nu?	  
b. In	  welke	  plaats	  zijn	  we	  nu?	  
c. In	  welk	  ziekenhuis	  (instelling)	  zijn	  we	  nu?	  
d. Wat	  is	  de	  naam	  van	  deze	  afdeling?
(0-­‐5)	  	  	  	  
e. Op	  welke	  verdieping	  zijn	  we	  nu? (0-­‐5)	  	  	  	  
3. Ik	  noem	  nu	  drie	  voorwerpen.	  Wilt	  u	  die	  herhalen	  nadat	  ik	  ze	  alle	  drie	  gezegd	  heb?
Onthoud	  ze	  want	  ik	  vraag	  u	  over	  enkele	  minuten	  ze	  opnieuw	  te	  noemen.	  
(Noem	  "appel,	  sleutel,	  tafel",	  neem	  1	  seconde	  per	  woord)	  (1	  punt	  
voor	  elk	  goed	  antwoord,	  herhaal	  maximaal	  5	  keer	  
tot	  de	  patiënt	  de	  drie	  woorden	  weet)	   (0-­‐3)	  	  	  	  
4. Wilt	  u	  van	  de	  100	  zeven	  aftrekken	  en	  van	  wat	  overblijft	  weer	  zeven	  aftrekken	  en	  zo	  
doorgaan	  tot	  ik	  stop	  zeg?	  
(Herhaal	  eventueel	  3	  maal	  als	  de	  persoon	  stopt,	  herhaal	  dezelfde	  instructie,	  geef	  
maximaal	  1	  minuut	  de	  tijd)	  Noteer	  hier	  het	  antwoord.	  
of	  
Wilt	  u	  het	  woord	  “‘worst”	  achterstevoren	   spellen?.	  
Noteer	  hier	  het	  antwoord.	   (0-­‐5)	  	  	  	  
5. Noemt	  u	  nogmaals	  de	  drie	  voorwerpen	  van	  zojuist.
(Eén	  punt	  voor	  elk	  goed	  antwoord).	   (0-­‐3)	  	  	  	  
6. Wat	  is	  dit?	  En	  wat	  is	  dat?	  
(Wijs	  een	  pen	  en	  een	  horloge	  aan.	  Eén	  punt	  voor	  elk	  goed	  antwoord). (0-­‐2)	  	  	  	  
7. Wilt	  u	  de	  volgende	  zin	  herhalen:	  "	  Nu	  eens	  dit	  en	  dan	  weer	  dat	  ".
(Eén	  punt	  als	  de	  complete	  zin	  goed	   is)	   (0-­‐1)	  	  	  	  
8. Wilt	  u	  deze	  woorden	  lezen	  en	  dan	  doen	  wat	  er	  staat’?
(papier	  met	  daarop	  in	  grote	  letters:	  "Sluit	  uw	  ogen")	   (0-­‐1)	  	  	  	  
9. Wilt	  u	  dit	  papiertje	  pakken	  met	  uw	  rechterhand,	  het	  dubbelvouwen	  
en	  het	  op	  uw	  schoot	  leggen?	  (Eén	  punt	  voor	  iedere	  goede	   handeling). (0-­‐3)	  	  	  	  
10. Wilt	  u	  voor	  mij	  een	  volledige	  zin	  opschrijven	  op	  dit	  stuk	  papier?	  (Eén	  
punt	  wanneer	  de	  zin	  een	  onderwerp	  en	  een	  gezegde	   heeft	  
en	  betekenis	  heeft).	   (0-­‐1)	  	  	  	  
11. Wilt	  u	  deze	  figuur	  natekenen?	  
(Figuur	  achterop	  dit	  papier.	  Eén	  punt	  als	  figuur	  geheel	  correct	  is	  nagetekend.
Er	  moet	  een	  vierhoek	  te	  zien	  zijn	  tussen	  de	  twee	  vijfhoeken)	   (0-­‐1)	  	  	  	  
TOTALE	  	  TEST	  SCORE:	   (0-­‐30)	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